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A B S T R A C T
Background
Medication-related adverse events in primary care represent an important cause of hospital admissions and mortality. Adverse events
could result from people experiencing adverse drug reactions (not usually preventable) or could be due to medication errors (usually
preventable).
Objectives
To determine the effectiveness of professional, organisational and structural interventions compared to standard care to reduce pre-
ventable medication errors by primary healthcare professionals that lead to hospital admissions, emergency department visits, and
mortality in adults.
Search methods
We searchedCENTRAL,MEDLINE, Embase, three other databases, and two trial registries on 4October 2016, together with reference
checking, citation searching and contact with study authors to identify additional studies. We also searched several sources of grey
literature.
Selection criteria
We included randomised trials in which healthcare professionals provided community-based medical services. We also included inter-
ventions in outpatient clinics attached to a hospital where people are seen by healthcare professionals but are not admitted to hospital.
We only included interventions that aimed to reduce medication errors leading to hospital admissions, emergency department visits,
or mortality. We included all participants, irrespective of age, who were prescribed medication by a primary healthcare professional.
Data collection and analysis
Three review authors independently extracted data. Each of the outcomes (hospital admissions, emergency department visits, and
mortality), are reported in natural units (i.e. number of participants with an event per total number of participants at follow-up). We
presented all outcomes as risk ratios (RRs) with 95% confidence intervals (CIs). We used the GRADE tool to assess the certainty of
evidence.
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Main results
We included 30 studies (169,969 participants) in the review addressing various interventions to prevent medication errors; four studies
addressed professional interventions (8266 participants) and 26 studies described organisational interventions (161,703 participants).
We did not find any studies addressing structural interventions. Professional interventions included the use of health information
technology to identify people at risk of medication problems, computer-generated care suggested and actioned by a physician, electronic
notification systems about dose changes, drug interventions and follow-up, and educational interventions ondruguse aimed at physicians
to improve drug prescriptions. Organisational interventions includedmedication reviews by pharmacists, nurses or physicians, clinician-
led clinics, and home visits by clinicians.
There is a great deal of diversity in types of professionals involved and where the studies occurred. However, most (61%) of the
interventions were conducted by pharmacists or a combination of pharmacists and medical doctors. The studies took place in many
different countries; 65% took place in either the USA or the UK. They all ranged from three months to 4.7 years of follow-up, they all
took place in primary care settings such as general practice, outpatients’ clinics, patients’ homes and aged-care facilities. The participants
in the studies were adults taking medications and the interventions were undertaken by healthcare professionals including pharmacists,
nurses or physicians. There was also evidence of potential bias in some studies, with only 18 studies reporting adequate concealment
of allocation and only 12 studies reporting appropriate protection from contamination, both of which may have influenced the overall
effect estimate and the overall pooled estimate.
Professional interventions
Professional interventions probably make little or no difference to the number of hospital admissions (risk ratio (RR) 1.24, 95%
confidence interval (CI) 0.79 to 1.96; 2 studies, 3889 participants; moderate-certainty evidence). Professional interventions make little
or no difference to the number of participants admitted to hospital (adjusted RR 0.99, 95% CI 0.92 to 1.06; 1 study, 3661 participants;
high-certainty evidence). Professional interventions may make little or no difference to the number of emergency department visits
(adjusted RR 0.71, 95% CI 0.50 to 1.02; 2 studies, 1067 participants; low-certainty evidence). Professional interventions probably
make little or no difference to mortality in the study population (adjusted RR 0.98, 95% CI 0.82 to 1.17; 1 study, 3538 participants;
moderate-certainty evidence).
Organisational interventions
Overall, it is uncertain whether organisational interventions reduce the number of hospital admissions (adjusted RR 0.85, 95% CI 0.71
to 1.03; 11 studies, 6203 participants; very low-certainty evidence). Overall, organisational interventions may make little difference to
the total number of people admitted to hospital in favour of the intervention group compared with the control group (adjusted RR
0.92, 95% CI 0.86 to 0.99; 13 studies, 152,237 participants; low-certainty evidence. Overall, it is uncertain whether organisational
interventions reduce the number of emergency department visits in favour of the intervention group compared with the control group
(adjusted RR 0.75, 95% CI 0.49 to 1.15; 5 studies, 1819 participants; very low-certainty evidence. Overall, it is uncertain whether
organisational interventions reduce mortality in favour of the intervention group (adjusted RR 0.94, 95% CI 0.85 to 1.03; 12 studies,
154,962 participants; very low-certainty evidence.
Authors’ conclusions
Based on moderate- and low-certainty evidence, interventions in primary care for reducing preventable medication errors probably
make little or no difference to the number of people admitted to hospital or the number of hospitalisations, emergency department
visits, or mortality. The variation in heterogeneity in the pooled estimates means that our results should be treated cautiously as the
interventions may not have worked consistently across all studies due to differences in how the interventions were provided, background
practice, and culture or delivery of the interventions. Larger studies addressing both professional and organisational interventions are
needed before evidence-based recommendations can be made. We did not identify any structural interventions and only four studies
used professional interventions, and so more work needs to be done with these types of interventions. There is a need for high-quality
studies describing the interventions in more detail and testing patient-related outcomes.
P L A I N L A N G U A G E S U M M A R Y
Actions to reduce medication errors in adults in primary care
What is the aim of this review?
2Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The aim of this Cochrane Review was to find out the best way to reduce medication errors by primary healthcare professionals in adult
patients that lead to hospital admissions, emergency department visits, and death. We wanted to know whether targeting individual
health professionals (e.g. with educational materials and reminders about drug dosage etc.), changing the organisation of primary care
(e.g. revising professional roles, such as nurse- or pharmacist-led prescribing etc.), or structural actions, such as organising quality
monitoring services can reduce medication errors by primary healthcare professionals. We collected and analysed relevant studies to
answer this question and found 30 studies.
Key messages
The 30 studies (169,969 participants) in this Cochrane Review showed that actions aimed at reducing medication errors, such as
medication reviews by pharmacists or physicians probably make little or no difference to the number of people admitted to hospital,
number of hospital admissions, number of emergency department visits, or death. In general, all the actions described in the review
were found to have unclear benefits. We did not find any studies that fitted the criteria of structural actions. The main limitation of
this review is the small number of studies addressing each method and the low-certainty of the evidence.
What was studied in the review?
Prescribing medications is one of the most powerful tools available to general practitioners (GPs) in the prevention and treatment
of disease. Medication-related adverse events could be the result of people either experiencing adverse drug reactions (not usually
preventable) or as a result of medication errors (usually preventable). We studied the effectiveness of professional and organisational
methods compared to standard care in primary care settings (examples of primary care settings include general practices, community
pharmacies, patient homes, community settings, outpatient clinics, and aged-care facilities) to reduce preventable medication errors
that lead to hospital admissions, emergency department visits, and death in adults who are prescribed medication in primary care.
What are the main results of the review?
We included 30 studies in our analysis. We classified 26 studies as organisational and the remaining four as professional actions. We
found no structural actions in our search. The studies included in this Cochrane Review showed that based on moderate- and low-
certainty evidence, actions in primary care for reducing preventable medication errors probably make little or no difference to the
number of people admitted to hospital or the number of hospitalisations, emergency department visits, or death. Most of the studies
took place in the UK and the USA; studies undertaken in high-income countries with disadvantaged populations, and in low- and
middle-income countries, were underrepresented. This might affect the generalisation of the results.
Certainty of the evidence
We found the overall certainty of evidence for the professional actions to vary considerably across the reported outcomes: moderate-
certainty for number of hospital admissions, high-certainty for number of people admitted to hospital, low-certainty for number of
emergency department visits, and moderate-certainty for deaths. The certainty of evidence for organisational actions was less varied:
very low-certainty for number of hospital admissions, low-certainty for number of people admitted to hospital, and very low-certainty
for number of emergency department visits and deaths.
More work needs to be done in improving the quality of the studies regarding selection of participants and adequate blinding of
participants and study assessors. Participants dropping out of the studies was another concern in the certainty of evidence. Funding of
the included studies came from various sources and it is difficult to decide whether the funding affected the results of the studies.
How up-to-date is this review?
We searched for studies that had been published up to 4 October 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Professional interventions compared to standard/usual care for prevention of medication errors
Patient or population: adults receiving medicat ion in primary care
Setting: primary and community care
Intervention: professional intervent ions (using health information technology to ident if y people at risk or using it to generate a pat ient care plan)
Comparison: standard/ usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard/
usual care
Risk with professional
interventions
Number of hospital ad-
missions
Study populat ion RR 1.24
(0.79 to 1.96)
3889
(2 RTs)
⊕⊕⊕©
Moderate1
The two studies had
wide conf idence inter-
vals.17 per 1000 21 per 1000
(13 to 33)
Number of people ad-
mit ted to hospital
Study populat ion RR 0.99
(0.92 to 1.06)
3661
(1 RT)
⊕⊕⊕⊕
High2
448 per 1000 443 per 1000
(412 to 475)
Number of emergency
department visits
Study populat ion RR 0.71
(0.50 to 1.02)
1067
(2 RTs)
⊕⊕©©
Low1,3
The two studies had
wide conf idence inter-
vals and select ion bias118 per 1000 85 per 1000
(59 to 121)
Mortality Study populat ion RR 0.98
(0.82 to 1.17)
3538
(1 RT)
⊕⊕⊕©
Moderate3
122 per 1000 119 per 1000
(100 to 142)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io; RT : randomised trial
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GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1We downgraded one level due to imprecision.
2We did not downgrade the outcomes because all included studies had low risk of bias and narrow conf idence intervals.
3We downgraded one level due to risk of bias (select ion bias).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
5
P
ro
fe
ssio
n
a
l,
stru
c
tu
ra
l
a
n
d
o
rg
a
n
isa
tio
n
a
l
in
te
r
v
e
n
tio
n
s
in
p
rim
a
ry
c
a
re
fo
r
re
d
u
c
in
g
m
e
d
ic
a
tio
n
e
rro
rs
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Medication-related (drug-related) adverse events in primary care
represent an important cause of hospital admissions and mortality
(Howard 2003). Medication-related adverse events could be the
result of people either experiencing adverse drug reactions (not
usually preventable) or as a result of medication errors (usually
preventable) (Bates 1995; Ioannidis 2001).
According to Edwards 2000, adverse drug reactions can be defined
as “an appreciably harmful or unpleasant reaction resulting from
an intervention related to the use of a medicinal product.” Medi-
cation errors on the other hand, are mostly preventable. A medica-
tion error is defined by Ferner 2006 as “a failure in the treatment
process that leads to, or has the potential to lead to, harm to the
patient.” They are mainly due to prescribing or medication man-
agement errors. A reduction of these types of prescribing/medi-
cation errors has been a high priority for healthcare policy in or-
der to improve the safety profile of the healthcare delivery system
(Howard 2003; Soe 2013).
A prospective cohort study has shown that within four weeks of
receiving a primary care prescription, 25% of participants expe-
rienced an adverse drug event, 11% of which were judged pre-
ventable (Gandhi 2003). A systematic review and meta-analysis
by Winterstein 2002 reported that a median 7.1% (inter-quartile
range 5.7% to 16.2%) of hospital admissions resulted from drug-
related problems, of which 59% were considered preventable (i.e.
attributable to error), while Howard 2007 reported that a median
of 3.7% of hospital admissions were preventable and drug-related.
Improving patient safety is, as a consequence, now a government
priority in many high-income and middle- and low-income coun-
tries, including the UK, USA and five African countries; Egypt,
South Africa, Morocco, Tanzania and Zimbabwe (Brown 2008;
WHO 2004).
Description of the intervention
In this review we examined interventions in primary care to re-
duce preventable medication errors that resulted in hospital ad-
missions, emergency department visits, and mortality. The three
main types of interventions that we examined included profes-
sional, organisational, and structural interventions as described by
Cochrane Effective Practice and Organisation of Care (EPOC)
(Appendix 1). Professional interventions included quality assur-
ance tools that provided educational interventions for practition-
ers or participants, such as teaching the use of structured assess-
ments with general practitioners (GPs). Organisational interven-
tions included revision of professional roles (e.g. nurse- or phar-
macist-led chronic disease clinics and nurse prescribing) and revi-
sion of clinical multidisciplinary teams (e.g. pharmacist-managed
medication reviews). Structural interventions included the organ-
isation of quality monitoring services. We used these interventions
for any type of primary care-based population, irrespective of their
characteristics. The comparator was no intervention or standard or
usual care. The selected outcomes included in the review were the
number of hospital admissions, emergency department visits, and
mortality. These outcomes were selected as they are tangible and
mostly reported in primary studies. We did not consider patient-
oriented or patient-mediated outcomes in this review due to the
complexity of the included interventions. We will consider these
outcomes in the updated review.
How the intervention might work
The three main interventions, mentioned above, used different
approaches to achieve a reduction in medication errors that led to
hospital admissions, emergency department visits, and mortality.
Professional interventions included continuing education and
quality assurance that provided educational interventions for prac-
titioners or participants, such as teaching the use of structured as-
sessments with GPs. Other examples of professional interventions
included drug education programmes for physicians that were run
by physicians, electronic health record systems that provided in-
formation about drugs and gave recommendations about chang-
ing doses, health technology that identified care home residents at
risk of falls, and computer-based drug-ordering systems that gave
suggestions to physicians and pharmacists.
Organisational interventions included revision of professional
roles (e.g. nurse- or pharmacist-led chronic disease clinics and
nurse prescribing) and revision of clinical multidisciplinary teams
(e.g. pharmacist-managedmedication reviews).Organisational in-
terventions may have included telephone consultations along with
home-based medication reviews by pharmacists or nurses. Such
interventions aimed at engaging workers in the management of
risk to increase patient safety.
Structural interventions included the organisation of quality mon-
itoring services. Examples of these interventions included struc-
tural approaches such as social, economic, and political interven-
tions that could improve public health outcomes by increasing
the willingness and ability of individuals to practice prevention.
An example of the latter would be the introduction of financial
incentives to healthcare workers to reduce medication errors. By
looking at all of these interventions in the current review, we can
begin to address the multiple perspectives of various stakeholders
who provide health care to individuals in primary care (Benning
2011).
Why it is important to do this review
Prescribing medications is one of themost powerful tools available
to GPs in the prevention and treatment of disease, and allevia-
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tion of symptoms (Spencer 2014). However, medication-related
adverse events arising as a result of primary care prescribing are an
important source of participant morbidity, much of which could
be prevented by higher-quality prescribing and medicines man-
agement (Howard 2007). To date, there is little information on
the interventions mentioned above, aimed at reducing preventable
medication-related adverse events in primary care due to errors. A
review undertaken by Ioannidis 2001, addressed interventions of
all types of medical errors in both primary and secondary care. It
highlighted the complexity in studying those types of interventions
aimed at minimising errors in healthcare delivery. Other reviews
by Durieux 2012 and O’Brien 2008 focused on interventions to
improve professional practice and healthcare outcomes, including
prescribing. A review by Royal 2006 found that there was weak
evidence to support pharmacist-led medication interventions be-
ing effective in reducing hospital admissions. However, none of
these reviews have focused on other types of interventions at the
professional, organisational or structural level that could possibly
reduce medication errors in the primary care setting.
Given that preventable medication errors in primary care are asso-
ciated with hospital admissions, emergency department visits, and
mortality, it is important to know whether there are any interven-
tions that have been found to be effective in reducing the occur-
rence of these outcomes. While members of our team published
a related systematic review on this topic (Royal 2006), there has
been no Cochrane Review of interventions aimed at reducing the
incidence of preventable medication errors that lead to hospital
admissions, emergency department visits, and mortality.
O B J E C T I V E S
To determine the effectiveness of professional, organisational and
structural interventions compared to standard care to reduce pre-
ventable medication errors by primary healthcare professionals
that lead to hospital admissions, emergency department visits, and
mortality in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials in this review. We excluded con-
trolled before-after studies and other non-randomised designs as
they provided much weaker evidence due to the non-randomisa-
tion of participants to experimental and control groups. We did
not impose any restriction on the language or country in which
studies were carried out.
Types of participants
We included studies directed at healthcare professionals and or-
ganisations involved in the provision of primary care in the com-
munity setting who were authorised to prescribe, sell or adminis-
ter medications, including primary care physicians (general prac-
titioners (GPs), family doctors, family physicians, family practi-
tioners), dental practitioners, community nurses, nurse practition-
ers, community pharmacists, dispensers in community pharmacies
and any other relevant healthcare providers. We included all adult
participants who were receiving a medication through the inter-
vention of the aforementioned primary healthcare professionals.
Examples of community settings included general practice, com-
munity pharmacies, and nursing and residential homes. We ex-
cluded studies of interventions for outpatients in a clinic attached
to a hospital or a day hospital unless these were specifically de-
scribed as primary care clinics.
Types of interventions
Using the taxonomy of interventions developed by EPOC, we
categorised interventions that improved patient safety by reducing
hospital admissions, emergency department visits, and mortality (
Appendix 1).We compared the interventionswith inactive control
interventions such as no treatment, or standard or conventional
care. We divided interventions into the following categories.
Professional interventions
Professional interventions included the use of health information
technology to identify people at risk ofmedication problems, com-
puter-generated care suggested and actioned by a physician, elec-
tronic notification systems about dose changes, drug interventions
and follow-up, and educational interventions on drug use aimed
at physicians to improve drug prescriptions.
Organisational interventions
Examples of organisational interventions included medication re-
views by pharmacists, nurses or physicians, clinician-led clinics,
and home visits by clinicians.
Structural interventions
Structural interventions included the organisation of quality mon-
itoring services. Structural approaches included social, economic,
and political interventions that could improve public health out-
comes by increasing the willingness and ability of individuals to
practice prevention. An example of the latter would be the in-
troduction of financial incentives to healthcare workers to reduce
medication errors.
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Types of outcome measures
We included studies that addressed preventable medication errors
with the following outcomes. All the outcomes below are included
in Summary of findings for the main comparison and Summary
of findings 2.
Primary outcomes
• Number of hospital admissions (this outcome takes into
account that one patient can have multiple admissions)
• Number of people admitted to hospital (this outcome
reports on the number of people admitted to hospital irrespective
of the number of times they were admitted during the study
period)
Secondary outcomes
• Number of emergency department visits
• Mortality
Search methods for identification of studies
EPOC’s Information Specialist, Paul Miller, developed the search
strategies in consultation with the review authors. The Informa-
tion Specialist searched the Cochrane Database of Systematic Re-
views and the Database of Abstracts of Reviews of Effects (DARE)
for related systematic reviews, and the databases listed below for
primary studies.
Electronic searches
We searched the following databases on 4 October 2016.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 9), in the Cochrane Library.
• MEDLINE Ovid (including epub ahead of print, in-process
and other non-indexed citations) (1946 to 4 October 2016).
• Embase, Ovid (1974 to 3 October 2016).
• Health Technology Assessment Database (NHSEED; 2015,
Issue 2), in the Cochrane Library.
• NHS Economic Evaluation Database (NHSEED; 2015,
Issue 2), in the Cochrane Library.
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; 1981 to 4 October 2016).
Search strategies are comprised of keywords and controlled vocab-
ulary terms. We applied no language or time limits. We searched
all databases from database start date to date of search. All search
strategies used are provided in Appendix 2.
Searching other resources
Grey literature
On 4October 2016 we conducted a grey literature search to iden-
tify studies not indexed in the databases listed above. Sources in-
cluded the sites listed below. We documented additional sources,
if any, in the review.
• Open Grey (opengrey.eu).
• Grey Literature Report (New York Academy of Medicine) (
greylit.org).
• Agency for Healthcare Research and Quality (AHRQ) (
ahrq.gov).
• Joanna Briggs Institute (joannabriggs.edu.au).
• National Institute for Health and Care Excellence (NICE) (
nice.org.uk).
Trial registries
We searched the following trial registries on 4 October 2016.
• International Clinical Trials Registry Platform (ICTRP),
Word Health Organization (WHO) (who.int/ictrp).
• ClinicalTrials.gov, US National Institutes of Health (NIH)
(clinicaltrials.gov).
We undertook the following.
• Screened individual journals and conference proceedings
(e.g. handsearch).
• Reviewed reference lists of all included studies, relevant
systematic reviews/primary studies/other publications.
• Contacted authors of relevant studies or reviews to clarify
reported published information/seek unpublished results/data.
• Contacted researchers with expertise relevant to the review
topic/EPOC interventions.
• Conducted cited reference searches for all included studies
in citations indexes.
Data collection and analysis
Selection of studies
Three review authors (HK, HC and BB) independently screened
the titles and abstracts to assess studies against the inclusion cri-
teria. We obtained full-text copies of all papers considered to be
of potential relevance and we contacted first authors of studies for
clarification, where necessary. We resolved disagreements about
relevance by discussion between the review authors. We entered all
included studies in Review Manager 5 software (Review Manager
2014).
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Data extraction and management
Three review authors (HK,HCandBB) independently completed
data extraction using a customised version of the EPOC data col-
lection checklist (EPOC 2017a). All three review authors met fre-
quently to discuss progress, with discrepancies resolved by dis-
cussion between the review authors. We grouped studies together
on the basis of similar interventions and common outcomes and
used ReviewManager 5 software tomanage and pool data (Review
Manager 2014), as mentioned in chapter 7 of theCochr ane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a). We
documented the selection process in sufficient detail to complete
a PRISMA flow chart (Liberati 2009), and a Characteristics of
excluded studies table.
Assessment of risk of bias in included studies
Three review authors (HK, HC and BB) independently assessed
the risk of bias of all included studies using the criteria described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b). We resolved differences through discussion.
We assessed seven parameters including random sequence gener-
ation, allocation concealment, blinding of participants and out-
come assessors, incomplete outcome data, selective reporting, and
other bias including protection against contamination and publi-
cation bias. We discussed the inclusion of the selected studies in
themeta-analysis based on their risk of bias. We assessed studies on
the basis of having low, unclear or high risk of bias. We included
all trials in the final meta-analysis.
Measures of treatment effect
For each of the primary outcomes listed above, we reported out-
comes for each study in natural units (i.e. number of participants
with an event per total number of participants at follow-up). We
examined funnel plots for evidence of publication bias and anal-
ysed data using Review Manager 5 (Review Manager 2014). We
presented results with 95% confidence intervals (CIs) and esti-
mates for dichotomous data (number of people admitted to hos-
pital) as risk ratios (RRs).
Unit of analysis issues
We examined the methods of analysis of all study types critically.
All randomised trials were appropriately analysed. We analysed
cluster-randomised trials at the same level as the allocation, thereby
avoiding unit-of-analyses errors (Alvarez 2001; Coleman 1999;
Gernant 2016; Kaczorowski 2011; Lapane 2011; Lowrie 2012;
Malet-Larrea 2016; Roberts 2001). Therefore, we did not need to
reanalyse the results and it was appropriate to combine them with
other randomised trials.
Dealing with missing data
We did not exclude any studies from the meta-analysis due to a
differential loss to follow-up or missing data. Most studies had
adequate reporting of the participants in their samples. We were
able to extract all the data needed for analysis from the included
studies. We did not need to contact any study authors for more
information.
Assessment of heterogeneity
Because trials may not have been carried out according to a com-
mon protocol, there were usually variations in participant groups,
clinical settings, concomitant care, etc. Therefore, we assessed het-
erogeneity between trial results. We considered trial data to be het-
erogeneous where the I2 statistic was greater than 40% (Higgins
2003). For analyses, we used the random-effects method. We at-
tempted to explain the differences between studies on the basis of
the characteristics of interventions in the included studies.
Assessment of reporting biases
We carefully assessed all studies for reporting bias. Reporting bias
was especially likely with outcomes that used participant self-re-
ports or self-administered surveys.
Data synthesis
We carried out statistical analysis using Review Manager 5 soft-
ware (Review Manager 2014). We used a random-effects meta-
analysis for combining data due to the clinical and methodolog-
ical heterogeneity between studies. We grouped studies based on
the two main interventions (i.e. professional and organisational).
Where appropriate, we carried out meta-analyses to establish the
effects of interventions onmedication-related hospital admissions,
emergency department visits, and mortality. We found no studies
addressing structural interventions and hence no analysis was un-
dertaken.
’Summary of findings table’ and GRADE
We included two ’Summary of findings’ tables for the main in-
tervention comparisons: ’professional interventions compared to
usual care’ (Summary of findings for the main comparison); and
’organisational interventions compared to usual care’ (Summary
of findings 2). The ’Summary of findings’ tables include the justifi-
cation for our decisions to downgrade or upgrade the evidence for
an outcome, along with comments to help the reader understand
the process. We included the following outcomes in the ’Sum-
mary of findings’ tables: number of hospital admissions, number
of people admitted to hospital, number of emergency department
visits, and mortality.
Three review authors (HK, HC and BB) used the GRADE tool to
independently judge the certainty of the evidence (high, moder-
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ate, low, and very low) with respect to five criteria (risk of bias, in-
consistency, indirectness, imprecision, and publication bias), with
disagreements resolved through discussion (Guyatt 2008). We
used methods and recommendations described in Section 8.5 and
Chapter 11 of the Cochrane Handbook for Systematic Reviews of
interventions and GRADEpro GDT software (GRADE pro GDT
2015; Higgins 2011b; Schünemann 2011). In addition, we used
the EPOCworksheets to write plain language statements to report
these findings in the review (EPOC 2017b).
Subgroup analysis and investigation of heterogeneity
We conducted the analyses based on the types of interventions
(professional, organisational, structural) as described by Deeks
2011. We undertook analyses for the following interventions.
1. Professional interventions, such as provision of educational
interventions for practitioners or participants.
2. Organisational interventions, including revision of
professional roles (e.g. nurse- or pharmacist-led chronic disease
clinics, nurse prescribing) and clinical multidisciplinary teams
(e.g. pharmacist-managed medication reviews).
We found no studies addressing structural interventions and there-
fore, we did not include this type of intervention in our review.
There was no other subgroup analysis undertaken in the review.
Sensitivity analysis
We used a sensitivity analysis to explore the influence of the fol-
lowing on effect size: repeating the analysis; and excluding any
high risk of bias studies to see how they influenced the results.
We did this in order to help understand whether the results of the
review are robust.
R E S U L T S
Description of studies
Results of the search
Searches of the main electronic databases led to identification of
14,604 titles. A search of the grey literature and of trial registries
yielded a total of five articles that did not make it in the final
included studies. Handsearching of the references listed did not
yield new studies.
We identified a total of 11,019 references after removal of du-
plicates. From reading titles and abstracts, we eliminated 10,960
as being not relevant to the review. Reasons for exclusions in-
cluded irrelevant interventions, study designs and populations (i.e.
not primary care settings). We obtained full papers for 89 refer-
ences. From these 89 papers, we excluded 59 papers for reasons
such as study design, study reported elsewhere and study not con-
ducted in a primary care setting, irrelevant outcomes and proto-
cols (see Characteristics of excluded studies). We included a total
of 30 papers reporting on 30 trials (see Characteristics of included
studies). We have provided an overview of the selection process in
a PRISMA flow diagram, Figure 1 (Liberati 2009).
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Figure 1. Study flow diagram
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Included studies
Method (design)
We included a total of 30 studies (169,969 participants) in this
review. Four studies addressed professional interventions (8266
participants) and 26 studies described organisational interven-
tions (161,703 participants). Overall, there were eight cluster-
randomised trials (Alvarez 2001; Coleman 1999; Gernant 2016;
Kaczorowski 2011; Lapane 2011; Lowrie 2012; Malet-Larrea
2016; Roberts 2001), and 22 randomised trials (Bernsten 2001;
Campins 2016; Frankenthal 2014;Garcia-Gollarte 2014;Gurwitz
2014; Hawes 2014; Holland 2005; Ibrahim 2013; Korajkic 2011;
Krska 2001; Lenaghan 2007;Malone 2000;Moertl 2009;Murray
2004; Nabagiez 2013; Okamoto 2001; Olesen 2014; Pai 2009;
Rytter 2010; Triller 2007; Zermansky 2001; Zermansky 2006.
They all ranged from three months to 4.7 years of follow-up.
A full description of the interventions of each study is included
in the ’Characteristics of included studies’, Table 1 and Table 2.
All cluster-randomised trials were appropriately analysed. Alvarez
2001 reported randomisation at the pharmacy level. They used
adjusted Pearson’s Chi2 to compare means. Coleman 1999 used
statistical techniques that accounted for potential within-practice
correlation that results from randomisation of practices. For con-
tinuous variables, they used a mixed model analysis of covariance
and regression analysis and for binary values, they used generalised
estimating equations. They derived P values from a t-distribution
rather than a normal distribution. Gernant 2016 used a multivari-
able logistic regression model using generalised estimating equa-
tions to examine the effect of the intervention on the probability
of 60-day all-cause emergency department utilisation. The anal-
ysis was approved by the Purdue University Institutional Review
Board. Kaczorowski 2011 fitted linear regression models by using
the Poisson distribution. Lapane 2011 analysed their results using
a Poisson regression model and accounted for the cluster trial de-
sign to provide estimates adjusted for potential confounders. In
contrast, Lowrie 2012 compared the main outcomes between the
intervention and control groups using a Cox proportional hazards
frailty model, which accounted for the cluster-randomisation de-
sign. Malet-Larrea 2016 included a random intercept for pharma-
cies nested within a group, to account for clustering of participants
within pharmacies, and was adjusted by covariate that could affect
hospital admissions (age, gender and number of health problems).
Differences between groups in hospital costs were analysed by hos-
pital admission and by participant, and the latter ones adjusted by
analysis of covariance (ANCOVA) for the number of health prob-
lems. Roberts 2001 used robust variance estimation techniques
(SUDAAN2012), in which the effect of clustering within nursing
homes on the variance was accounted for.
Participants and study setting
There is a great deal of diversity in types of professionals in-
volved and where the studies occurred. However, most (61%)
of the interventions were conducted by pharmacists or a com-
bination of pharmacists and medical doctors. The studies took
place in many different countries; 65% took place in either
the USA or the UK. The study settings included general prac-
tices (Coleman 1999; Gurwitz 2014; Krska 2001; Lowrie 2012;
Murray 2004; Zermansky 2001), community pharmacies (Alvarez
2001; Bernsten 2001;Malet-Larrea 2016), patient homes or com-
munity settings (Campins 2016; Gernant 2016; Kaczorowski
2011; Holland 2005; Ibrahim 2013; Lenaghan 2007; Olesen
2014; Rytter 2010; Triller 2007), outpatient clinics (Hawes 2014;
Korajkic 2011; Malone 2000; Moertl 2009; Okamoto 2001; Pai
2009), and aged care facilities (Frankenthal 2014; Garcia-Gollarte
2014; Lapane 2011; Roberts 2001; Triller 2007; Zermansky
2006).
Interventions
We included a total of 30 studies (169,969 participants) in this
review.
Four studies (8266participants) reported onprofessional interven-
tions (Garcia-Gollarte 2014;Gurwitz 2014; Lapane 2011;Murray
2004). Two of these studies (3889 participants) reported on the
number of hospital admissions (Lapane 2011; Murray 2004), one
study (3661 participants) reported on the number of people ad-
mitted to hospital (Gurwitz 2014), one study (3538 participants)
reported on mortality (Lapane 2011), and two studies (1067 par-
ticipants) reported on the number of emergency department visits
(Garcia-Gollarte 2014; Murray 2004).
A total of 26 studies (161,703 participants) reported on organ-
isational interventions (Alvarez 2001; Bernsten 2001; Campins
2016; Coleman 1999; Frankenthal 2014; Gernant 2016; Hawes
2014; Holland 2005; Ibrahim 2013; Kaczorowski 2011; Korajkic
2011; Krska 2001; Lenaghan 2007; Lowrie 2012; Malet-Larrea
2016; Malone 2000; Moertl 2009; Nabagiez 2013; Okamoto
2001; Olesen 2014; Pai 2009; Roberts 2001; Rytter 2010;
Triller 2007; Zermansky 2001; Zermansky 2006). Eleven tri-
als (6203 participants) reported on number of hospital ad-
missions (Coleman 1999; Holland 2005; Ibrahim 2013; Krska
2001; Lenaghan 2007; Lowrie 2012; Malone 2000; Moertl 2009;
Nabagiez 2013; Okamoto 2001; Rytter 2010). A total of 13 stud-
ies (152,237 participants) reported on the number of people ad-
mitted to hospital (Alvarez 2001; Bernsten 2001; Campins 2016;
Frankenthal 2014; Hawes 2014; Kaczorowski 2011; Korajkic
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2011; Malet-Larrea 2016; Nabagiez 2013; Olesen 2014; Triller
2007;Zermansky 2001;Zermansky 2006). Five studies (1819par-
ticipants) reported on emergency department visits (Alvarez 2001;
Coleman 1999; Gernant 2016; Hawes 2014; Ibrahim 2013), and
12 studies (154,962 participants) reported on mortality (Campins
2016; Holland 2005; Kaczorowski 2011; Lenaghan 2007; Lowrie
2012; Moertl 2009; Olesen 2014; Pai 2009; Roberts 2001; Triller
2007; Zermansky 2001; Zermansky 2006).
We did not find any studies that fitted the criteria of structural
interventions. This was in concordance with the EPOC taxonomy
of interventions (Appendix 1).
The ’Characteristics of included studies’ tables provide a summary
of the interventions and comparisons. The interventions varied.
Professional interventions included the use of health information
technology to identify people at risk ofmedication problems: com-
puter-generated care suggested and actioned by physicians; elec-
tronic notification system about dose changes, drug interventions
and follow-up; and educational interventions on drug use aimed
at physicians to improve drug prescriptions. Organisational inter-
ventions included medication reviews by pharmacists, nurses or
physicians, clinician-led clinics and home visits by clinicians.
Outcomes
The primary outcomes were number of hospital admissions and
number of people admitted to hospital. A total of 13 studies
(10,092 participants) reported on number of hospital admis-
sions (Coleman 1999; Holland 2005; Ibrahim 2013; Krska 2001;
Lapane 2011; Lenaghan 2007; Lowrie 2012;Malone 2000;Moertl
2009; Murray 2004; Nabagiez 2013; Okamoto 2001; Rytter
2010); and 14 studies (155,898 participants) reported on num-
ber of people admitted to hospital (Alvarez 2001; Bernsten 2001;
Campins 2016; Frankenthal 2014; Kaczorowski 2011; Gurwitz
2014; Hawes 2014; Korajkic 2011; Malet-Larrea 2016; Nabagiez
2013; Olesen 2014; Triller 2007; Zermansky 2001; Zermansky
2006).
The secondary outcomes were the number of emergency depart-
ment visits and mortality. Seven studies (2886 participants) re-
ported on the number of emergency department visits (Alvarez
2001; Coleman 1999; Garcia-Gollarte 2014; Gernant 2016;
Hawes 2014; Ibrahim 2013; Murray 2004); and 13 studies
(158,500 participants) reported on mortality (Campins 2016;
Holland 2005; Kaczorowski 2011; Lenaghan 2007; Lapane 2011;
Lowrie 2012;Moertl 2009; Olesen 2014; Pai 2009; Roberts 2001;
Triller 2007; Zermansky 2001; Zermansky 2006).
Excluded studies
We have summarised the 59 excluded studies, with the reasons
for their exclusion in the ’Characteristics of excluded studies’ ta-
ble. We excluded studies with an unsuitable design (Furniss 2000;
Graffen 2004; Hugtenburg 2009; Lee 1996; Leendertse 2011;
Leendertse 2013; Mills 2001; Montero-Balosa 2016; Moreno
2016; Ni 2016; Safran 1993; Saltzberg 2011). Other reasons for
exclusion were studies that did not occur in a primary care setting
(Alassaad 2014; Barker 2012; Bell 2016; Bonnet-Zamponi 2013;
Briggs 2015; Gorgas 2012; Hanlon 1996; Keane 2014; Naunton
2003;Neven2016; Xin 2014); results reported elsewhere (Sturgess
2003); data for outcomes not available (Cowper 1998; Knowlton
1994; Liu 2010; Yuan 2003); interventions not relevant to the
review (Al-Arifi 2014; Benard-Laribiere 2015; Carrington 2013;
Fredericks 2013; Pinnock 2013); outcomes not relevant to the re-
view (Barker 2016; Barnes 2014; Basheti 2016; Billington 2015;
Clyne 2015; Clyne 2016; Dhalla 2014; Geurts 2016; Guthrie
2016; Hallsworth 2016; Huiskes 2014; Malin 2016; Perula 2014;
Setter 2009; Sinnott 2015; Wolf 2015); and 10 studies were pub-
lished protocols (Alicic 2016; Bhatt 2014; Clyne 2013; Desveaux
2016; Elliott 2014; Forster 2015; Phung 2013; Przytula 2015;
Stingl 2016;Wooster 2016), as described in the PRISMA diagram
(see Figure 1).
Risk of bias in included studies
We have presented details of risk of bias in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
A total of 21 studies reported adequate sequence generation
(Bernsten 2001; Campins 2016; Frankenthal 2014; Garcia-
Gollarte 2014; Gernant 2016; Gurwitz 2014; Hawes 2014;
Holland 2005; Kaczorowski 2011; Krska 2001; Lowrie 2012;
Malet-Larrea 2016; Malone 2000; Okamoto 2001; Olesen 2014;
Pai 2009; Roberts 2001; Rytter 2010; Triller 2007; Zermansky
2001; Zermansky 2006); and 18 reported adequate conceal-
ment of allocation (Bernsten 2001; Campins 2016; Frankenthal
2014; Gernant 2016; Gurwitz 2014; Hawes 2014; Holland 2005;
Kaczorowski 2011; Lenaghan 2007; Lowrie 2012; Malone 2000;
Malet-Larrea 2016;Murray 2004; Pai 2009; Roberts 2001; Rytter
2010; Triller 2007; Zermansky 2001).
Blinding
Thirteen studies adequately blinded measurements of partici-
pants and personnel delivering the intervention (Bernsten 2001;
Campins 2016; Coleman 1999; Garcia-Gollarte 2014; Gernant
2016; Gurwitz 2014; Kaczorowski 2011; Krska 2001; Lapane
2011; Lowrie 2012;Murray 2004; Pai 2009;Triller 2007), whereas
adequate blinding of outcome assessment was undertaken in
19 studies (Bernsten 2001; Campins 2016; Frankenthal 2014;
Garcia-Gollarte2014;Gurwitz 2014;Hawes 2014;Holland2005;
Kaczorowski 2011; Korajkic 2011; Krska 2001; Malet-Larrea
2016; Murray 2004; Nabagiez 2013; Olesen 2014; Pai 2009;
Roberts 2001; Rytter 2010; Triller 2007; Zermansky 2006).
Eleven studies reported an unclear risk of detection bias (Alvarez
2001; Coleman 1999; Gernant 2016; Ibrahim 2013; Lapane
2011; Lenaghan 2007; Lowrie 2012; Malone 2000; Moertl 2009;
Okamoto 2001; Zermansky 2001).
Incomplete outcome data
A total of five studies had high risk of attrition bias (Alvarez
2001; Bernsten 2001; Hawes 2014; Nabagiez 2013; Pai 2009).
Twenty-two studies adequately addressed problems with incom-
plete outcomes (Campins 2016; Frankenthal 2014;Gernant2016;
Gurwitz 2014; Holland 2005; Ibrahim 2013; Kaczorowski 2011;
Korajkic 2011; Krska 2001; Lapane 2011; Lenaghan 2007; Lowrie
2012; Malet-Larrea 2016; Malone 2000; Moertl 2009; Okamoto
2001; Olesen 2014; Roberts 2001; Rytter 2010; Triller 2007;
Zermansky 2001; Zermansky 2006), that is, these studies reported
complete outcome data or they replaced any missing outcome data
using a recognised statistical method, such as last observation car-
ried forward with participants remaining in the group to which
they had been allocated.
Selective reporting
There was no selective reporting in the included studies. All studies
assessed their predefined primary and secondary outcomes.
Other potential sources of bias
Other potential sources of bias included protection against con-
tamination, publication bias and other bias.
Protection against contamination bias
A total of 12 studies adequately protected against contamination
bias (Bernsten 2001; Coleman1999;Gernant 2016; Lapane 2011;
Lowrie 2012; Murray 2004; Nabagiez 2013; Olesen 2014; Pai
2009; Roberts 2001; Rytter 2010; Triller 2007); whereas 16 stud-
ies, had unclear risk of protection against contamination (Alvarez
2001; Campins 2016; Frankenthal 2014; Gurwitz 2014; Hawes
2014; Holland 2005; Ibrahim 2013; Kaczorowski 2011; Korajkic
2011; Lenaghan 2007; Malet-Larrea 2016; Malone 2000; Moertl
2009; Okamoto 2001; Zermansky 2001; Zermansky 2006), and
two studies clearly did not adequately protect against contami-
nation bias (Garcia-Gollarte 2014; Krska 2001). Contamination
bias occurs when members of the control group are inadvertently
exposed to the intervention, thus potentially minimising the dif-
ference in outcomes between the two groups (Higgins 2011b).
Publication bias
Publication bias did not take place amongst the professional in-
terventions due to the small number of studies included in the
review. We have shown funnel plots of the main outcomes for the
organisational interventions as follows: number of hospital admis-
sions (Figure 3); number of people admitted to hospital (Figure 4);
number of emergency department visits (Figure 5); and mortality
(Figure 6). There was no evidence of publication bias.
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Figure 3. Funnel plot of comparison: 2 Organisational interventions, outcome: 2.1 Number of hospital
admissions
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Figure 4. Funnel plot of comparison: 2 Organisational interventions, outcome: 2.2 Number of people
admitted to hospital
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Figure 5. Funnel plot of comparison: 2 Organisational interventions, outcome: 2.3 Number of emergency
department visits
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Figure 6. Funnel plot of comparison: 2 Organisational interventions, outcome: 2.4 Mortality
Other bias
A total of 22 studies had an unclear risk of ’other bias’ (Bernsten
2001; Campins 2016; Coleman 1999; Gernant 2016; Gurwitz
2014; Hawes 2014; Ibrahim 2013; Korajkic 2011; Krska 2001;
Lapane 2011; Lowrie 2012; Malet-Larrea 2016; Malone 2000;
Murray 2004; Nabagiez 2013; Okamoto 2001; Olesen 2014; Pai
2009; Roberts 2001; Rytter 2010; Zermansky 2001; Zermansky
2006). Seven studies had a high risk of ’other bias’ (Alvarez 2001;
Frankenthal 2014; Garcia-Gollarte 2014; Kaczorowski 2011;
Lenaghan 2007; Moertl 2009; Triller 2007), while only one study
had a low risk of ’other bias’ (Holland 2005). Other biases in-
cluded inappropriate administration of the intervention, such as
the method of training used to deliver the intervention or level
of knowledge of the health professional delivering the interven-
tion. Short length of the intervention was a bias in some studies
(Kaczorowski 2011; Triller 2007), with the level of knowledge of
the pharmacist or health professional delivering the intervention a
bias in other studies. For example, in the study by Lenaghan 2007,
research was carried out in one rural general practice with a single
experienced review pharmacist, which may have had a bearing on
the generalisability of the results.
In Bernsten 2001, one aspect of the study that was not rigorously
controlled was the training of participating pharmacists. A study
manual was provided to each participating pharmacist, followed
by a one-day training session. Further training was provided in
individual countries; however, the extent of this was driven by
available resources. Other biases include small sample sizes in the
intervention arms; with 48 participants in Moertl 2009 and 77
participants in Triller 2007, and poor pharmacist-prescriber com-
munication, which may have reduced the efficacy of the interven-
tion (Triller 2007). Alvarez 2001 did not report on any pre-inter-
vention data for most of the outcome measures. Garcia-Gollarte
2014 had a short intervention of a six-month period and a short
follow-up of threemonths. Frankenthal 2014 conducted the study
in only one geriatric centre.
There was a total of eight cluster-randomised studies included
in the review (Alvarez 2001; Coleman 1999; Gernant 2016;
Kaczorowski 2011; Lapane 2011; Lowrie 2012; Malet-Larrea
2016; Roberts 2001). Cluster-randomised studies include other
potential biases such as recruitment bias and complete loss of a
cluster in a trial. The extent of this type of bias was not fully re-
ported and therefore we considered it under this section.
Effects of interventions
19Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
See: Summary of findings for themain comparison Professional
interventions compared to standard/usual care for prevention
of medication errors; Summary of findings 2 Organisational
interventions compared to standard/usual care for prevention of
medication errors
Professional interventions
We performed a meta-analysis on the number of hospital admis-
sions and the number of emergency department visits, as theywere
the only outcomes reported by more than one study. We have pre-
sented effect estimates and certainty of evidence for each outcome
in Summary of findings for the main comparison (see Appendix
3 for the full GRADE evidence profile). We obtained all reported
data from the published papers.
Primary outcomes
Wemeasured hospital admissions as either the number of hospital
admissions or the number of people admitted to hospitals.
1. Number of hospital admissions
Two studies (3889 participants) reported on the number of hospi-
tal admissions (Lapane 2011; Murray 2004). Overall, professional
interventions in health information technology to identify people
at risk of medication problems in the case of Lapane 2011, or the
computer-generated care suggested and actioned by the physician
described by Murray 2004, reported an increase in the number of
hospital admissions, but the 95% confidence interval (CI) indi-
cates that it probably makes little or no difference (risk ratio (RR)
1.24, 95% CI 0.79 to 1.96; moderate-certainty evidence). There
was no significant heterogeneity (I2 = 0%, P = 0.44) across the
studies, as shown inSummary of findings for themain comparison.
2. Number of people admitted to hospital
One study (3661 participants) reported on number of people ad-
mitted to hospital (Gurwitz 2014). The study authors found that
the intervention, which included an electronic notification system
about dose changes, drug interactions, and follow-up, made little
or no difference to the number of people admitted to hospital (ad-
justed RR 0.99, 95% CI 0.92 to 1.06; high-certainty evidence).
Secondary outcomes
1. Number of emergency department visits
Two studies (1067 participants) reported on this outcome (Garcia-
Gollarte 2014; Murray 2004). Garcia-Gollarte 2014 described an
educational intervention on drug use aimed at physicians to im-
prove drug prescriptions. Murray 2004 described an intervention
including computer-generated care suggested and actioned by the
physician. Both professional interventions described by the study
authors may make little or no difference to the number of emer-
gency department visits (adjusted RR 0.71, 95% CI 0.50 to 1.02;
low-certainty evidence). There was no significant heterogeneity
among the two studies (I2 = 0%, P = 0.64).
2. Mortality
One study (3538 participants) reported on the number of deaths
(Lapane 2011). The health information technology to identify
people at risk of medication problems probably makes little or
no difference to the number of deaths in the study population
(adjusted RR 0.98, 95% CI 0.82 to 1.17; moderate-certainty ev-
idence).
Organisational interventions
We performed a meta-analysis on the number of hospital admis-
sions, number of people admitted to hospital, the number of emer-
gency department visits, and mortality. We have presented effect
estimates and certainty of evidence for each outcome in Summary
of findings 2 (see Appendix 4 for the full GRADE evidence pro-
file). We obtained all reported data from the published papers.
Primary outcome
1. Number of hospital admissions
Eleven trials (6203 participants) reported on the number of hos-
pital admissions (Coleman 1999; Holland 2005; Ibrahim 2013;
Krska 2001; Lenaghan 2007; Lowrie 2012; Malone 2000; Moertl
2009; Nabagiez 2013; Okamoto 2001; Rytter 2010). The organ-
isational interventions included medication reviews by pharma-
cists, nurses or physicians, clinician-led clinics, and home visits by
clinicians. Most interventions included optimisation of the med-
ications that participants were taking or home visits by healthcare
practitioners, or both. Overall, it is uncertain whether organisa-
tional interventions (which included pharmaceutical care or med-
ication reviews by a doctor, a pharmacist, or a nurse, home visits,
educational interventions with a pharmacist) reduce the number
of hospital admissions (adjusted RR 0.85, 95% CI 0.71 to 1.03;
very low-certainty evidence. There was significant heterogeneity
(I2 = 75%, P < 0.0001) across the studies (Analysis 2.1). The di-
rection of the effect was consistent in 10 out of 11 trials. Holland
2005 reported an increase in the total number of hospital admis-
sions (adjusted RR 1.31, 95% CI 1.13 to 1.50; based on very low-
certainty evidence. The study authors explained these findings by
indicating that their study was not statistically powered to detect
changes in hospital admissions and new admissions. The study au-
thors explained the unusual increase in hospital admissions among
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participants by concluding that the participants were better in-
formed about adverse events through the pharmacist intervention,
and this promoted help-seeking behaviour, which resulted in an
admission.
We undertook a sensitivity analysis by removing studies at high
risk of bias (Holland 2005; Krska 2001; Moertl 2009; Nabagiez
2013), and again it is uncertain whether organisational interven-
tions (which included pharmacist home visits, pharmaceutical care
plan, home-based nurse care and home visits by physician assis-
tants) reduce the number of hospital admissions (adjusted RR
0.86, 95% CI 0.72 to 1.03). Ibrahim 2013, Moertl 2009 and
Rytter 2010 showed a reduction in hospital admissions with a rela-
tively narrow confidence interval: adjusted RR 0.40, 95% CI 0.22
to 0.74 (Ibrahim 2013); RR 0.38, 95% CI 0.19 to 0.72 (Moertl
2009); and RR 0.76, 95%CI 0.61 to 0.95 (Rytter 2010), in favour
of the interventions. These three studies were characterised by fre-
quent follow-up by the clinical pharmacists. In the case of Ibrahim
2013, there was a three-month follow-up and a once-a-week tele-
phone conversation; Moertl 2009 had frequent follow-up by the
clinical pharmacists at three, six, nine, and 12 months; and Rytter
2010 also had three follow-up contacts by GPs and district nurses.
2. Number of people admitted to hospital
A total of 13 studies (152,237 participants) reported on the num-
ber of people admitted to hospital (Alvarez 2001; Bernsten 2001;
Campins 2016; Frankenthal 2014; Hawes 2014; Kaczorowski
2011; Korajkic 2011; Malet-Larrea 2016; Nabagiez 2013; Olesen
2014; Triller 2007; Zermansky 2001; Zermansky 2006). Most
of the organisational interventions described included medication
reviews by pharmacists, nurses or physicians, clinician-led clinics,
and home visits by clinicians.Overall, organisational interventions
may make little or no difference to the total number of people
admitted to hospital in favour of the intervention group compared
with the control group (adjusted RR 0.92, 95% CI 0.86 to 0.99;
low-certainty evidence) with significant heterogeneity (I2 = 47%,
P = 0.03). Three studies showed that the organisational interven-
tions reduced the total number of people admitted to hospital, as
the RRwas less than 1 (Bernsten 2001;Hawes 2014;Malet-Larrea
2016).
We undertook a sensitivity analysis by removing studies at high
risk of bias (Alvarez 2001; Bernsten 2001; Frankenthal 2014;
Hawes 2014; Kaczorowski 2011; Malet-Larrea 2016; Nabagiez
2013; Triller 2007), and again, the intervention made little or no
difference to the number of people admitted to hospital (adjusted
RR 0.98, 95% CI 0.85 to 1.13) with low, non-significant hetero-
geneity between studies (I2 = 28%, P = 0.23).
Secondary outcomes
1. Number of emergency department visits
Five studies (1819 participants) reported on emergency depart-
ment visits (Alvarez 2001; Coleman 1999; Gernant 2016; Hawes
2014; Ibrahim 2013). Overall, it is uncertain whether organisa-
tional interventions including medication reviews by pharmacists,
nurses or physicians, clinician-led clinics, and home visits by clin-
icians reduce emergency department visits in favour of the in-
tervention group compared with the control group (adjusted RR
0.75, 95% CI 0.49 to 1.15; very low-certainty evidence). Please
refer to Summary of findings 2.
There was also significant heterogeneity between the studies (I2 =
73%, P = 0.005). We undertook a sensitivity analysis by removing
studies at high risk of bias (Alvarez 2001; Hawes 2014). Phar-
maceutical care and care transition clinic interventions may make
little or no difference in emergency department visits (adjusted
RR 0.68, 95% CI 0.37 to 1.27) with significant heterogeneity
between studies (I2 = 79%, P = 0.009).
All studies showedwide confidence intervals, and althoughAlvarez
2001 showed an increase in the number of emergency department
visits in favour of the intervention, this study had high risk of bias
as there was a high proportion of incomplete data in the outcomes
measured.
2. Mortality
A total of 12 studies (154,962 participants) reported on mortal-
ity (Campins 2016; Holland 2005; Kaczorowski 2011; Lenaghan
2007; Lowrie 2012;Moertl 2009; Olesen 2014; Pai 2009; Roberts
2001; Triller 2007; Zermansky 2001; Zermansky 2006). Over-
all, it is uncertain whether organisational interventions, which in-
cluded medication reviews by pharmacists, nurses or physicians,
clinician-led clinics, and home visits by clinicians reduce mortal-
ity in favour of the intervention group (adjusted RR 0.94, 95%
CI 0.85 to 1.03; very low-certainty evidence) with non-significant
heterogeneity (I2 = 37%, P = 0.10). Please refer to Summary of
findings 2.
We undertook sensitivity analysis by removing studies at high
risk of bias (Holland 2005; Kaczorowski 2011; Lenaghan 2007;
Moertl 2009; Olesen 2014; Roberts 2001), and we found that
interventions addressing home visits by pharmacists, educational
sessions to assess cardiovascular risk, medication reviews, home-
based nurse care, and nurse education probably made little or no
difference to mortality (adjusted RR 1.02, 95% CI 90 to 1.17).
There was no significant heterogeneity between studies after the
removal of the six studies (I2 = 0%, P = 0.45).
Structural interventions
We did not find any studies that fitted the criteria of structural
interventions.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Organisational interventions compared to standard/usual care for prevention of medication errors
Patient or population: adults receiving medicat ion in primary care
Setting: primary care
Intervention: organisat ional intervent ions (provision of pharmaceut ical care, medicat ion reviews, follow-up visits by a healthcare professional including a pharmacist , nurse
or physician)
Comparison: standard/ usual care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard/
usual care
Risk with organisa-
tional interventions
Number of hospital ad-
missions
Study populat ion RR 0.85
(0.71 to 1.03)
6203
(11 RTs)
⊕©©©
Very low1,2,3
Some studies had un-
clear risk of bias (selec-
t ion and attrit ion), high
heterogeneity and wide
conf idence intervals
274 per 1000 233 per 1000
(194 to 282)
Number of people ad-
mit ted to hospital
Study populat ion RR 0.92
(0.86 to 0.99)
152,237
(13 RTs)
⊕⊕©©
Low1,3
Some studies had un-
clear risk of bias (se-
lect ion, attrit ion and
performance bias) and
wide conf idence inter-
vals
13 per 1000 13 per 1000
(11 to 14)
Number of emergency
department visits
Study populat ion RR 0.75
(0.49 to 1.15)
1819
(5 RTs)
⊕©©©
Very low1,2,3
Studies had unclear risk
of bias (select ion, per-
formance and attrit ion
bias), high heterogene-
ity and wide conf idence
intervals
234 per 1000 176 per 1000
(115 to 269)
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Mortality Study populat ion RR 0.94
(0.85 to 1.03)
154,962
(12 RTs)
⊕©©©
Very low3,4
Studies had high risk of
select ion, attrit ion and
performance bias and
wide conf idence inter-
vals
50 per 1000 47 per 1000
(43 to 52)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io; RT : randomised trial.
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1We downgraded one level for unclear risk of bias (select ion and attrit ion bias).
2We downgraded one level for inconsistency (high heterogeneity across studies).
3We downgraded one level for imprecision.
4We downgraded two levels for high risk of bias (select ion, performance and attrit ion bias).
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D I S C U S S I O N
Summary of main results
The studies included in this Cochrane Review showed that, based
onmoderate- and low-certainty evidence, interventions in primary
care for reducing preventable medication errors probably make lit-
tle or no difference to the number of people admitted to hospital
or the number of hospitalisations, emergency department visits,
or mortality. Most of the interventions took place in the UK and
theUSA; studies undertaken in high-income countries with disad-
vantaged populations, and in low- and middle-income countries,
were underrepresented. This might affect the generalisability of
the results. We undertook sensitivity analysis by removing studies
at high risk of bias and detecting whether there was any difference
on the overall effect size. Overall, there is no evidence of an effect
in any of the outcomes.
Overall completeness and applicability of
evidence
The types of interventions included in this review were based
on the taxonomy of interventions developed by Cochrane EPOC
(Appendix 1); four studies used professional interventions and 26
studies used organisational interventions. The professional inter-
ventions included the use of health information technology to
identify people at risk of medication problems: computer-gener-
ated care suggested and actioned by a physician; electronic notifi-
cation systems about dose changes, drug interventions and follow-
up; and educational interventions on drug use aimed at physicians
to improve drug prescriptions. Organisational interventions con-
sisted of medication reviews by pharmacists, nurses or physicians,
clinician-led clinics and home visits by clinicians.
The interventions described in the reviewwere complex and gener-
ally multifaceted, which resulted in significant heterogeneity. The
variation in heterogeneity in the pooled estimates means that our
results should be treated cautiously as the interventions may not
have worked consistently across all studies due to differences in
how the interventions were provided, background practice, set-
ting, healthcare system, or delivery of the interventions. Another
potential limitation is the quality of the studies. The methods
sections of the studies provided varying levels of detail on how
complex interventions were developed, the design of the trials or
how staff were trained to deliver the interventions. There was also
evidence of potential bias in some studies, with only 18 studies
reporting adequate concealment of allocation and only 12 stud-
ies reporting appropriate protection from contamination, both of
whichmay have influenced the overall effect estimate and the over-
all pooled estimate.
Certainty of the evidence
The certainty of the evidence obtained from the ’Summary of find-
ings’ tables using the GRADE system highlights the very low to
high certainty of the evidence reported by the studies. The primary
outcomes of number of hospital admissions and number of people
admitted to hospital were reported to have very low- to high-cer-
tainty evidence, respectively. Mortality was reported in 13 studies
(1 study involving professional interventions, moderate-certainty
evidence; and 12 studies involving organisational interventions,
very low-certainty evidence), with the main type of biases being
detection and performance bias. We considered studies reporting
on emergency department visits to have low-certainty evidence for
professional interventions and very low-certainty evidence for or-
ganisational interventions using the GRADE system, due to study
design and heterogeneity. Further research and better study de-
signs are likely to change the overall estimate reported using these
outcomes.
The Methods sections provided few details about study method-
ology and how complex interventions were delivered. The overall
quality of the evidence presented in this review is either at high
risk or unclear risk of bias. The main limitations were the het-
erogeneity between studies, the imprecision in results due to the
wide confidence intervals amongst studies, unclear selection bias,
performance and detection bias, and attrition bias.
Potential biases in the review process
The number of studies that we were able to combine in the meta-
analysis was somewhat small due to subclassification of the inter-
ventions and because not all studies reported on all the outcomes
of interest mentioned in the review. We did not place any lan-
guage restrictions on the search strategy. The review included one
study written in Spanish (Alvarez 2001). We were able to pool
the data from this study with the help of a Spanish-speaking col-
league. Despite the limited number of studies that were included,
funnel plots of studies reporting the outcomes of interest showed
no apparent publication bias (Figure 3; Figure 4; Figure 5; Figure
6). Another limitation of the review included the definitions of
’pharmaceutical care’ and ’pharmaceutical review’ described in the
studies, which may have led to different interventions. We also
did not consider studies where participants were treated in the
emergency department of hospitals, although we are aware that at
times people could receive treatment in the emergency department
without being admitted to hospital. We will consider these types
of studies in our updated review. Finally, a sensitivity analysis with
a separate comparison of cluster- and individual randomised trials
may have yielded different results, and we will consider including
this in our updated review.
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Agreements and disagreements with other
studies or reviews
Few studies have examined whether the types of interventions that
were investigated in this review lead to reductions in hospital ad-
missions, emergency department visits, or mortality. One of the
few reviews that studied this problem (Royal 2006), found that
pharmacist-led medication reviews were effective in reducing hos-
pital admissions, although restricting the analysis to randomised
trials did not produce a significant benefit.
Previous observational studies addressing similar interventions also
provide limited evidence of their effectiveness. A controlled study
byHugtenburg 2009, which included 37 community pharmacists
and 715 participants, and examined the impact of medication re-
views and participant counselling at discharge from the hospital
by community pharmacists, found that the intervention was not
effective at reducing mortality. Another open controlled study,
conducted by Leendertse 2013, examined the effect of reviewing
medications in primary care by pharmacists. They found that the
intervention did not significantly reduce medication-related hos-
pital admissions. Moreover, a study by Safran 1993 examined the
effect of an electronicmedical record used by physicians to care for
people with HIV on hospitalisation, emergency visits and mortal-
ity. The study authors found that the intervention was significant
for emergency department visits, but not for mortality or hospital-
isations. Our study mirrors these findings in that the interventions
investigated in this review had little or no effect on the number
of people admitted to hospital, number of hospital admissions,
number of emergency department visits, or mortality.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence from this review does not fully support the benefits
of interventions to reduce medication-related preventable errors
with respect to any of the outcomes of interest thatwere reported in
this review. Both professional and organisational interventions had
little or no significant effect on the outcomes of interest. Therefore,
organisations implementing interventions to improve medication
safety in primary care should be aware that the evidence endorsing
these interventions is limited, both in number andmethodological
quality.
Implications for research
Larger studies addressing both professional and organisational in-
terventions and reporting on the number of people admitted to
hospital and emergency department visits are needed before evi-
dence-based recommendations can be made, given that only one
studywith 3661 participants addressing professional interventions
and 13 studies with 8960 participants reported on the number of
people admitted to hospital in primary care following organisa-
tional interventions. Emergency department visits were only re-
ported by two studies (1067 participants) describing professional
interventions and five studies (1819 participants) describing or-
ganisational interventions.
Further, large studies exploring which interventions involving
healthcare professionals (nurse, physician or pharmacist) are likely
to have a beneficial effect in preventing errors in primary care
should also be addressed. Furthermore, longer time frames for in-
terventions and a focus on high risk participants/therapies would
also help. The quality of the studies needs to be improved as the
certainty of the evidence was very low to high. The methods sec-
tions of the studies provided varying levels of detail on how com-
plex interventions were developed, the design of the trials, or how
staff were trained to deliver the interventions. We did not iden-
tify any structural interventions and only four studies used pro-
fessional interventions, so more work needs to be done with these
types of interventions. Most of the studies did not provide details
of what constituted ’usual care’, so this can also be improved in
future studies.
A C K N OW L E D G E M E N T S
The authors would like to thank Brian Serumaga for his work
on earlier versions of the review. In addition, the authors would
like to thank Paul Miller (EPOC Information Specialist) for sup-
port with the search strategies, Emma Tavender and Clare Doo-
ley (EPOC Managing Editors) for their support with the review,
Ignacio Ricci Cabello for his translation of the Spanish article
(Alvarez 2001), Eric Harvey (Peer Reviewer), Luke Vale (EPOC
Economics Editor), Burnard Bernard (EPOC Editor), Christiana
Kartsonaki (EPOC Statistician), Pierre Durieux (EPOC Contact
Editor), and Denise Mitchell (Copy-editor).
National Institute for Health Research (NIHR), via Cochrane In-
frastructure funding to Cochrane Effective Practice and Organi-
sation of Care (EPOC). The views and opinions expressed therein
are those of the authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, National Health Service
(NHS) or the Department of Health.
The Australasian Satellite of Cochrane EPOC is funded by the
Australian Government National Health and Medical Research
Council (NHMRC); it is a partnership between Cochrane EPOC
and Monash University.
25Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Alvarez 2001 {published data only}
Alvarez de Toledo F, Arcos Gonzalez P, Eyaralar Riera T,
Abal Ferrer FF, Dago Martinez A, Cabiedes Miragaya L,
et al. Pharmaceutical care in people who have had acute
coronary episodes (TOMCOR study). Revista Espanola de
Salud Publica 2001;75:375–87.
Bernsten 2001 {published data only}
Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjaer
B, Grundberger E, et al. Improving the well-being of elderly
patients via community pharmacy-based provision of
pharmaceutical care: a multicentre study in seven European
countries. Drugs & Aging 2001;18:63–77.
Campins 2016 {published data only}
Campins L, Serra-Prat M, Gozalo I, Lopez D, Palomera E,
Agusti C, et al. REMEI Group. Randomized controlled
trial of an intervention to improve drug appropriateness in
community-dwelling polymedicated elderly people. Family
Practice 2016;34(1):36–42.
Coleman 1999 {published data only}
Coleman EA, Grothaus LC, Sandhu N, Wagner EH.
Chronic care clinics: a randomized controlled trial of a new
model of primary care for frail older adults. Journal of the
American Geriatrics Society 1999;47:775–83.
Frankenthal 2014 {published data only}
Frankenthal D, Lerman Y, Kalendaryev E, Lerman Y.
Intervention with the screening tool of older persons
potentially inappropriate prescriptions/screening tool to
alert doctors to right treatment criteria in elderly residents
of a chronic geriatric facility: a randomized clinical trial.
Journal of the American Geriatrics Society 2014;62(9):
1658–65.
Garcia-Gollarte 2014 {published data only}
Garcia-Gollarte F, Baleriola-Julvez J, Ferrero-Lopez
I, Cuenllas-Diaz A, Cruz-Jentoft AJ. An educational
intervention on drug use in nursing homes improves health
outcomes resource utilization and reduces inappropriate
drug prescription. Journal of the American Medical Directors
Association 2014;15(12):885–91.
Gernant 2016 {published data only}
Gernant SA, Snyder ME, Jaynes H, Sutherland JM, Zillich
AJ. The effectiveness of pharmacist-provided telephonic
medication therapy management on emergency department
utilization in home health patients. Journal of Pharmacy
Technology 2016;32(5):179–84.
Gurwitz 2014 {published data only}
Gurwitz JH, Field TS, Ogarek J, Tjia J, Cutrona SL,
Harrold LR, et al. An electronic health record-based
intervention to increase follow-up office visits and decrease
rehospitalization in older adults. Journal of the American
Geriatrics Society 2014;62(5):865–71.
Hawes 2014 {published data only}
Hawes EM, Maxwell WD, White SF, Mangun J, Lin
FC. Impact of an outpatient pharmacist intervention on
medication discrepancies and health care resource utilization
in posthospitalization care transitions. Journal of Primary
Care & Community Health 2014;5(1):14–8.
Holland 2005 {published data only}
Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L,
Lipp A, et al. Does home based medication review keep
older people out of hospital? The HOMER randomised
controlled trial. BMJ Open 2005;330:293.
Ibrahim 2013 {published data only}
Ibrahim R, Saber-Ayad M. Continuous outpatient warfarin
counseling and its effects on adherence. Asian Journal of
Pharmaceutical and Clinical Research 2013;6:101–4.
Kaczorowski 2011 {published data only}
Kaczorowski J, Chambers LW, Dolovich L, Paterson JM,
Karwalajtys T, Gierman T, et al. Improving cardiovascular
health at population level: 39 community cluster
randomised trial of cardiovascular health awareness program
(CHAP). BMJ 2011;342:d442.
Korajkic 2011 {published data only}
Korajkic A, Poole SG, MacFarlane LM, Bergin PJ, Dooley
MJ. Impact of a pharmacist intervention on ambulatory
patients with heart failure: a randomised controlled study.
Journal of Pharmacy Practice & Research 2011;41:126–31.
Krska 2001 {published data only}
Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D,
Duffus PRS, et al. Pharmacist-led medication review in
patients over 65: a randomized, controlled trial in primary
care. Age and Ageing 2001;30:205–11.
Lapane 2011 {published data only}
Lapane KL, Hughes CM, Daiello LA, Cameron KA,
Feinberg J. Effect of a pharmacist-led multicomponent
intervention focusing on the medication monitoring phase
to prevent potential adverse drug events in nursing homes.
Journal of the American Geriatrics Society 2011;59:1238–45.
Lenaghan 2007 {published data only}
Lenaghan E, Holland R, Brooks A. Home-based medication
review in a high risk elderly population in primary care--
the POLYMED randomised controlled trial. Age & Ageing
2007;36:292–7.
Lowrie 2012 {published data only}
Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS,
McConnachie A, et al. Pharmacist intervention in primary
care to improve outcomes in patients with left ventricular
systolic dysfunction. European Heart Journal 2012;33:
314–24.
Malet-Larrea 2016 {published data only}
Malet-Larrea A, Goyenechea E, Garcia-Cardenas V,
Calvo B, Arteche JM, Aranegui P, et al. The impact of
a medication review with follow-up service on hospital
26Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
admissions in aged polypharmacy patients. British Journal
of Clinical Pharmacology 2016;82(3):831–8.
Malone 2000 {published data only}
Malone DC, Carter BL, Billups SJ, Valuck RJ, Barnette DJ,
Sintek CD, et al. An economic analysis of a randomized,
controlled, multicenter study of clinical pharmacist
Interventions for high-risk veterans: the IMPROVE study.
Pharmacotherapy: The Journal of Human Pharmacology and
Drug Therapy 2000;20:1149–58.
Moertl 2009 {published data only}
Moertl D, Berger R, Hammer A, Huelsmann M, Hutuleac
R, Pacher R. B-type natriuretic peptide predicts benefit from
a home-based nurse care in chronic heart failure. Journal of
Cardiac Failure 2009;15:233–40.
Murray 2004 {published data only}
Murray MD, Harris LE, Overhage JM, Zhou XH, Eckert
GJ, Smith FE, et al. Failure of computerized treatment
suggestions to improve health outcomes of outpatients
with uncomplicated hypertension: results of a randomized
controlled trial. Pharmacotherapy 2004;24:324–37.
Nabagiez 2013 {published data only}
Nabagiez JP, Shariff MA, Khan MA,Molloy WJ, McGinn Jr
JT. Physician assistant home visit program to reduce hospital
readmissions. Journal of Thoracic and Cardiovascular Surgery
2013;145:225–33.
Okamoto 2001 {published data only}
Okamoto MP, Nakahiro K. Pharmacoeconomic
evaluation of a pharmacist-managed hypertension clinic.
Pharmacotherapy: The Journal of Human Pharmacology and
Drug Therapy 2001;21:1337–44.
Olesen 2014 {published data only}
Olesen C, Harbig P, Buus KM, Barat I, Damsgaard EM.
Impact of pharmaceutical care on adherence, hospitalisations
and mortality in elderly patients. International Journal of
Clinical Pharmacy 2014;36(1):163–71.
Pai 2009 {published data only}
Pai AB, Boyd A, Depczynski J, Chavez IM, Khan N, Manley
H. Reduced drug use and hospitalization rates in patients
undergoing hemodialysis who received pharmaceutical care:
a 2-year, randomized, controlled study. Pharmacotherapy:
The Journal of Human Pharmacology & Drug Therapy 2009;
29:1433–40.
Roberts 2001 {published data only}
Roberts MS, Stokes JA, King MA, Lynne TA, Purdie DM,
Glasziou PP, et al. Outcomes of a randomized controlled
trial of a clinical pharmacy intervention in 52 nursing
homes. British Journal of Clinical Pharmacology 2001;51:
257–65.
Rytter 2010 {published data only}
Rytter L, Jakobsen HN, Ronholt F, Hammer AV, Andreasen
AH, Nissen A, et al. Comprehensive discharge follow-up
in patients’ homes by GPs and district nurses of elderly
patients. A randomized controlled trial. Scandinavian
Journal of Primary Health Care 2010;28:146–53.
Triller 2007 {published data only}
Triller DM, Hamilton RA. Effect of pharmaceutical care
services on outcomes for home care patients with heart
failure. American Journal of Health-System Pharmacy 2007;
64:2244–9.
Zermansky 2001 {published data only}
Zermansky AG, Petty DR, Raynor DK, Freemantle N,
Vail A, Lowe CJ. Randomised controlled trial of clinical
medication review by a pharmacist of elderly patients
receiving repeat prescriptions in general practice. BMJ
2001;323:1340–3.
Zermansky 2006 {published data only}
Zermansky AG, Alldred DP, Petty DR, Raynor DK,
Freemantle N, Eastaugh J, et al. Clinical medication review
by a pharmacist of elderly people living in care homes -
randomised controlled trial. Age & Ageing 2006;35:586–91.
References to studies excluded from this review
Al-Arifi 2014 {published data only}
Al-Arifi M, Abu-Hashem H, Al-Meziny M, Said R,
Aljadhey H. Emergency department visits and admissions
due to drug related problems at Riyadh military hospital
(RMH), Saudi Arabia. Saudi Pharmaceutical Journal 2014;
22(1):17–25.
Alassaad 2014 {published data only}
Alassaad A, Bertilsson M, Gillespie U, Sundstrom J,
Hammarlund-Udenaes M, Melhus H. The effects of
pharmacist intervention on emergency department visits in
patients 80 years and older: subgroup analyses by number
of prescribed drugs and appropriate prescribing. PLoS ONE
2014;9(11):e111797.
Alicic 2016 {published data only}
Alicic RZ, Short RA, Corbett CL, Neumiller JJ, Gates BJ,
Daratha KB, et al. Medication intervention for chronic
kidney disease patients transitioning from hospital to home:
study design and baseline characteristics. American Journal
of Nephrology 2016;44(2):122–9.
Barker 2012 {published data only}
Barker A, Barlis P, Berlowitz D, Page K, Jackson B, Lim
WK. Pharmacist directed home medication reviews in
patients with chronic heart failure: a randomised clinical
trial. International Journal of Cardiology 2012;159:139–43.
Barker 2016 {published data only}
Barker EA, Pond ST, Zaiken K. Impact of medication
onboarding: a clinical pharmacist-run “onboarding”
telephone service for patients entering a primary care
practice. Journal of Pharmacy Technology 2016;32(1):9–15.
Barnes 2014 {published data only}
Barnes KD, Tayal NH, Lehman AM, Beatty SJ. Pharmacist-
driven renal medication dosing intervention in a primary
care patient-centered medical home. Pharmacotherapy
2014;34(12):1330–5.
Basheti 2016 {published data only}
Basheti IA, Tadros OK, Aburuz S. Value of a community-
based medication management review service in Jordan: a
27Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
prospective randomized controlled study. Pharmacotherapy:
The Journal of Human Pharmacology & Drug Therapy 2016;
36(10):1075–86.
Bell 2016 {published data only}
Bell SP, Schnipper JL, Goggins K, Bian A, Shintani
A, Roumie CL, et al. Effect of pharmacist counseling
intervention on health care utilization following hospital
discharge: a randomized control trial. Journal of General
Internal Medicine 2016;31(5):470–7.
Benard-Laribiere 2015 {published data only}
Benard-Laribiere A, Miremont-Salame G, Perault-Pochat
MC, Noize P, Haramburu F, centres EMIR Study Group
on behalf of the French network of pharmacovigilance.
Incidence of hospital admissions due to adverse drug
reactions in France: the EMIR study. Fundamental &
Clinical Pharmacology 2015;29(1):106–11.
Bhatt 2014 {published data only}
Bhatt V, Masilamani S, Hardin-Oliver C. Initiation of
pharmaceutical services for the management of asthma and
chronic obstructive pulmonary disease in a community
pharmacy. Journal of the American Pharmacists Association
2014;54(2):e171.
Billington 2015 {published data only}
Billington J, Coster S, Murrells T, Norman I. Evaluation of
a nurse-led educational telephone intervention to support
self-management of patients with chronic obstructive
pulmonary disease: a randomized feasibility study. COPD:
Journal of Chronic Obstructive Pulmonary Disease 2015;12
(4):395–403.
Bonnet-Zamponi 2013 {published data only}
Bonnet-Zamponi D, d’Arailh L, Konrat C, Delpierre S,
Lieberherr D, Lemaire A, et al. Drug-related readmissions
to medical units of older adults discharged from acute
geriatric units: results of the optimization of medication in
aged multicenter randomized controlled trial. Journal of the
American Geriatrics Society 2013;61:113–21.
Briggs 2015 {published data only}
Briggs S, Pearce R, Dilworth S, Higgins I, Hullick C, Attia
J. Clinical pharmacist review: a randomised controlled trial.
Emergency Medicine Australasia 2015;27(5):419–26.
Carrington 2013 {published data only}
Carrington MJ, Chan YK, Calderone A, Scuffham PA,
Esterman A, Goldstein S, et al. A multicenter, randomized
trial of a nurse-led, home-based intervention for optimal
secondary cardiac prevention suggests some benefits for men
but not for women: the Young at Heart study. Circulation.
Cardiovascular quality and outcomes 2013;6(4):379–89.
Clyne 2013 {published data only}
Clyne B, Bradley MC, Smith SM, Hughes CM, Motterlini
N, Clear D, et al. Effectiveness of medicines review with
web-based pharmaceutical treatment algorithms in reducing
potentially inappropriate prescribing in older people in
primary care: a cluster randomized trial (OPTI-SCRIPT
study protocol). Trials 2013;14:72.
Clyne 2015 {published data only}
Clyne B, Smith SM, Hughes CM, Boland F, Bradley
MC, Cooper JA, et al. Effectiveness of a multifaceted
intervention for potentially inappropriate prescribing
in older patients in primary care: a cluster-randomized
controlled trial (OPTI-SCRIPT study). Annals of Family
Medicine 2015;13(6):545–53.
Clyne 2016 {published data only}
Clyne B, Cooper JA, Hughes CM, Fahey T, Smith SM. A
process evaluation of a cluster randomised trial to reduce
potentially inappropriate prescribing in older people in
primary care (OPTI-SCRIPT study). Trials 2016;17(1):
386.
Cowper 1998 {published data only}
Cowper PA, Weinberger M, Hanlon JT, Landsman PB,
Samsa GP, Uttech KM, et al. The cost-effectiveness of a
clinical pharmacist intervention among elderly outpatients.
Pharmacotherapy: The Journal of Human Pharmacology and
Drug Therapy 1998;18:327–32.
Desveaux 2016 {published data only}
Desveaux L, Gomes T, Tadrous M, Jeffs L, Taljaard M,
Rogers J, et al. Appropriate prescribing in nursing homes
demonstration project (APDP) study protocol: pragmatic,
cluster-randomized trial and mixed methods process
evaluation of an Ontario policy-maker initiative to improve
appropriate prescribing of antipsychotics. Implementation
Science 2016;11:45.
Dhalla 2014 {published data only}
Dhalla IA, O’Brien T, Morra D, Thorpe KE, Wong BM,
Mehta R, et al. Effect of a postdischarge virtual ward on
readmission or death for high-risk patients: a randomized
clinical trial. JAMA 2014;312(13):1305–12.
Elliott 2014 {published data only}
Elliott RA, Putman KD, Franklin M, Annemans L,
Verhaeghe N, Eden M, et al. Cost effectiveness of a
pharmacist-led information technology intervention for
reducing rates of clinically important errors in medicines
management in general practices (PINCER) (Provisional
abstract). PharmacoEconomics 2014;32(6):573–90.
Forster 2015 {published data only}
Forster AJ, Erlanger TE, Jennings A, Auger C, Buckeridge
D, Walraven C, et al. Effectiveness of a computerized
drug-monitoring program to detect and prevent adverse
drug events and medication non-adherence in outpatient
ambulatory care: study protocol of a randomized controlled
trial. Trials 2015;16:2.
Fredericks 2013 {published data only}
Fredericks S, Yau T. Educational intervention reduces
complications and rehospitalizations after heart surgery.
Western Journal of Nursing Research 2013;35(10):1251–65.
Furniss 2000 {published data only}
Furniss L, Burns A, Craig SK, Scobie S, Cooke J, Faragher
B. Effects of a pharmacist’s medication review in nursing
homes. Randomised controlled trial. British Journal of
Psychiatry 2000;176:563–7.
28Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Geurts 2016 {published data only}
Geurts MM, Stewart RE, Brouwers JR, De Graeff PA, De
Gier JJ. Implications of a clinical medication review and a
pharmaceutical care plan of polypharmacy patients with a
cardiovascular disorder. International Journal of Clinical
Pharmacy 2016;38(4):808–15.
Gorgas 2012 {published data only}
Gorgas TM, Pez VF, Camos RJ, De Puig CE, Jolonch SP,
Homs PE, et al. Integrated pharmaceutical care programme
in patients with chronic diseases. Farmacia Hospitalaria
2012;36:229–39.
Graffen 2004 {published data only}
Graffen M, Kennedy D, Simpson M. Quality use of
medicines in the rural ambulant elderly: a pilot study. Rural
& Remote Health 2004;4:184.
Guthrie 2016 {published data only}
Guthrie B, Kavanagh K, Robertson C, Barnett K, Treweek
S, Petrie D, et al. Data feedback and behavioural change
intervention to improve primary care prescribing safety
(EFIPPS): multicentre, three arm, cluster randomised
controlled trial. BMJ 2016;354:i4079.
Hallsworth 2016 {published data only}
Hallsworth M, Chadborn T, Sallis A, Sanders M, Berry D,
Greaves F, et al. Provision of social norm feedback to high
prescribers of antibiotics in general practice: a pragmatic
national randomised controlled trial. Lancet 2016;387
(10029):1743–52.
Hanlon 1996 {published data only}
Hanlon JT,Weinberger M, Samsa GP, Schmader KE, Uttech
KM, Lewis IK, et al. A randomized, controlled trial of a
clinical pharmacist intervention to improve inappropriate
prescribing in elderly outpatients with polypharmacy.
American Journal of Medicine 1996;100:428–37.
Hugtenburg 2009 {published data only}
Hugtenburg JG, Borgsteede SD, Beckeringh JJ. Medication
review and patient counselling at discharge from the hospital
by community pharmacists. Pharmacy World and Science
2009;31:630–7.
Huiskes 2014 {published data only}
Huiskes VJ, Kruijtbosch M, Ensing R, Meijs M, Meijs VM,
Van den Bemt BJ. The effectiveness of a medication review
on the number of drug related problems in outpatient
cardiology patients: a randomized clinical trial. British
Journal of Clinical Pharmacology 2014;78(4):766–7.
Keane 2014 {published data only}
Keane K. Reducing medication errors by educating nurses
on bar code technology. MEDSURG Nursing 2014;23(5):
Suppl 1, 10-1.
Knowlton 1994 {published data only}
Knowlton CH, Knapp DA. Community pharmacists help
HMO cut drug costs. American Pharmacy 1994;NS34:
36–42.
Lee 1996 {published data only}
Lee YP, Schommer JC. Effect of a pharmacist-managed
anticoagulation clinic on warfarin-related hospital
readmissions. American Journal of Health-System Pharmacy
1996;53:1580–3.
Leendertse 2011 {published data only}
Leendertse AJ, De Koning GH, Goudswaard AN,
Belitser SV, Verhoef M, De Gier JJ, et al. The effect of a
pharmaceutical care process on medication related hospital
admissions in the elderly in an integrated primary care
setting: results of the Pharm study. International Journal of
Clinical Pharmacy 2011;33 (2):337.
Leendertse 2013 {published data only}
Leendertse AJ, de Koning GH, Goudswaard AN, Belitser
SV, Verhoef M, De Gier HJ, et al. Preventing hospital
admissions by reviewing medication (PHARM) in primary
care: an open controlled study in an elderly population.
Journal of Clinical Pharmacy and Therapeutics 2013.
Liu 2010 {published data only}
Liu MY, Li YJ, Zhu W, Wei M. Effects of intensive clinic
follow-up on management and short-term outcome for
patients with heart failure. Circulation 2010;122 (2):e33–4.
Malin 2016 {published data only}
Malin A. Use of electronic medication administration
records to reduce perceived stress and risk of medication
errors in nursing homes. Journal of Forensic Nursing 2016;
34(7):329.
Mills 2001 {published data only}
Mills A. Pharmacist medication review decreased death, and
number and cost of drugs prescribed for residents in nursing
homes. Evidence Based Mental Health 2001;4:63.
Montero-Balosa 2016 {published data only}
Montero-Balosa MC, Palma-Morgado D, Sanchez-Blanco J,
Perez-Fuentes MF, Vela-Marquez MC, Lacalle-Remigio JR.
Intervention to reduce potential events in elderly patients.
International Journal of Clinical Pharmacy 2016;38 (6):
492–3.
Moreno 2016 {published data only}
Moreno G, Fu JY, Chon J, Whitmire N, Tseng CH, Grotts
J, et al. Impact of pharmacists on the primary care team
on emergency room visits and hospitalizations for poorly
controlled patients with diabetes. Journal of General Internal
Medicine 2016;31(2 SUPPL. 1):S263–4.
Naunton 2003 {published data only}
Naunton M, Peterson GM. Evaluation of home-based
follow-up of high-risk elderly patients discharged from
hospital. Journal of Pharmacy Practice & Research 2003;33:
176–82.
Neven 2016 {published data only}
Neven D, Paulozzi L, Howell D, McPherson S, Murphy
SM, Grohs B, et al. A randomized controlled trial of a
citywide emergency department care coordination program
to reduce prescription opioid related emergency department
visits. Journal of Emergency Medicine 2016;51(5):498–505.
Ni 2016 {published data only}
Ni W, Colayco D, Hashimoto J, Komoto K, Gowda C,
Wearda B, et al. Impact of an ambulatory care pharmacy-
based transition of care program on hospital readmissions
and cost. Value in Health 2016;19(3):A28.
29Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Perula 2014 {published data only}
Perula TL, Pulido OL, Perula TC, Gonzalez LJ, Olaya CI,
Ruiz MR, et al. Efficacy of motivational interviewing for
reducing medication errors in chronic patients over 65 years
with polypharmacy: results of a cluster randomized trial.
Medicina Clinica 2014;143(8):341–8.
Phung 2013 {published data only}
Phung J. Reducing hospital readmissions: a pilot study
of pharmacists’ role on an American Indian reservation.
Journal of the American Pharmacists Association 2013;53(2):
e41.
Pinnock 2013 {published data only}
Pinnock H, Hanley J, McCloughan L, Todd A, Krishan A,
Lewis S, et al. Effectiveness of telemonitoring integrated
into existing clinical services on hospital admission for
exacerbation of chronic obstructive pulmonary disease:
researcher blind, multicentre, randomised controlled trial.
BMJ 2013;347:f6070.
Przytula 2015 {published data only}
Przytula K, Bailey SC, Galanter WL, Lambert BL, Shrestha
N, Dickens C, et al. A primary care, electronic health
record-based strategy to promote safe drug use: study
protocol for a randomized controlled trial. Trials 2015;16:
17.
Safran 1993 {published data only}
Safran C, Rind DM, Davis RM, Currier J, Ives D, Sands
DZ, et al. An electronic medical record that helps care for
patients with HIV infection. The Annual Symposium on
Computer Applications in Medical Care. 1993:224–8.
Saltzberg 2011 {published data only}
Saltzberg M, Arhinful E, Lynch S, Olurin O, Nordenson
M. Control your heart for the future study (CHF): unique
partnership to reduce resource utilization among high risk
heart failure patients. Journal of the American College of
Cardiology 2011;1:E1213.
Setter 2009 {published data only}
Setter SM, Corbett CF, Neumiller JJ, Gates BJ, Sclar
DA, Sonnett TE. Effectiveness of a pharmacist-nurse
intervention on resolving medication discrepancies for
patients transitioning from hospital to home health care.
American Journal of Health-System Pharmacy 2009;66:
2027–31.
Sinnott 2015 {published data only}
Sinnott C, Mercer SW, Payne RA, Duerden M, Bradley
CP, Byrne M. Improving medication management in
multimorbidity: development of the multimorbidity
collaborative medication review and decision making (MY
COMRADE) intervention using the behaviour change
wheel. Implementation Science 2015;10:132.
Stingl 2016 {published data only}
Stingl JC, Kaumanns KL, Claus K, Lehmann ML,
Kastenmuller K, Bleckwenn M, et al. Individualized versus
standardized risk assessment in patients at high risk for
adverse drug reactions (IDRUG) - study protocol for a
pragmatic randomized controlled trial. BMC Family Practice
2016;17:49.
Sturgess 2003 {published data only}
Sturgess IK, McElnay JC, Hughes CM, Crealey G.
Community pharmacy based provision of pharmaceutical
care to older patients. Pharmacy World & Science 2003;25:
218–26.
Wolf 2015 {published data only}
Wolf C, Pauly A, Mayr A, Gromer T, Lenz B, Kornhuber
J, et al. Pharmacist-led medication reviews to identify and
collaboratively resolve drug-related problems in psychiatry
- a controlled, clinical trial. PLoS ONE 2015;10(11):
e0142011.
Wooster 2016 {published data only}
Wooster J, Gurney M, Hecht K, Kucera A. Impact
of community pharmacist-performed medication
reconciliations in post-discharge patients on 30-day hospital
readmission rates. Journal of the American Pharmacists
Association 2016;56(3):e92.
Xin 2014 {published data only}
Xin C, Ge X, Yang X, Lin M, Jiang C, Xia Z. The impact
of pharmaceutical care on improving outcomes in patients
with type 2 diabetes mellitus from China: a pre- and
postintervention study. International Journal of Clinical
Pharmacy 2014;36(5):963–8.
Yuan 2003 {published data only}
Yuan Y, Hay JW, McCombs JS. Effects of ambulatory-care
pharmacist consultation on mortality and hospitalization.
American Journal of Managed Care 2003;9:45–56.
Additional references
APA 2008
American Pharmacists Association, National Association
of Chain Drug Stores Foundation. Medication therapy
management in pharmacy practice: core elements of an
MTM service model (version 2.0). Journal of the American
Pharmacists Association 2008;48(3):341–53. [DOI:
10.1331/JAPhA.2008.08514
Bates 1995
Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD,
Servi D, et al. Prevention study group. Incidence of adverse
drug events and potential adverse drug events. Implications
for prevention. JAMA 1995;274(1):29–34.
Benning 2011
Benning A, Ghaleb M, Suokas A, Dixon-Woods M,Dawson
J, Barber N, et al. Large scale organisational intervention to
improve patient safety in four UK hospitals: mixed method
evaluation. BMJ 2011;342:d195.
Brown 2008
Brown C, Lilford R. Evaluating service delivery interventions
to enhance patient safety. BMJ 2008;337(a2764):159–63.
CHAP 2017
CHAP - Cardiovascular Health Awareness Program. www.
chapprogram.ca (accessed prior to 26 June 2017).
Danmarks 2004
Danmarks Apotekerforening, Pharmakon. Medication
review. Managing Medication Manual 2004; Vol. 1, issue
1:1–21.
30Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Datascope Patient Monitoring 1996 [Computer program]
Datascope Patient Monitoring. Passport Service Manual.
Montvale, NJ: Datascope Corp, 1996.
Deeks 2011
Deeks JJ, Higgins JP, Altman DG (editors). Chapter 9:
Analysing data and undertaking meta-analyses. In: Higgins
JP, Green S, editor(s). Cochrane Handbook for Systematic
Reviews of Interventions. Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Durieux 2012
Durieux P, Trinquart L, Colombet I, Nies J, Walton
RT, Rajeswaran A, et al. Computerized advice on drug
dosage to improve prescribing practice. Cochrane Database
of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/
14651858.CD002894
Edwards 2000
Edwards IR, Aronson JK. Adverse drug reactions:
definitions, diagnosis, and management. Lancet 2000;356
(9237):1255–9.
EPOC 2017a
Cochrane Effective Practice, Organisation of Care
(EPOC). Screening, data extraction and management.
EPOC resources for review authors. Available from
epoc.cochrane.org/epoc-specific-resources-review-authors
2017.
EPOC 2017b
Cochrane Effective Practice, Organisation of Care (EPOC).
EPOC worksheets for preparing a ’Summary of findings’
table using GRADE. EPOC resources for review authors.
Available from epoc.cochrane.org/epoc-specific-resources-
review-authors 2017.
Ferner 2006
Ferner RE, Aronson JK. Clarification of terminology in
medication errors: definitions and classification. Drug
Safety 2006;29(11):1011–22.
Field 2012
Field TS, Garber L, Gagne SJ, Tjia J, Preusse P, Donovan JL,
et al. Technological resources and personnel costs required
to implement an automated alert system for ambulatory
physicians when patients are discharged from hospitals to
home. Journal of Innovation in Health Informatics 2013;20
(2):87–93.
Gallagher 2008
Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D.
STOPP (Screening Tool of Older Person’s Prescriptions)
and START (Screening Tool to Alert Doctors to Right
Treatment). Consensus validation. International Journal of
Clinical Pharmacology and Therapeutics 2008; Vol. 46,
issue 2:72–83.
Gandhi 2003
Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J,
Burdick E, et al. Adverse drug events in ambulatory care.
New England Journal of Medicine 2003;348(16):1556–64.
GRADE pro GDT 2015 [Computer program]
McMaster University (developed by Evidence Prime).
GRADEpro GDT. Version accessed 31 January 2017.
Hamilton (ON): McMaster University (developed by
Evidence Prime), 2015.
Guyatt 2008
Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y,
Alonso-Coello P, et al. GRADE Working Group. GRADE:
an emerging consensus on rating quality of evidence and
strength of recommendations. BMJ 2008;336(7650):
924–6.
Hepler 1990
Hepler CD, Strand LM. Opportunities and responsibilities
in pharmaceutical care. American Journal of Hospital
Pharmacy 1990;47(3):533–43.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327:
557–60.
Higgins 2011a
Higgins JP, Deeks JJ, editor(s). Chapter 7: Selecting
studies and collecting data. In: Higgins JP, Green S,
editor(s). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Higgins 2011b
Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8:
Assessing risk of bias in included studies. In: Higgins JP,
Green S, editor(s). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Howard 2003
Howard RL, Avery AJ, Howard PD, Partridge M.
Investigation into the reasons for preventable drug related
admissions to a medical admissions unit: observational
study. Quality & Safety in Health Care 2003;12(4):280–5.
Howard 2007
Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G,
Lucassen P, et al. Which drugs cause preventable admissions
to hospital? A systematic review. British Journal of Clinical
Pharmacology 2007;63(2):136–47.
Ioannidis 2001
Ioannidis JP, Lau J. Evidence on interventions to reduce
medical errors: an overview and recommendations for
future research. Journal of General Internal Medicine 2001;
16(5):325–34.
Liberati 2009
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC,
Ioannidis JP, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration.
PLoS Medicine 2009;6(7):e1000100.
31Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lowe 2000
Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects
of a medicine review and education programme for older
people in general practice. British Journal of Clinical
Pharmacology 2000;50(2):172–5.
McDonald 1999
McDonald CJ, Overhage JM, Tierney WM, Dexter PR,
Martin DK, Suico JG, et al. The Regenstrief Medical
Record System: a quarter century experience. International
Journal of Medical Informatics 1999;54(3):225–53.
O’Brien 2008
O’Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-
Jensen J, Kristoffersen DT, et al. Educational outreach
visits: effects on professional practice and health care
outcomes. Cochrane Database of Systematic Reviews 2008,
Issue 4. [DOI: 10.1002/14651858.CD000409
O’Mahony 2015
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN,
Ryan C, Gallagher P. STOPP/START criteria for potentially
inappropriate prescribing in older people: version 2. Age &
Ageing 2015;44(2):213–8.
Overhage 1999
Overhage JM, Lukes A. Practical, reliable, comprehensive
method for characterizing pharmacists’ clinical activities.
American Journal of Health-System Pharmacy 1999;56(23):
2444.
Remme 1997
Members of the Task Force from the Working Group on
Heart Failure of the European Society of Cardiology. The
treatment of heart failure. European Heart Journal 1997;18
(5):736.
Remme 2001
Remme WJ, Swedberg K. Guidelines for the diagnosis and
treatment of chronic heart failure. European Heart Journal
2001;22(23):1527–60.
Review Manager 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Royal 2006
Royal S, Smeaton L, Avery AJ, Hurwitz B, Sheikh A.
Interventions in primary care to reduce medication related
adverse events and hospital admissions: systematic review
and meta-analysis. Quality and Safety in Health Care 2006;
15(1):23–31. [DOI: 10.1136/qshc.2004.012153
Schünemann 2011
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE,
Glasziou P, Guyatt GH. Chapter 11: Presenting results
and ‘Summary of findings’ tables. In: Higgins JPT, Green
S (editors), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from www.
handbook.cochrane.org.
Soe 2013
Soe A, Apampa B, Fernando B, Maaskant J, Neubert A,
Thayyil S, et al. Interventions for reducing medication
errors in children in hospital. Cochrane Database of
Systematic Reviews 2013, Issue 2. [DOI: 10.1002/
14651858.CD006208
Spencer 2014
Spencer R, Bell B, Avery AJ, Gookey G, Campbell SM.
Identification of an updated set of prescribing-safety
indicators for GPs. British Journal of General Practice 2014;
64:e181–90.
SUDAAN 2012 [Computer program]
Research Triangle Park. SUDAAN: professional software
for survey data analysis. Version 11. NC: Research Triangle
Park, 2012.
Tobias 1999
Tobias DE, Feinberg JL, Troutman WG. The MDS-
Med Guide: a Tool for the new millennium. Consultant
Pharmacist 1999;14(8):831–60.
WHO 2004
World Health Organization (WHO). Pharmacovigilance:
ensuring the safe use of medicines. WHO Policy
Perspectives on Medicines 2004; Vol. No. 009.
Winterstein 2002
Winterstein AG, Sauer BC, Hepler CD, Poole C.
Preventable drug related hospital admissions. Annals of
Pharmacotherapy 2002;36(7-8):1238–48.
Wong 2008
Wong JD, Bajcar JM, Wong GG, Alibhai SMH, Huh
J-H, Cesta A, et al. Medication reconciliation at
hospital discharge: evaluating discrepancies. Annals of
Pharmacotherapy 2008;42(10):1373–9.
References to other published versions of this review
Khalil 2013
Khalil H, Avery AJ, Chambers H, Bell B, Serumaga B,
Sheikh A. Interventions in primary care for reducing
preventable medication errors that lead to hospital
admissions, mortality and emergency department visits.
Cochrane Database of Systematic Reviews 2013, Issue 11.
[DOI: 10.1002/14651858.CD003942
Smeaton 2002
Smeaton L, Sheikh A, Avery A, Royal S, Hurwitz B, Dewey
M. Interventions for reducing preventable drug-related
hospital admissions or preventable drug-related morbidity
in primary care. Cochrane Database of Systematic Reviews
2002, Issue 4. [DOI: 10.1002/14651858.CD003942
∗ Indicates the major publication for the study
32Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alvarez 2001
Methods Cluster-RT (randomisation at the pharmacy level)
Study duration: 1 year
Participants 735 at beginning of the study, 600 at the end of the study (data are on the 600 reported
below)
Setting: community pharmacies
Diagnostic criteria: CHD
Age (years) (mean): intervention group: 64.8 years; control group: 65.8 years
Sex female n (%): intervention group: 79 (29.5%); control group: 94 (29%)
Country: Spain
Comorbidity: not reported
Sociodemographics: not reported
Ethnicity: not reported
Date of study: not reported
Interventions 1 intervention group
Intervention group: pharmacies allocated to that group provided pharmaceutical care,
consisting of the prevention, identification and solution of medication-related problems
Control group: care as usual
Pharmaceutical care consisted of the following: offering the pharmaceutical care service
to participants and to their corresponding GPs, initial interview and assessment of the
therapeutic plan, registration of data during the subsequent visits in order to allow the
identification of medication-related problems, and intervention to solve the problem
Outcomes • Frequency of hospital emergency room visits, number of people admitted to
hospital and length-of-stay in ICU, all of them due to coronary causes (data obtained
from external sources)
• Health-related QoL score (SF-36, measured before and after the intervention)
• Participant knowledge of CHD risk factors (only measured at the end of the
study)
• Participant knowledge of their drugs, and subjective perception of the
anticoagulant drugs and beta-blockers (only measured at the end of the study)
• Satisfaction with pharmaceutical care service and perception of pharmacist’s
professional competence (only measured at the end of the study)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
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Alvarez 2001 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported. Pharmacists may have been
blinded, as they all received training on
methods to treat CHD (in order to ensure
that differences after the intervention are
due to the intervention per se and not due
to differences in theoretical knowledge on
methods to treat CHD)
Incomplete outcome data (attrition bias)
All outcomes
High risk High proportion of incomplete outcome
data for most to the measures
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Low risk All outcomes were reported
Protection against contamination bias Unclear risk Unclear
Other bias High risk For most of the outcome measures no pre-
intervention data were collected. We con-
sidered other bias due to cluster randomi-
sation
Bernsten 2001
Methods RT
Study duration: 18 months
Setting: community pharmacy
Participants 2454 participants were recruited: 1290 intervention participants and 1164 control par-
ticipants were assessed at baseline although there were subsequent dropouts
Diagnostic criteria: participants were eligible if they were ≥ 65 years, taking 4 or more
prescribed medicines, and oriented with respect to time, place, and person. They were
required to be community dwelling and regular visitors to a community pharmacy.
Participants could not be housebound or in a nursing facility
Age (years) (mean ± SD): intervention: 735 (58%); control: 663 (57%); no significant
difference
Sex female n (%): intervention: 735 (58%); control: 663 (57%); no significant difference
Country: 7European countries;Denmark,Germany,TheNetherlands,Northern Ireland
(co-ordinating centre), Portugal, Republic of Ireland and Sweden
Comorbidity: there were no significant differences between intervention and control
participants at baseline
Sociodemographics: none of note, although participants from 2 countries (Republic of
Ireland and Portugal) did not complete the study
Ethnicity: not reported
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Bernsten 2001 (Continued)
Date of study: unclear although published in 2001
Interventions 104 intervention pharmacies
A pharmaceutical care programme was involved and a manual was distributed to all the
intervention sites detailing the intervention. Pharmacists assessed participants to identify
drug-related problems using a structured approach. Pharmacists used several sources of
information including informal questioning of the participant, the participant’s GP, and
pharmacy records. Pharmacists also formulated a monitoring and intervention plan for
each participant, which included participant education about drugs and their medical
condition, using improvement inmedication compliance strategies, and simplifying drug
regimens
Control group: participants were treated as per the usual care with no pharmaceutical
care plan provided
Outcomes Data relating to health and economic outcomes were collected for each participant at
baseline, 6, 12 and 18 months. These included hospital admissions
Notes The study authors note that the training of pharmacists was not rigorously controlled.
Although a study manual was provided along with a 1-day training session, additional
training was not consistently provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sites were randomly allocated as control or
intervention sites
Allocation concealment (selection bias) Low risk Concealment was adequate as sites rather
than individual participantswere randomly
allocated. Also, all units were allocated at
the start of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk As pharmacies were the unit of randomi-
sation, this appears to be low risk. Control
pharmacists provided usual care and inter-
vention pharmacists only provided the in-
tervention
Incomplete outcome data (attrition bias)
All outcomes
High risk Those participants who withdrew from the
study were significantly older and in poorer
health
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This is less important for our purpose as we
are looking at objective outcomes (hospi-
talisations, ED visits, and mortality)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
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Protection against contamination bias Low risk No evidence of contamination of the inter-
vention group with the control
Other bias Unclear risk 1 aspect of the study that was not rigorously
controlled was the training of participating
pharmacists. A study manual was provided
to each participating pharmacist, followed
by a 1-day training session. Further train-
ing was provided in individual countries;
however, the extent of this was driven by
the available resources
Campins 2016
Methods RT
15 months
Participants 503 participants: 252 intervention, 251 control; final sample 242 intervention, 246
control
Setting: primary care centres
Diagnostic criteria: elderly people (> 70 years) on ≥ 8 drugs
Interventions The intervention consisted of 3 consecutive phases. First, a trained and experienced
clinical pharmacist evaluated all drugs prescribed to each participant using the GP-
GP algorithm and based their decision about appropriateness on the STOPP/START
criteria. Second, the pharmacist discussed recommendations for each drug with the
participant’s physician in order to come up with a final set of recommendations. Finally,
these recommendations were discussed with the participant, and a final decision was
agreed by physicians and their patients in a face-to-face visit
Control group participants followed the usual treatments and control procedures of their
physicians
Outcomes Main outcome measures regarding intervention effectiveness were as follows
• number of medications prescribed at 3, 6 and 12 months
• (treatment restart ratio (after discontinuation)
• primary care and emergency department consultation rate for acute conditions
• hospitalisation rate
• mortality rate
• baseline, 3-month and 6-month self-reported QoL (measured using
EuroQoL-5D, www.euroqol.org)
• baseline, 3-month and 6-month treatment
Adherence was measured using the Morisky-Green test.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Participants were blindly randomised to 1 or other of the 2
study arms. Assignment was based on a list of random numbers
generated by a statistical programme
Allocation concealment (selection bias) Low risk Each family physician received 10 sealed, opaque envelopes with
identification numbers (assigned consecutively in strict chrono-
logical order of recruitment) on the back. Each envelope con-
tained a card with the same identification number and the in-
tervention group to which the subject was assigned. Envelopes
were not prepared in primary care centres but in the research
unit
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Low risk because pharmacists only treated intervention partic-
ipants and did not know that the participants they interacted
with were in a study. Also, participants did not appear to know
whether they were receiving an intervention or not
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very few people dropped out.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes of interest were objective
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Protection against contamination bias Unclear risk Prescribing physicians who received recommendations from the
pharmacist regarding intervention group participants also had
participants in the control group, so the control group could
have benefited from the intervention
Other bias Unclear risk Study has limited statistical power to detect effects for outcomes
of interest
Coleman 1999
Methods Cluster-RT. The unit of randomisation was the physician practice
Study duration: 2 years
Participants Total participants: 169 participants, 9 physician groups
Participants aged ≥ 65 in ambulatory setting, chronic-care clinics
Age: intervention 77.3%; control 77.4%; no SD provided; P = 0.70
Sex female (%): intervention 47.9%; control 49.6%; no SD provided; P = 0.81
Country: USA
Diabetes: intervention 53.2%; control 48.6%; P = 0.62
Education > 12 years: intervention 77.1%; control 66.7%; P = 0.1
Married: intervention 55.2%; control 58.3%; P = 0.63
Income < USD 15,000: intervention 15.8%; control 14%; P = 0.75
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Hospitalised in prior year: intervention 46.7%; control 39.7%; P = 0.15
Mean chronic disease score: intervention 7.3; control 7.7; P = 0.06
Mean risk score: intervention 0.55; control 0.53; P = 0.35
Ethnicity: non-white: intervention 2.8%; control 4.1%; P = 0.54
Interventions Intervention practices (5 physicians, 96 participants) held half-day, chronic-care clinics
every 3-4 months. These clinics included an extended visit with the physician and nurse
dedicated to planning chronic-disease management, a pharmacist visit that emphasised
reduction of polypharmacy and high-risk medications, and a patient self-management
group
Control practices (4 physicians, 73 participants) received usual care
Outcomes Emergency visits (mean/year) and hospitalisations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was not mentioned nor
how it was done.
Allocation concealment (selection bias) Unclear risk Allocation was not mentioned nor how it
was done.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This would be impossible.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some participants did not complete the
study and were reported in the study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No explanation given
Selective reporting (reporting bias) Low risk All outcomes were reported.
Protection against contamination bias Low risk It is hard to determine if the intervention
group interacted with the control group
Other bias Unclear risk Unclear. We considered other bias due to
cluster randomisation
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Frankenthal 2014
Methods RT
18 months
Chronic-care geriatric facility
Participants 359 participants: 183 intervention, 176 control; final sample: 160 intervention, 146
control
Interventions The intervention consisted of a medication review by the study pharmacist for all resi-
dents at study opening and 6 and 12 months later using the The STOPP/START crite-
ria. Interventional recommendations that the study pharmacist made for residents in the
intervention group but not in the control group were discussed with the chief physician
at study opening and after 6 months. The chief physician decided whether to accept
these recommendations and implement prescribing changes
Control: usual care
Outcomes Outcome measures included:
• average number of falls
• hospitalisations
• QoL as assessed using the Medical Outcomes Study 12-item SF-12 and the costs
of medications
• functioning was also assessed using the Functional Independence Measure, 20,
which rates 18 ADL
Outcomes were measured at the beginning of the study and at the 12-month follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Fixed, stratified randomisation was used
to allocate residents to groups accord-
ing to the 3 types of residents: ADL-de-
pendent, ADL-independent, and primar-
ily cognitively impaired. Participants who
wereADL-dependentwith impaired cogni-
tion were assigned to the ADL-dependent
group. Randomisation for each level was
according to simple list randomisations
Allocation concealment (selection bias) Low risk A physician who was not part of the study
randomised participants. Group allocation
was concealed from the study pharmacist,
and participants were assigned to 1 of the
2 groups using sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Pharmacists were aware that they were in-
teracting with the intervention group
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Most participants completed the study and
there was no apparent difference between
intervention and control group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Number of hospitalisations is an objective
measure.
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Protection against contamination bias Unclear risk The intervention pharmacist only inter-
acted with intervention participants, but
may have interacted with pharmacists in
the control group
Other bias High risk Only 1 geriatric centre was investigated
Garcia-Gollarte 2014
Methods RT
Participants 1018 residents: 516 intervention, 502 control
Final sample: 59 physicians, 716 nursing home residents
Intervention: 29 doctors, 372 nursing home residents
Control: 30 doctors, 344 nursing home residents
Diagnostic criteria: residents aged ≥ 65 years and clinically stable (no change in pre-
scription in last 2 months)
Setting: private organisation
Interventions 6 months professional intervention
A nursing home physician, expert in drug use in older people, delivered a structured
educational intervention
The programme included: general aspects of prescription and drug use in geriatric pa-
tients, how to reduce the number of drugs, to perform a regular review of medications,
to avoid inappropriate drug use, to discontinue drugs that do not show benefits, and to
avoid under-treatment with drugs that have shown benefits. It also discussed in detail
some drugs frequently related to adverse drug reactions in older people. Educational
material and references were given to participants
Finally, two, 1-h workshops reviewed practical, real life cases and promoted practice
changes in participants. The educator offered further on-demand advice on prescriptions
for the next 6 months. This intervention was reinforced through a single review by the
researchers, using standard appropriateness criteria, STOPP-START
Control: physicians in the control group did not receive any intervention or information
about an educational intervention delivered in other centres
Outcomes Outcome measures were as follows:
• appropriateness and quality of drug use. The STOPP-START criteria were used
to assess the drugs that were actively used by each resident at the beginning of the study
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and 9 months later (3 months after the intervention was finished). The number of
individuals with potentially inappropriate prescriptions, duplicate class of drugs, and
antipsychotic use are reported here.
• incidence of selected geriatric syndromes. The number of falls and the number of
episodes of delirium were recorded for the 3-month period before the intervention
started, and the 3-month period immediately after the 6-month intervention finished.
This allowed for comparing the control and the intervention group, and also for
assessing time changes in both groups. Falls and delirium are systematically registered
in the clinical records of all the participant nursing homes.
• health resource utilisation. The number of visits to physicians and nurses, the
number of visits to an emergency room, and the total number of days spent in hospital
were also recorded for the 3-month period before the intervention started, and the 3-
month period after the 6-month intervention finished. These are also regularly
registered in the clinical records of all the participant nursing homes.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done using random number tables.
Allocation concealment (selection bias) Unclear risk There was no mention made of sequence concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Physicians in both groups were informed that there was a com-
pany programme aimed to improve drug prescription (to ex-
plain why data on prescriptions was collected in their centres)
but were blinded to the fact that the educational intervention
was being assessed. Also, participants did not know they were
receiving an intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30%of participantswere lost to the study, but it is unclear if there
was differential attrition in intervention and control groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Number of emergency room visits and length of hospitalisations
are objective outcomes
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Protection against contamination bias High risk Although nursing homes in the intervention and control groups
were separate, some cross-contamination because of informal
contacts between physicians may have occurred
Other bias High risk Short intervention period (6 months) and short follow-up (3
months)
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Gernant 2016
Methods Cluster-RT
Participants 656 home care participants (intervention n = 297, usual care n = 359) were available for
this study
Interventions The intervention began approximately 3 days after in-home health admission when a
pharmacy technician completed telephonic medication reconciliation with the partici-
pant and/or caregiver. Then a trained pharmacist would consult with the participant or
caregiver via telephone for an average of 30 min to complete a scheduled comprehensive
medication therapy review to identify and resolve any medication-related problems. The
pharmacist constructed a personal medication record and a medication-related action
plan for the participant. The action planwas a participant-centred document that assisted
participants, caregivers, and the pharmacist in the resolution of identified medication-
related problems
Control group: standard/usual care
Outcomes The primary outcome of this studywas participant-level, 60-day, all-cause EDutilisation.
This outcome was defined as a dichotomous variable (i.e. the participant visited the ED
1 or more times following the intervention or they did not)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Site and participant randomisation was a 2-step process. Firstly
a simple random sample of 40 co-ordinating home healthcare
centres, with a monthly census of ≥ 20 admitted participants,
was selected among 419 care centres from a nationwide Home
Health Agency (Amedisys, Inc, BatonRouge, LA). Then, at each
study site, using blocks of 7 participants, and constrained for
equal allocation to study intervention or usual care groups
Allocation concealment (selection bias) Low risk Home Health Agency nurses were blinded to their participants’
group assignment to prevent bias during the initial in-home
admissions assessment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants did not know to which group they were allocated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Selective reporting (reporting bias) Low risk All outcomes were reported.
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Protection against contamination bias Low risk Cluster-randomisation with a small chance of contamination
Other bias Unclear risk Unclear
Gurwitz 2014
Methods RT, total study duration not provided
Participants 5077 hospital discharges: 2563 intervention discharges, 2514 control discharges
Final sample: 1870 intervention, 1791 control
Setting: large multispecialty group practice
Diagnostic criteria: ≥ 65 years discharged from hospital to home
Interventions Professional intervention
Intervention: an automated system was developed to facilitate the flow of information
to the medical group’s primary care providers about individuals who were discharged to
home from the hospital
In addition to notifying providers about an individual’s discharge, the system provided
information about new drugs at the time of hospital discharge, warnings about selected
drug-drug interactions, recommendations for consideration of dose changes and labo-
ratory monitoring of high-risk medications, and alerts to the provider’s support staff to
schedule a post hospitalisation office visit within 1 week of discharge
Control: care as usual
Outcomes Whether discharged individuals had an office visit with a primary care physician in the
7-, 14-, and 30-day periods after hospital discharge was determined, as was whether a
participant was rehospitalisation within 30 days. Information related to office visits and
hospitalisations was ascertained from the medical group’s electronic health record and
from health plan data, which allowed for determination of whether a rehospitalisation
had occurred at any hospital and not just the primary hospital that served individuals
under the care of the medical group. Analysts blinded to intervention status determined
these outcomes at least 6 months after completion of the study
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random number generator was used to assign
a discharge to the intervention or control group
Allocation concealment (selection bias) Low risk Computer allocated discharges
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Automated system was used. Also participants
were not aware of which group they were in
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comparable rates of attrition in intervention
and control groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Analysts blinded to intervention status deter-
mined the outcomes. (The trialist reviewing the
data (JHG) was unaware of which type of unit
the event had occurred on.)
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Protection against contamination bias Unclear risk The study is a cluster design and the authors
stated the following, “Efforts were made to
limit crossover of prescribers between inter-
vention and control units, however, some pre-
scribers worked simultaneously on both inter-
vention and control units.”
Other bias Unclear risk Unclear risk
Hawes 2014
Methods RT
18 months
Participants 61 participants: 24 intervention, 37 control
Unclear how many participants were analysed
Setting: healthcare system’s outpatient family medicine centre
Diagnostic criteria:
In the first year of the study, inclusion criteria had to be 1 of the following 3 criteria:
• reason for admission was heart failure, COPD, hyperglycaemic crisis, stroke, or
non-ST elevation myocardial infarction/unstable angina (NSTEM/UA)
• > 3 hospitalisations in the past 5 years
• ≥ 8 scheduled medication anticipated at discharge
In the second year, the criteria were changed to the following:≥ 8 scheduledmedications
anticipated at discharge
Interventions Organisational.
Participants in the intervention group were scheduled for a care transitions clinic visit
with a clinical pharmacist approximately 72 h post discharge, and prior to the post-
hospitalisation, primary care-provider visit. The visit involved performing a complete
medication history, identifying and resolvingmedication discrepancies, creating a current
medication list for both the medical record and the participant, and counselling on
appropriate medication use. During these visits, the pharmacist identified discrepancies
between the best possible medication discharge list and the discharge summary, and
characterised medication discrepancies using predefined categories
Study participants in the usual care group were scheduled to see their primary care
provider for a post-hospitalisation visit with no interim pharmacist intervention. Medi-
cation discrepancies of study participants not attending care transitions visits were iden-
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tified and characterised by study personnel in the same manner as those in the interven-
tion group
Study personnel reviewed study participants’ medical records to quantify 30-day ED
visits and rehospitalisation at the study institution. All study participants received a
phone call approximately 30 days after discharge to report hospitalisations or ED visits
at outside institutions. Only hospitalisations and ED visits at the study institution were
included for those participants who were not able to be contacted after 3 phone call
attempts
Both the intervention and control group received clinical pharmacy services for the
familymedicine inpatient service andoutpatient familymedicine clinic. Inpatient clinical
pharmacists conducted rounds with the medical team daily, reviewed and monitored
medications for effectiveness and safety, and made recommendations to the physician
staff to optimisemedications. Participants in both groups received this usual care from the
inpatient pharmacist. The role of the inpatient pharmacist in the study was to collaborate
with the inpatient medical team to create a BPMDL for all study participants just prior
to discharge. The BPMDL was used to identify medication discrepancies, and it served
as the gold standard list of medications that the participant should take after discharge.
The BPMDL accounted for home medications, medication changes made during the
hospitalisation, and medications that should be initiated or discontinued on discharge
Outcomes The 3 prespecified primary outcomes of this study were a composite of the occurrence
of a hospital admission or an ED visit within 30 days after hospital discharge and the
resolution of medication discrepancies before the primary care provider visit. Secondary
outcomes include the individual rates of rehospitalisation and ED visits within 30 days
after discharge
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk For the first year of study, a random number generator was used
to randomise participants. For the second year, block randomi-
sation with a block size of 4 was used
Allocation concealment (selection bias) Low risk A computer was used to randomise
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants did not know they were receiving the intervention,
however, pharmacists may have been aware that they were de-
livering the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk Half of the intervention participants did not participate in the
clinic visit
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Hospital admissions and emergency room visits are objective
outcomes
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Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Protection against contamination bias Unclear risk It cannot be determined if the control group was contaminated
by the intervention
Other bias Unclear risk Small sample size. Also, recall bias may have operated as par-
ticipants provided a self-report of hospitalisations and ED visits
outside of the study institution. It is not clear what was the final
analysis sample
Holland 2005
Methods RT
Setting: home visit study (primary care)
Study duration: 6 months
Participants 872 participants in a home visit study. Researchers recruited patients from four general
hospitals and six community hospitals if they were aged ≥ 80 years, admitted as an
emergency, intended to be discharged to their own home or warden-controlled accom-
modation, and prescribed ≥ 2 drugs on discharge
Exclusion criteria: participants received dialysis treatment and participation in an inten-
sive discharge service on 1 site
Age (years) (mean ± SD): intervention 85.4 (4); control 85.5 (4); not significant
Sex female n (%): intervention 262 (61.1); control 272 (63.8); not tested for significance
Country: UK
Comorbidity: baseline diagnosis: cardiovascular (total): intervention 134 (31.2), con-
trol 144 (33.8); myocardial infarction/angina: intervention 57 (13.3), control 65 (15.
3); heart failure: intervention 38 (8.9), control 34 (8.0); musculoskeletal (total): inter-
vention 61 (14.2), control 65 (15.3); fracture: intervention 37 (8.6), control 40 (9.4)
; gastrointestinal (total): intervention 47 (11.0), control 54 (12.7); respiratory (total):
intervention 48 (11.2), control 49 (11.5); COPD/asthma: intervention 15 (3.5), con-
trol 13 (3.1); lower respiratory tract infection: intervention 16 (3.7), control 22 (5.2);
neurological: intervention 40 (9.3), control 25 (5.9); stroke/transient ischaemic attack:
intervention 16 (3.7), control 14 (3.3); senility/dementia: intervention 16 (3.7), control
6 (1.4); genitourinary: intervention 17 (4.0), control 16 (3.8); cancer (total): interven-
tion 15 (3.5), control 7 (1.6); other or unclassified: intervention 67 (15.6), Control 66
(15.5)
Sociodemographic: not mentioned
Ethnicity: not mentioned
Participants recruited between October 2000 and December 2002
Interventions Initial referral to a review pharmacist included a copy of the participant’s discharge letter.
Pharmacists arranged home visits at times when they could meet participants and carers.
Pharmacists assessed participants’ ability to self-medicate and drug adherence, and they
completed a standardised visit form. Where appropriate, they educated the participant
and carer, removed out of date drugs, reported possible drug reactions or interactions
to the general practitioner, and reported the need for a compliance aid to the local
pharmacist. Where a compliance aid was recommended, this was provided within the
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trial and a filling fee was paid to the local pharmacist. 1 follow-up visit occurred at 6-8
weeks after recruitment to reinforce the original advice
Control participants received usual care.
Outcomes The primary outcome was total number of emergency admissions to hospital over 6
months. Secondary outcomes included deaths, admissions to residential homes and
nursing homes, and self-assessedQoLmeasured using the EQ-5D. Participants also rated
their health on a visual analogue scale from 100 (perfect health) to 0 (worst imaginable
health). The EQ-5D and visual analogue scales were collected at baseline, 3 months, and
6 months. Data were collected on emergency admissions from hospital episode statistics
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Third party telephone randomisation
based on a computer-generated sequence
in blocks of varying length. Randomisation
appeared adequate
Allocation concealment (selection bias) Low risk Sequence was concealed based on what is
noted above about sequence generation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was not done as stated in the
manuscript, “Because of the nature of the
intervention, no “placebo” could be pro-
vided. Participantswere told after randomi-
sation which group they were in.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up of the main outcome (hospital
admissions) was good-only 3% of partici-
pants withdrew or were lost to follow-up
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This is less important for our purpose as we
are looking at objective outcomes (hospi-
talisations, ED visits, and mortality)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Protection against contamination bias Unclear risk It can not be determined if the control
group has been contaminated by interven-
tion
Other bias Low risk There is no other bias.
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Methods RT
Setting: community participants
Follow up: 3 months
Participants 240 participants discharged to the community for the first time on oral anticoagulant
warfarin (regardless of strength, gender, or age)
There was no significant difference between the groups in terms of age, all participants
60.2 years ± 17.84
Sex of participants: male 160 (58.3%). There was no statistically significant difference
found between the groups based on indication for anticoagulation, with atrial fibrillation
representing themost common indication. All participants lived close to the participating
medical centre and could access it easily
Country: United Arab Emirates
Comorbidity: atrial fibrillation: 82 (34.2%), valve replacement: 37(15.4%), CHF:32
(13.3%), peripheral artery disease: 8 (3.33%), left ventricular thrombus: 7 (2.91%),
stroke: 9 (3.75%)
Interventions Intervention (Group A) was the ’counselled’ group, whereas, control (Group B) was the
’non-counselled’ group
After initial physician/pharmacist consultation in a standard care setting, 1 group was
thoroughly counselled, defined by the following:
• Once-a-week telephone consultation reviewing a series of pre-designed set of
questions (same questions asked weekly)
• 2 home visits per month per participant by either a nurse or a pharmacist
(reviewing questions and basic information). Visits were 12-14 days apart, generally.
• Any additional contact as requested by the participant in the intervention group.
The other group received no follow-up consultation other than what was ordered by
their own physician in a standard care setting. This group was asked only to visit the
anticoagulation clinic twice a month for 3 months to evaluate international normalised
ratio levels
Outcomes Number of adverse events, emergency visits and inpatients admissions
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation is not described
Allocation concealment (selection bias) Unclear risk The first 240 participants discharged or
prescribed for the first time warfarin (re-
gardless of strength, gender, or age) were
divided randomly and assigned a interven-
tion or control group
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not fully described: separation of interven-
tion and control groups is not exclusive
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss of participants from the study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described how and who measured the
outcomes
Selective reporting (reporting bias) Low risk The study reported the proposed outcome.
Protection against contamination bias Unclear risk It is not clear if the control group was con-
taminated by the intervention
Other bias Unclear risk Not applicable
Kaczorowski 2011
Methods 2-arm, community, cluster-randomised trial
Study duration: 3 years
39 eligible communities were stratified, geographically defined according to municipal
boundaries, by population size (3 strata) and geographical location (4 strata). An inde-
pendent expert in cluster-randomised trials then used a random number generator to
randomly allocate communities in each stratum to receive either CHAP or no interven-
tion
Participants 39 communities (148,589 participants) initially and 145,441 participants after follow-
up post intervention
Setting: 39 eligible communities, geographically defined according to municipal bound-
aries, by population size (3 strata) and geographical location (4 strata); community-based
Sex male (%): intervention communities 42.65 ± 1.19, control communities 42.92 ± 2.
16
Country: Ontario, Canada
Comorbidity:
No. of prescription drugs in previous year: control communities: 7.25 (0.49), interven-
tion communities: 6.98 (0.54)
No. of comorbidity groups in previous 2 years: control communities: 7.31 (0.30), inter-
vention communities: 7.17 (0.50)
Charlson comorbidity index in previous 2 years: control communities: 0.57 (0.09),
intervention communities: 0.58 (0.11)
Diabetes (%): control communities: 22.16 (2.34), intervention communities: 21.20 (2.
79)
History of congestive heart failure (%): control communities: 12.19 (1.91), intervention
communities: 12.45 (2.34)
Rurality index: control communities 28.96 (13.60), intervention communities: 31.63
(14.09)
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Low-income status (%): control communities: 16.95 (8.55), intervention communities:
18.57 (11.33)
Ethnicity: Not stated.
Interventions Communities were randomised to receive CHAP (n = 20) or no intervention (n = 19)
In CHAP communities, residents aged ≥ 65 were invited to attend volunteer-run car-
diovascular risk assessment and education sessions held in community-based pharmacies
over a 10-week period; automated blood pressure readings and self-reported risk factor
data were collected and shared with participants and their family physicians and phar-
macists
In both intervention and control arms, residents received the usual health promotion
and healthcare services available to all Ontarians under its publicly financed universal
health insurance programme
Outcomes Rates of hospital admission for acute myocardial infarction, CHF, and stroke in these
39 communities and the 2001 census population estimates for people aged ≥ 65 years
and over for power calculations
Notes A potential limitation of CHAP is the short duration of the intervention. The 10-week
exposure to CHAP may be too short to affect hospital admission rates
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The 39 eligible communities were strati-
fied by size of the population ≥ 65 years (3
groups) and geographic location (4 groups)
, forming seven substrata
Communities within each stratum were
randomly allocated to either the interven-
tion (n = 20) or control arm of the study (n
= 19) by an independent expert in cluster-
randomised trials not associated with the
study
Allocation concealment (selection bias) Low risk The independent expert in cluster-ran-
domised trials was not associated with the
study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although intervention community mem-
bers (older adults, family physicians, vol-
unteers, pharmacists) were clearly aware of
their group assignment, the names of con-
trol communities were not publicised and
control community members were not no-
tified that the study was taking place
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition reported. Cluster-randomised
trial of communities reporting rates of hos-
pitalisation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Though unlikely, community members’
knowledge of the evaluation could influ-
ence outcomes, but hospitalisation rates
were retrieved from a population-based ad-
ministrative health dataset
Selective reporting (reporting bias) Low risk Data retrieved from routinely collected,
population-based administrative health
data
Protection against contamination bias Unclear risk It is hard to determine if the control group
is contaminated with the intervention
Other bias High risk Short duration of the intervention may
have had an impact on detection of out-
comes such as hospital admissions.We con-
sidered other bias due to cluster randomi-
sation
Korajkic 2011
Methods RT
Setting: ambulatory setting
9 months
Participants 70 participants
Ambulatory setting
Attendees at a heart failure outpatient clinic, > 18 years, hadNew YorkHeart Association
class II, III or IV heart failure, stable signs and symptoms of heart failure, clinically
euvolaemic, daily frusemide dose up to a maximum of 320 mg, treatment with other
drugs such as beta-blockers, digoxin, vasodilators and spironolactone was permitted
Participants were excluded if they were not on frusemide; were on a daily frusemide
dose above 320 mg and/or thiazide diuretic; had baseline renal impairment (serum
creatinine concentration > 200 µmol/L or on dialysis); had a severe psychiatric illness or
moderate-severe dementia; life expectancy of < 3 months; severe hearing impairment or
legal blindness; or had difficulty understanding and speaking English and did not have
an interpreter or family member to assist. Other exclusions included scheduled cardiac
surgery; heart transplant candidacy; inability to give informed consent; and no access to
a telephone
Interventions Pharmacist intervention focused on participants improving self-care, recognising symp-
toms of fluid retention, measuring weight daily and self-adjusting diuretic dose using
frusemide
Intervention group: participants assigned to the intervention group received usual care
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plus pharmacist intervention
The intervention was provided to every participant in the intervention group and con-
sisted of a 30-min educational session during the clinic appointment. The pharma-
cist intervention focused on participants improving self-care, recognising symptoms of
fluid retention, measuring weight daily and self-adjusting diuretic dose using a flexible
frusemide dose-adjustment regimen, and improving knowledge and understanding of
heart failure and heart failure medications
Usual care (control group): usual care was provided to all of the eligible participants by a
cardiologist, heart failure nurse co-ordinators and a dietitian during the clinic appoint-
ment. Usual care consisted of assessment of clinical status and medications, education
on daily weight measurement, diet, fluid and sodium management, and recognition of
signs and symptoms of fluid retention and dehydration. In case of a sudden increase in
weight of more than 1 kg/d for 2 d, participants were encouraged to contact the heart
failure nurse co-ordinators for advice in consultation with the cardiologist to self-adjust
their frusemide dose. The heart failure nurse co-ordinators followed up participants 48
h after a dose adjustment to assess if their weight had decreased and condition improved
The key difference between the groups was that the control group called a heart failure
nurse co-ordinator to discuss frusemide dose modification, while the intervention group
adjusted the diuretic dose themselves
Outcomes Hospital readmissions due to fluid overload: measured at 1st, 2nd and 3rd months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation occurred after selection cri-
teria had been observed. No description of
the randomisation method/sequence gen-
eration was presented
Allocation concealment (selection bias) Unclear risk A significant number of heart failure par-
ticipants were not good candidates for the
intervention. Only 1 in 3 participants who
met inclusion criteria remained eligible af-
ter application of exclusion criteria
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is unclear if participants were blinded to
the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessments and readmissions were eval-
uated and confirmed by an independent
doctor blinded to the randomisation using
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data from participants, hospital admissions
records and medical records
Selective reporting (reporting bias) Low risk All outcomes were reported as mentioned
at the start of the trial
Protection against contamination bias Unclear risk It can not be determined if the intervention
group interacted with the control group
Other bias Unclear risk The intervention was delivered by the same
pharmacist. It precludes study of other fac-
tors, such as pharmacist attitudes or be-
haviours that may have promoted delivery
of the intervention and limit the generalis-
ability of the intervention
This study was conducted at a single insti-
tution, and the resultsmay reflect local pop-
ulation characteristics and patterns of care
Krska 2001
Methods RT
Duration of study: 3 months
Participants 332 participants completed study (168 intervention and 164 control)
Setting: general practice
Diagnostic criteria: the inclusion criteria for participants were≥ 65 years, regular request
for ≥ 4 medicines via the computerised repeat prescribing system and ≥ 2 chronic
diseases. Exclusion criteria were dementia and being considered by the GP to be unable
to cope with the study
Age (years) (mean ± SD): intervention 74.8 (6.2), control 75.2 (6.6)
Sex female n (%): intervention 95 (56.5%), control 106 (64.6%)
Country: UK
Comorbidity: mean no. of chronic diseases: intervention 3.9 (1.4), control 3.8 (1.4), P
= 0.968
Sociodemographics: nothing of note
Ethnicity: not mentioned
Date of study: not mentioned but paper received by journal on 23 December 1999
Interventions 1 intervention group
Intervention group: a pharmaceutical care planwas drawnup for each intervention group
participant, listing all potential and actual pharmaceutical care issues, together with the
desired output(s), the action(s) planned to achieve the output(s) and the outcomes of
any potential pharmaceutical care issues already resolved by the pharmacist. Copies of
the plan were inserted in the participants’ medical notes and given to their GP, who was
asked to indicate their level of agreement with each pharmaceutical care issue identified
and with the actions. The pharmacist then implemented all remaining agreed actions,
assisted by other practice staff where appropriate
Control participants were similarly interviewed and pharmaceutical care issues identified,
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although no pharmaceutical care plan was implemented. Participants were advised to
consult any usual carers or health-care professionals in response to direct queries during
interview
Outcomes Number of hospital admissions
Notes The pharmacists undertaking the medication review also administered the SF-36 ques-
tionnaire and identified all care issues. There is also potential for GPs receiving recom-
mendations for some participants to increase their tendency to note similar issues in
control participants. In some cases the care plan was not fully implemented by 3 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using random number tables, 1 practice from each
of the 6 resultant categories was selected and invited
to participate. 1 practice refused and a further prac-
tice was randomly selected. Participants were ran-
domly allocated to the intervention or control group
Allocation concealment (selection bias) Unclear risk Although a random number table was used to se-
lect practices, it was not clear whether participant
assignment to intervention and control groups was
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was adequate because pharmacists only treated
intervention participants and did not know that the
participants they interacted with were in a study.
Also, participants did not appear to know whether
they were receiving an intervention or not
Incomplete outcome data (attrition bias)
All outcomes
Low risk Equal numbers of participants in the control and in-
tervention groups withdrew from the study. Around
14% to 15 % of the participants withdrew in each
group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This is less important for our purpose as we are look-
ing at objective outcomes (hospitalisations, ER vis-
its, and mortality)
Selective reporting (reporting bias) Low risk There is no evidence that there was selective report-
ing of results
Protection against contamination bias High risk It can not be determined if the control group was
contaminated with the intervention group
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Other bias Unclear risk In some cases, the care plan had not been fully im-
plemented by the 3-month follow-up
Lapane 2011
Methods Cluster-RT
Study duration: 2 years
Participants 6523 participants
Final sample: 1769 control, 1769 intervention
Diagnostic criteria: not relevant as homes were the unit of analysis not individuals
Age (years) (mean ± SD): average age of residents was not reported. At baseline 16%
of the residents in both intervention and control homes were aged 65-74 years, 36%
in intervention homes and 35% in usual care homes were 75-84 years, and 40% of the
residents in the intervention homes and 36% in the usual care homes were ≥ 85 years.
During the intervention period, 15% in both groups were 65-74 years, 39% were 75-
84 years, and 39% were ≥ 85 years
Sex, female n (%): at baseline, 72% of the residents in the intervention homes and
68% in the usual-care homes were female. During the intervention period, 74% of the
residents in the intervention and usual-care homes were female
Country: USA
Comorbidity: (intervention, control), dementia (35.4, 43.4); Alzheimer’s disease (12.7,
14.6), cancer (8.3, 12.1), diabetes mellitus (27.5, 31.0), cerebrovascular accident (22.2,
22.4), heart failure (26.5 , 28.5), coronary artery disease (18.6, 16.2), arrhythmia (15.
8, 15.8), hypertension (64.9, 61.8), other cardiovascular disease (23.6, 28.0)
Sociodemographics: nothing reported other than race
Ethnicity: 18% in intervention group and 11% in usual care group were minority race
at baseline. During the intervention period, 19% of both groups were minority race
Date of study: 2003-2004
Interventions Professional intervention
The overarching idea was to use health information technology to engage consultant
pharmacists and nursing staff to identify residents at risk for delirium and falls, imple-
ment proactive monitoring plans as appropriate, and provide reports to assist consultant
pharmacists in conducting the medication regimen review
Intervention: A Geriatric Risk Assessment MedGuide database for falls and delirium was
integrated into the pharmacies’ commercial pharmacy software system (Rescot LTCP
System) for the intervention homes
Control: usual care
Outcomes Incidence of potential delirium, falls, hospitalisations potentially due to adverse drug
events, and mortality
Notes Residents in the intervention homes experienced fewer falls, less potential delirium, and
death, but more hospitalisations than in the comparison homes. In new admissions,
there appeared to be a trend toward lower mortality (adjusted hazard ratio 0.88, 95% CI
0.66 to 1.16) and a lower overall hospitalisation rate (adjusted hazard ratio 0.89, 95%
CI 0.72 to 1.09) and a clear reduction in the rate of potential delirium (adjusted hazard
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ratio 0.42, 95% CI 0.35 to 0.52) in the intervention homes than the comparison homes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Cluster-randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Low risk All outcomes were reported.
Protection against contamination bias Low risk It can not be determined if the intervention group
was contaminated with the control group
Other bias Unclear risk There is no evidence of the presence of other bias.
We considered other bias due to cluster randomi-
sation
Lenaghan 2007
Methods RT
6 months
Participants 136 participants registered with 1 general practice (1 participant from each group with-
drew shortly after randomisation)
Home-based
> 80 years, living at home, taking≥ 4 oralmedications, and had≥ 1 additionalmedicine-
related risk factor Participants were excluded if they were resident in a care home or if
there was documented use of an adherence aid
Age: intervention 84.5 years, control 84.1 years (no SD supplied)
Gender female: intervention 46 (67.6%), control 42 (63.6%)
Country: UK
Sociodemographics: living alone: intervention 44 (64.7%), control 43 (65.1%); social
class (I, II, III): intervention 33 (48.5%), control 29 (43.9%); 9% of practice were aged
over 80 years (twice the national average)
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Ethnicity: 98.5% of the local town population were white, compared to 90.9% for
England
Interventions Comparing home-based medication review with standard care
The intervention: the pharmacist was asked to identify cases where adverse drug reactions
or drug interactions may be occurring. This was noted using a tick box on themedication
review form after detailed information had been gained from the participant regarding
all over-the-counter and prescribed drugs
The control group received standard care
Outcomes • Non-elective hospital admissions during the 6-month follow-up period
• Deaths
• Admission to care homes
• Number of drug items prescribed
• Self-assessed QoL
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No indication of random sequencing
Allocation concealment (selection bias) Low risk Randomisationwas carried out by a third party andwas stratified
by whether the participant lived alone
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is unclear if participants were blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported and reasons for attrition presented
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome data on hospital admissions were provided by hospital
episode statistics (not self-report) and are therefore unlikely to
be biased
Selective reporting (reporting bias) Low risk Outcome data on hospital admissions were provided by hospital
episode statistics (not self-report) and are therefore unlikely to
be biased
Protection against contamination bias Unclear risk Unclear
Other bias High risk Research was carried out in 1 rural general practice with a sin-
gle experienced review pharmacist, which has a bearing on the
generalisability of the results
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Methods Study design: a cluster-randomised design, this provides protection against contamina-
tion across trial groups when trial participants are managed within the same setting.
Participants in practices in the UK were managed by all GPs within the practice; the
control intervention was mediated by GPs, this precluded individual, participant-level
randomisation
Study duration: median follow-up was 4.7 years
Participants 2164 participants (174 practices)
Setting: general practice
Diagnostic criteria: consenting participants were eligible if aged ≥ 18 years and had
left ventricular systolic dysfunction confirmed by cardiac imaging conducted at a local
hospital (transthoracic echocardiography in 90% of cases). Participants did not have
to have symptoms or signs of heart failure. Family doctors received a semi quantitative
report of left ventricular systolic function (normal, mild, moderately or severely reduced)
instead of ejection fraction
Age (years) (mean ± SD): pharmacist intervention, 70.6 (10.3) and control 70.6 (10.1)
Sex female n (%): pharmacist intervention 320 (29%), control 329 (31%)
Country: UK
Comorbidity: hypertension, myocardial infarction, pharmaceutical care issue, coronary
artery bypass grafting, atrial fibrillation or flutter, diabetes mellitus, stroke, respiratory
disease, asthma
Sociodemographics: not mentioned
Ethnicity: not mentioned
Date of study: from 25 October 2004-6 September 2007
Interventions 1 intervention and 1 control
Participants from practices assigned to the intervention were offered a 30-min appoint-
ment with a pharmacist. The main aim of this review was optimisation of medical treat-
ment for left ventricular systolic dysfunction according to guidelines (supplementary
material online). If there was agreement between the pharmacist and the participant
during the consultation and subsequently with the family doctor, medications were ini-
tiated, discontinued, or modified by the pharmacist during 3-4 subsequent weekly or
fortnightly consultations. Family doctors provided usual care thereafter
No instructions were given to family doctors in the usual care practices. The study
pharmacists did not collect information on symptoms or examine the participants as this
was not part of their professional training
Outcomes • Death from any cause or hospital admission for heart failure (the primary
outcome)
• Death from any cause or hospital admission for a cardiovascular cause
• The number of participants admitted to hospital for any reason, for a
cardiovascular cause, and for heart failure
• The number of deaths attributed to a non-cardiovascular cause
Notes There was no difference inmortality or hospital admissions between the intervention and
the control group. (Mortality from heart failure should be reported in the final analysis
as this intervention was targeting heart failure management)
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was generated by a com-
puter
Allocation concealment (selection bias) Low risk Computer
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Cluster randomisation was undertaken
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Low risk All outcomes were reported
Protection against contamination bias Low risk It can not be determined if the intervention
group mixed with the control group
Other bias Unclear risk Unclear. We considered other bias due to
cluster randomisation
Malet-Larrea 2016
Methods Cluster-RT (pharmacies were the cluster unit of randomisation)
Participants 31; 17 intervention and 14 control, this was also the final sample that was analysed
Setting: community pharmacists
Diagnostic criteria: participants were ≥ 65, used≥ 5 medications for ≥ 6 months, with
the ability to complete the EuroQol 5D questionnaire
Interventions Organisational
IIntervention group: pharmacists allocated to the intervention group provided the med-
ication with follow-up service according to national guidelines. The medication review
with follow-up service started with a comprehensive interview undertaken in a private
area of the pharmacy. The pharmacist collected relevant information about the partic-
ipant’s health problems, medicines used, clinical and biological parameters (gathered
through medical records provided by the participant or measured in the pharmacy),
medication use, lifestyle habits and concerns about diseases and medications. Pharma-
cists also assessed the level of control of health problems by using information referred
by participants’ and/or clinical and biological parameters, depending on the type of
health problem (i.e. pain versus hyperlipidaemia) and classified every health problem
as controlled, uncontrolled or unknown. After performing a comprehensive medication
review, the pharmacist identified negative clinical outcomes related to medicines and
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drug-related problems. Subsequently, an action plan was agreed upon by the participant
and the physician if required. This medication review with follow-up service was focused
on both participants’ outcomes and medication use process and required a commitment
to follow-up
The usual care consisted of dispensing medicines prescribed by physicians and advice on
minor ailments
Outcomes Medication-related hospital admission was the primary outcome of this sub analysis.
Hospital admissions were recorded in participants’ visits to the pharmacies and the
medication related ones were identified through the expert panel after the fieldwork.
Kappa values ranging from 0.61 to 1 were considered as an acceptable incidence rate
ratio to measure the agreement among experts
The cost of hospital admissions estimated by diagnosis-related group was a secondary
outcome and the diagnosis-related groups were recorded after the fieldwork
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pharmacies were randomised to the inter-
vention or control group by an indepen-
dent researcher
Allocation concealment (selection bias) Low risk An independent researcher performed ran-
domisationusing a computer-generated list
of random numbers
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither the participants nor pharmacists
were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was little attrition and comparable
rates for intervention and control group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk For the sub analysis, the expert panel was
blind as to which group the participants
belonged so whether a hospital admission
was medication-related was not affected
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Protection against contamination bias Unclear risk Although pharmacies were randomised to
control and intervention groups, informal
contact between pharmacists may have led
to contamination
Other bias Unclear risk There is no evidence of other bias.
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Methods A prospective, multisite RT
Duration of study: 12 months
Participants Of 1054participants enrolled at the 9VeteransAffairs clinics, 523were randomised to the
intervention and531 to the control group.Of these, 950participants completed 6-month
follow-up questionnaires and 931 completed the study. Of participants completing the
study, 447 were in the intervention group and 484 were in the control group
Setting: Veterans Affairs clinics
Interventions: clinical input by pharmacists
Diagnostic criteria: participants were considered at high risk for drug-related problems
if they met ≥ 3 of the following criteria: were taking ≥ 5, were taking ≥ 12 doses/d,
had ≥ 3 chronic medical conditions, had ≥ 4 changes in their drug regimen over the
past year, had a history of noncompliance with drug therapy, or were taking an agent
that required therapeutic drug monitoring
Age: (years) mean ± SD: 67 ± 10.1
Sex n (%): intervention group 21 (0.04%), control, 20 (0.04%)
Country: USA
Comorbidity: hypertension, angina, hyperlipidaemia, arthritis, diabetes and COPD
Sociodemographics: not mentioned
Ethnicity: not mentioned
Interventions 1 intervention and 1 control
The intervention group was given a protocol to follow; the protocol indicated that each
participant should have ≥ 3 visits with the clinical pharmacist during the study, but
participants could be seen as frequently as deemed necessary to ensure appropriate care.
Visits were to occur between or concurrent with appointments with the primary care
provider or other physicians
The control group followed the usual care with no specific protocol given to clinicians
Outcomes Number of hospitalisations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned using
a central computer
Allocation concealment (selection bias) Low risk Computer-based
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk Some participants did not complete the
study and were reported in the study
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear how it was done
Selective reporting (reporting bias) Low risk All outcomes were reported
Protection against contamination bias Unclear risk It is not possible to determine if the control
group was contaminated with the interven-
tion group
Other bias Unclear risk It is unclear if there are other biases.
Moertl 2009
Methods Prospective, randomised study design
Study duration: 2 years
The major limitation of the study was selection bias because only participants who
responded to a letter of invitation had the opportunity to take part in the study
Participants 96 participants took part in the study; 48 were randomised to the nurse group and 48
to the non-nurse group
Setting: outpatient heart failure clinic
Diagnostic criteria: participants who survived index hospitalisation were invited by letter
to a visit for treatment optimisation at the outpatient heart failure unit. Among the
participants who appeared at the ambulatory visit, those with a verified heart failure
diagnosis and residing < 50 km from Vienna were eligible for the nurse intervention and
therefore offered to participate in the present study. Baseline evaluation was performed
by a cardiologist specialising in the management of heart failure. The ambulatory visit
comprised a patient history, physical examination, electrocardiogram, a routine blood
analysis, and, if necessary, an echocardiography. Furthermore, blood samples were taken
for later analysis of natriuretic peptides. The participants were thoroughly informed
about the disease of CHF and recommendations were made regarding medication, self-
assessment of weight, blood pressure and pulse, and diet and exercise management
The baseline demographic, clinical, and therapeutic characteristics were not statistically
different between the nurse group and the non-nurse group
Age (years) (mean ± SD): non-nurse, control (66 ± 13); nurse, intervention 70 ± 12
Country: Vienna, Austria
Comorbidity: hypertension, diabetes, respiratory diseases
Sociodemographics: not reported
Ethnicity: Austrian (unclear if they were all white)
Interventions 1 intervention and 1 control. There were 48 participants in each group
Intervention: home-based nurse care
Participants in the nurse group were visited by a nurse specialised in caring for people
with heart failure on the initial visit at the outpatient heart failure unit and then at their
home 3, 6, 9, and 12 months after randomisation
At home visits, the nurse checked and recorded weight, symptoms and signs of heart
failure, heart rate and blood pressure, and organised and reviewed blood analyses on
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demand, especially of electrolytes and renal parameters. Furthermore, the nurse had to
check for and, in co-ordination with the treating physician, implement guideline-based
medication.Moreover, the nurse was in charge of individualised participant and caregiver
education and enhancement of self-management. If the nurse noted any deterioration in
the participant’s status, she reported to the treating physician or advised the participant
to visit the treating physician
Control group received the usual care provided
Outcomes Admission for heart failure at 12 months and 24 months
Mortality at 12 months and 24 months
Notes The major limitation of the study is selection bias because only participants who re-
sponded to a letter of invitation had the opportunity to take part in the study
See notes to other relevant studies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is unclear how the sequence generation
was done.
Allocation concealment (selection bias) High risk The major limitation of the study was se-
lection bias because only participants who
responded to a letter of invitation had the
opportunity to take part in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is unclear if participants were blinded to
the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk There is no incomplete outcome data.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Independent data collector
Selective reporting (reporting bias) Low risk All outcomes were reported as mentioned
at the start of the trial
Protection against contamination bias Unclear risk Unclear
Other bias High risk Small sample size
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Murray 2004
Methods RT with a 2 x 2 factorial design using physician and pharmacist interventions, which
resulted in 4 groups of participants: physician intervention only, pharmacist intervention
only, intervention by physician and pharmacist, and intervention by neither physician
nor pharmacist (control)
Study duration: 1 year
Participants Total participants 712 with uncomplicated hypertension
Control: (n = 171), pharmacist intervention: (n = 180), physician intervention: (n =
181), dual intervention: (n = 180)
Setting: large, inner-city, academic, internal medicine practice affiliated with the Indiana
University School of Medicine. The primary venues for this study were the general
medicine practice and the Wishard Memorial Hospital outpatient pharmacy, which at
the time of the study were located 1 floor apart in the Regenstrief Health Centre
Eligibility for this study required that participants had evidence in their electronic med-
ical records of hypertension as an active outpatient diagnosis or, in the absence of such a
diagnosis, all of the following: ≥ 2 systolic blood pressure measurements of ≥ 140 mm
Hg, ≥ 2 diastolic blood pressure measurements of ≥ 90 mm Hg, and a prescription for
≥ 1 antihypertensive agent. Qualifying antihypertensive agents were ace-converting en-
zyme inhibitors, b-blockers, calcium channel blockers, oral clonidine and topical patch,
diuretics, and other less commonly prescribed drugs such as methyldopa and reserpine.
Participants were excluded from taking part if they had evidence (diagnoses or test re-
sults) indicating the presence of a cardiovascular complication such as coronary artery
disease, myocardial infarction, stroke, heart failure, or renal insufficiency
Age mean ± SD: control: 54 ± 11, pharmacist intervention: 54 ± 11, physician interven-
tion: 56 ± 11, dual intervention: 54 ± 11
Gender female n (%): control: 75 (44%), pharmacist intervention: 79 (44%), physician
intervention: 78 (43%), dual intervention: 81 (45%)
Country: USA
Comorbidity: none stated
Sociodemographics: potential participants who were able to communicate (could hear
and speak English and understand instructions), had access to a working telephone, and
were willing to provide written informed consent were enrolled
Formal education, mean ± SD (years), control: 11 ± 3, pharmacist intervention: 10 ± 3,
physician intervention: 11 ± 3, dual intervention: 11 ± 3
Married (%), control: 30, pharmacist intervention: 29, physician intervention: 28, dual
intervention: 30
Number of people in household,mean ± SD , control: 2.3 ± 1.5, pharmacist intervention:
2.6 ± 1.7, physician intervention: 2.3 ± 1.4, dual intervention: 2.2 ± 1.2
Live alone (%), control: 32, pharmacist intervention: 28, physician intervention: 32,
dual intervention: 30
Ethnicity: unknown; control: 57 (33%), pharmacist intervention: 61 (34%), physician
intervention: 58 (32%), dual intervention: 58 (32%)
Interventions Physician intervention
The computer-based ordering system generated care suggestions for both intervention
and control groups; however, the suggestions were displayed by the computer to physi-
cians and/or pharmacists for participants randomised to the appropriate intervention
groups. This allowed the researchers to assess the numbers and types of interventions
that the control group was eligible to receive as well as those in the 3 intervention groups.
For participants in the physician intervention group, all care suggestions based solely on
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earlier Regenstrief medical records system data were generated at the time that the en-
counter form was printed and were displayed at the end of the drug list. All hypertension
care suggestions for intervention participants were displayed as “suggested orders” on
physicians’ workstations when they wrote orders after participant visits. This computer
screen displayed the actual suggested order, possible actions for each order (order or
omit), and a brief explanation of the rationale for the order. Physicians could list full
guidelines and literature citations associated with the specific suggestions by using the
workstation’s ’help’ key
Pharmacist Intervention
When any participant brought a new or refill prescription (written in any affiliated clinic,
physician’s office, orWishardHospital emergency department) to theWishard outpatient
pharmacy, a pharmacy technician entered the data into the Regenstrief medical records
system pharmacy module. This was required for all prescriptions because it was the only
way to generate and complete a financial transaction for prescriptions in the outpatient
pharmacy. After entering prescription data, a high-speed printer created a label to affix to
the participant’s drug container. The technician who filled the prescription notified the
pharmacist for all intervention participants. The labelled drug product was checked by a
pharmacist who dispensed the agent to the participant and provided counselling. For this
study the researchers created the pharmacist intervention recording system. This software
programme was used by all Wishard pharmacists to document all pharmaceutical care
interventions provided to any outpatient. For participants enrolled in this study only
(regardless of study group), care suggestions generated by the Regenstrief medical records
system or the outpatient workstations (in response to data entered by the physician, e.g.
new antihypertensive prescriptions) were stored in the pharmacist intervention recording
system. For participants randomised to receive care from an intervention pharmacist
who had such care suggestions, the high-speed printer printed a note together with drug
container labels directing the pharmacist to the pharmacist intervention recording system
to display care suggestions that were identical to those viewed by intervention physicians
Physician and pharmacist (dual) Intervention
Control group: the control group did not receive any interventions by either physician
nor pharmacist
Outcomes The primary end point was generic health-related QoL. Secondary end points were
symptom profile and side effects from antihypertensive drugs, number of emergency de-
partment visits and hospitalisations, blood pressure measurements, participant satisfac-
tion with physicians and pharmacists, drug therapy compliance, and health care charges
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were taken on a next-in-line
basis - no random sequence, but sequen-
tially allocated to either intervention or
control. Physicianswere randomly assigned
to practices. There were no details of how
randomisation was generated
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Allocation concealment (selection bias) Low risk Participating physicians and pharmacists
were unaware of the study hypothesis
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participating physicians and pharmacists
were unaware of the study hypothesis. All
research assistants and interviewers were
blinded to group assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data extracted from Regenstrief medical
records system records for ED visits, hospi-
talisations and mortality
Selective reporting (reporting bias) Low risk All selected outcomes were reported. Ran-
dom audit (10%) of all paper records from
intervention and control groups
Protection against contamination bias Low risk It is hard to determine if the control group
was contaminated with the intervention
group
Other bias Unclear risk Unclear. There is no evidence of other bias
Nabagiez 2013
Methods RT
Study duration: 13 months
Participants 701 participants
Setting: home
Diagnostic criteria: all participants discharged to home following coronary artery bypass
graft procedure and/or valve repair or replacement and/or aneurysm repair, or other
cardiac procedure
Age (years) (mean ± SD): intervention group: 62.8 (10.6), control group: 63.2 (10.9)
Sex female n (%): intervention group: 73 (21.5%), control group: 88 (24.4%)
Country: USA
Comorbidity n (%): diabetes mellitus: intervention 123 (34.0), control 111 (32.6); hy-
pertension: intervention 268 (74.2), control 283 (83.2); dyslipidaemia: intervention 263
(72.8), control 274 (80.5); dialysis: intervention 8 (2.2), control 7 (2.0); cerebrovascular
accident: intervention 15 (4.1), control 9 (2.6); COPD: intervention 44 (12.1), control
30 (8.8); peripheral vascular disease: intervention 29 (8.0); control 25 (7.3); previous
myocardial infarction: intervention 146 (40.4), control 144 (42.3); CHF: intervention
51 (14.1), control 48 (14.1); arrhythmia: intervention 37 (10.2), control 39 (11.4)
Sociodemographics: not stated
Ethnicity: intervention group: 289 (84.4%)white, 53 (15.5%)non-white; control group:
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318 (88%) white, 43 (11.9%) non-white
Date of study: August 2009-September 2011
Interventions 1 intervention group 340 participants, control 361 participants
Hospital-employed, cardiothoracic physician assistants conducted home visits on post-
discharge days 2 and 5, with occasional variation due to participant availability and
Sundays, on which no house calls were made. The same hospital-based physician assis-
tants responsible for perioperative and intraoperative care were assigned to make house
calls. During a house call, the physician assistant performed a focused physical exam
and reviewed the participant’s medications. Adjustments were made to the participant’s
medications, and new medications were prescribed as necessary. The surgical wounds
were examined carefully and all participant concerns were addressed. Prescriptions were
written for antibiotics, blood work, or imaging studies when indicated. Arrangements
were made if the participant needed to be evaluated as an inpatient. All findings were
documented on the visit form
Both groups were seen in the office on post-discharge weeks 2 and 4
The control group was seen at home by standard visiting nurses without any specialty
training or expertise in caring for people with cardiac surgery
Outcomes Hospital admissions/number of people admitted to hospital
Notes Not sure of randomisation and these were hospital-based physician assistants working
in homes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear from the document
Allocation concealment (selection bias) Unclear risk Unclear from the document
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear from the document
Incomplete outcome data (attrition bias)
All outcomes
High risk 19% of the participants in the intervention group re-
fused to participate or failed to respond to requests to
participate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This is less important for our purpose aswe are looking
at objective outcomes (hospitalisations, ED visits, and
mortality)
Selective reporting (reporting bias) Low risk No evidence of this
Protection against contamination bias Low risk No contamination
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Other bias Unclear risk Unclear. There is no evidence of other bias
Okamoto 2001
Methods Prospective, randomised, comparative study
Duration: 6 months
Participants 330 participants with mild-to-moderate essential hypertension
Age, years (mean ± SD): intervention 61.95 ± 11.4, control 61.71 ± 11.3, P = 0.85
Sex female n (%): intervention 72 (44%), control 90 (54%)
Country: USA, California
No statistically significant differences were noted between the groups. Concurrent disease
(number of participants) intervention 98, control 95, P = 0.74
Smoker (number of participants): intervention 15, control 9, P = 0.18
Alcohol consumer (number of participants): intervention 12, control 9, P = 0.47
Sociodemographics: not reported
Ethnicity: not reported
Interventions Hypertension care provided by either the pharmacist-managed hypertension clinic or
physician-managed general medical clinics
In the pharmacist-managed hypertension clinic, a clinical pharmacist managed the treat-
ment of participants, who made up the experimental group. Physicians were contacted
and provided consent for any therapeutic changes but were asked not to adjust drug
therapy unless a lack of intervention would be dangerous for the participant
In the physician-managed clinic, physicians managed the treatment of participants in-
dependently with no pharmacy intervention; this was the control group
Participants randomly assigned to the pharmacist-managed hypertension clinic group
were counselled by the clinical pharmacist. The pharmacist informed the participants
that an effort would be made to decrease the number of drugs they took for hypertension
or to alter their therapy by administering more appropriate or less expensive drugs to
achieve similar or improved blood pressure control. The pharmacist determined themost
appropriate antihypertensive regimen for the participant and ordered laboratory tests as
needed. The pharmacist also provided education on nonpharmacologic ways to control
blood pressure
Control group: participants randomised to the physician-managed clinic group were re-
ferred back to their primary care provider for hypertension treatment. These participants
received no intervention, and physicians treated them in the customary manner
Outcomes Number of hospitalisations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation, but no description of se-
quence generation
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Allocation concealment (selection bias) Unclear risk Not clear. The document does not state
whether the allocationwas concealed or not
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is unclear if participants were blinded to
the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates in both groups are compa-
rable for various reasons
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of data collection is not clear.
Selective reporting (reporting bias) Low risk All outcomes were reported as mentioned
at the start of the trial
Protection against contamination bias Unclear risk It is hard to determine if the intervention
group was contaminated with the control
group
Other bias Unclear risk It would have been more desirable to have
only newly diagnosed participants, but the
sample size was already small. Results can-
not be extrapolated to other physician
groups
Olesen 2014
Methods RT
Duration: not provided
Participants 630 participants, 315 intervention, 315 control. Final sample analysed 253 intervention,
264 control
Setting: pharmaceutical care was provided at home
Diagnostic criteria: participants aged≥ 65 on 5 prescription medications taken without
assistance
Interventions Organisational
Participants in the ‘pharmaceutical care’ group were visited at home by a pharmacist at
the beginning of the project. The pharmacist examined the medicines list with regard to
possible side-effects, interactions, and administration, then tried to make the regime less
complex, informed the participants meanwhile about the drugs, listened to questions
concerning the drugs, handed over information leaflets, and motivated adherence. Nine
different pharmacists were involved and adhered to the Danish manual for pharmaceuti-
cal care: ‘Medication Review -Managing Medicine Manual’. The aim of the ‘Medication
Review - Managing Medicine’ is to prevent, identify, and resolve drug-related problems
and to contribute to rational pharmacotherapy for participants and society
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Control participants were not provided any intervention.
Outcomes The primary endpoint was treatment adherence assessed by a pill-count in all participants
during 1 year. Only oral prescription drugs taken throughout the study period were
included in the adherence calculation. In addition, a project nurse visited all participants
initially, then at 6 and 12 months to photograph pills to be counted later by a ‘counter
pen’ (a combination of a marker and a digital counter). The adherence rate (%) per drug
was calculated as mean adherence rate during 1 year. We also calculated adherence rates
for the intervals of 0-6 and 6-12 months. Secondary outcome measures included drug-
related problems, hospitalisations and mortality measured during the intervention year
and at 2-year follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned to control and inter-
vention groups
Allocation concealment (selection bias) Unclear risk No mention is made of allocation concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Pharmacist was aware of whether the participant was in
the intervention group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Little differential attrition between intervention and con-
trol groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Hospitalisations and mortality are objective outcomes.
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Protection against contamination bias Low risk Control group participants were not provided any phar-
maceutical intervention
Other bias Unclear risk According to the study authors, control participants were
not exposed to any intervention, but something was done
and this was not specified
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Methods Prospective, randomised, controlled, longitudinal, 2-year pilot study
Participants 104 participants, nonprofit university-affiliated dialysis clinic
Participants > 18 years with end-stage renal disease who were undergoing a stable
haemodialysis regimen for at least 3 months
Age (yrs ± SD): intervention 56.3 ± 15, control 60.5 ± 14.7
Sex female n (%): intervention 22 (39), control 28 (60), P < 0.03
Country: USA, New Mexico
Baseline clinical characteristics: length of time participant had been receiving haemodial-
ysis (years): intervention 2.8 ± 1.8, control 2.4 ± 2.2
Number of drugs used: intervention 10 ± 4, control 10 ± 4
Cost of drugs (USD); intervention 430 ± 197, control 451 ± 267
Comorbidity: end-stage renal disease aetiology
Diabetes mellitus n (%): intervention 22 (39), control 23 (49)
Hypertension n (%): intervention 18 (32), control 12 (26)
White n (%): intervention 13 (23), control 16 (34)
Hispanic n (%): intervention 17 (30), control 15 (32)
Native American n (%): intervention 13 (23), control 5 (11)
Interventions Intervention group: effects of pharmaceutical care, consisting of 1-1, in-depth drug
therapy reviews conducted by a clinical pharmacist, versus
Control group: standard care, consisting of brief drug therapy reviews conducted by a
nurse on several participant outcomes in ambulatory participants undergoing haemodial-
ysis
Participants assigned to pharmaceutical care had drug therapy reviews conducted by a
nephrology-trained clinical pharmacist or 1 of 2 pharmacists completing postdoctoral
training in nephrology pharmacotherapy. Types of drug-related problems were recorded
and evaluated by using a previously described method. All drug-related problems were
assigned to 10 possible categories: untreated indications, improper drug selection, sub
therapeutic dosage, overdose, adverse drug reactions, drug interactions, failure to receive
drugs, medical record discrepancy, inadequate education of participant or health care
professional, and drug use without indication. The drug-related problems were further
categorised into therapeutic drug classes, and the outcome related to the drug-related
problem intervention was captured
The standard care group served as the control group. The participants in the standard
care group received periodic drug profile updates by dialysis nursing staff as mandated
by the dialysis clinic policy and procedure. These are typically brief interactions in which
participants are queried as to whether any drugs have changed since the last review
Outcomes Mortality
Notes The study experienced high attrition due to death, transplantation, or transfer to a
different facility, with about 50% of participants remaining at the end of study
The study also did not conduct an assessment of the relationship between drug-related
problem resolution and hospitalisations, which could provide useful information as to
whether targeted pharmaceutical care interventions would be helpful
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned, by dialysis shift but no
description of sequence generation
Allocation concealment (selection bias) Low risk Randomisationwas conducted by the clinic
nurse manager, who had no affiliation with
the study, by drawing the shift name from
an opaque envelope and assigning the first
3 drawn shifts to pharmaceutical care and
the remainder to standard care
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding as far as participants and person-
nel were not communicating - different
shifts
Incomplete outcome data (attrition bias)
All outcomes
High risk There was a high level of attrition due to
death, transplantation or transfer to a dif-
ferent facility, with about 50% of partici-
pants remaining at the end of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome data on hospital admissions were
provided by hospital episode statistics (not
self-report) and are therefore unlikely to be
biased
Selective reporting (reporting bias) Low risk All outcomes were reported as mentioned
at the start of the trial
Protection against contamination bias Low risk It can not be determined if the intervention
group was contaminated with the control
group
Other bias Unclear risk Unclear. It is unclear if there is other bias.
Roberts 2001
Methods Cluster-RT
Study duration: 12 months
Participants 3230 participants
Setting: nursing homes
Diagnostic criteria: none provided
Age: participant characteristics not provided in terms of mean age, just percent of sample
in intervention and control groups that were in particular age ranges
Sex: participant characteristics not provided
Country: Australia
Comorbidity: not provided
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Ethnicity: participant characteristics not provided
Date of study: unknown although paper was initially received for publication in May
2000
Interventions 1 intervention group
The 12-month intervention involved 3 phases: introducing a new professional role to
stakeholders with relationship building, nurse education, and medication review by
pharmacists who had a postgraduate diploma in clinical pharmacy
The clinical pharmacy service model introduced to each nursing home was supported
with activities such as focus groups facilitated by a research nurse, written and telephone
communication, and face-to-face professional contact between nursing home staff and
clinical pharmacists on issues such as drug policy and specific resident problems, together
with education and medication review. This was a multifaceted intervention directly
targeting nursing homes. Most of the contact with GPs was indirect using the existing
relationships between nursing homes and visiting GPs. A number of focus groups and
personal interviews about the project were conducted with GPs
Control nursing homes continued with usual care.
Outcomes Mortality was collected at the end of the 12-month study.
Notes No significant changes were observed in annual mortality rates or frequency of hospital-
isations between intervention and control nursing home groups
It is unclear from Table 5, which shows the mortality and hospitalisation data, how the
study authors arrived at their figures or their conclusions. Therefore, we were unable to
use the data to calculate hospitalisations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Nursing homeswere selected for the interven-
tion treatment by random draws from a hat
Allocation concealment (selection bias) Low risk Not clear if this was done although the homes
were independently assigned to the control
or intervention groups. However, according
to the EPOC criteria, the risk of bias for this
study is low because units, in this case nursing
homes, were assigned rather than individuals
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear, although with the objective out-
comes that we are interested in this is less of a
concern (according to EPOC risk of bias cri-
teria)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Control and intervention groups did not ap-
pear to differ in terms of attrition
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This is less important for our purpose as we
are looking at objective outcomes (hospitali-
sations, ED visits, and mortality)
Selective reporting (reporting bias) Low risk No evidence of this
Protection against contamination bias Low risk There is indication to suggest that the in-
tervention was contaminated by the control
group
Other bias Unclear risk The limited duration of the study and size of
the samplemay have compromised the ability
to detect an effect. We considered other bias
due to cluster randomisation
Rytter 2010
Methods RT
Study duration: 26 weeks
Participants 148 intervention, 145 control
Setting: primary care
Age: median, intervention 84 years, control 83 years
Sex female n (%): intervention 66%, control 66%
Country: Denmark
Diagnosis: cardiovascular disease: intervention 45 (30%), control 28 (19%); other in-
tervention 103 (70%), control 117 (81%); P = 0.02
Sociodemographics: housing: living in private home intervention: 95%, control 97%;
widow/widower: intervention 59%, control 57%; married: intervention 30%, control
29%; divorced/single: intervention 11%, control 14%
Ethnicity: unclear, possibly white Danish
Date of study: November 2003-June 2005
Interventions 1 intervention and 1 control
The intervention follow-up consisted of 3 contacts. The main intervention was a joint
home visit involving both the GP and the district nurse. It was conducted approximately
1 week after discharge and was guided by an agenda
Control group: standard care
Outcomes The primary outcome measures were hospital readmissions of any kind and the concor-
dance between the GP’s knowledge of the medical treatment and what the participant
was actually taking
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was generated by a computer.
Allocation concealment (selection bias) Low risk Computer
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk This would be impossible
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Independent team
Selective reporting (reporting bias) Low risk All outcomes were reported
Protection against contamination bias Low risk There is no indication to suggest that the intervention
was contaminated by the control group
Other bias Unclear risk It is unclear if there are other risks not accounted for.
Triller 2007
Methods RT
Study duration: 201 days (3-week intervention and 180 days of follow-up)
Participants 154 participants
Setting: home
Diagnostic criteria: participants had to have a primary or secondary diagnosis of heart
failure and were referred to receive skilled nursing services
Age (years) (mean ± SD): control: 78.1 (11.2), intervention: 81.3 (9.3), participants had
to be ≥ 21 years
Female n (%): control: 55 (72), intervention: 56 (73)
Country: USA
Comorbidity: heart failure
Sociodemographics: the catchment area provided participants from urban, suburban,
and rural environs and from across all socioeconomic classes. According to census data,
89% of the population of these 3 counties combined is white, and 87% of adults have
a high school diploma. Median household income for the counties is approximately
USD 47,000 (2003 data). Non-English-speaking participants were included if adequate
translation services were available from family members or friends
Ethnicity: unknown; it is difficult to ascertain the ethnicity from the information given
control 68 (88%), intervention 75 (97%)
Date of study: 1 July 2002 to end 2004
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Interventions 1 intervention: pharmaceutical care services
Pharmaceutical care services consisted of an initial comprehensive in-home medication
assessment (concurrent with agency admission) and 2 follow-up visits (7-10 and 18-21
days later). The follow-up visits were contingent on the participant’s continued receipt
of visiting nurse services (i.e. participants discharged from the visiting nurse before 21
days would not receive all of the pharmacist’s planned visits). Throughout the 3-week
intervention period, the clinical pharmacist accessed and reviewed all pertinent physician
notes and laboratory test values via the National Endowment for the Humanities data
system and interacted with prescribers on behalf of the participants as necessary
Control participants received the usual care provided by the visiting nurse association.
Visiting nurse services (provided to both groups) included basic nursing care and a brief
physical assessment and medical history
Outcomes Hospitalisations and mortality were assessed during a 180 day follow-up period
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk This was adequate: “Patients provided in-
formed consent for study participation and
were randomised to receive usual care or
usual care plus pharmaceutical care by
means of a computer-generated random
numbers table in blocks of four.”
Allocation concealment (selection bias) Low risk This was adequate: “Once informed con-
sent was received, the nurse obtained a
baseline quality-of life assessment (using
the SF-12) and then accessed a sealed enve-
lope containing the group assignment from
the intake office.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding or a lack of blinding was unlikely
to affect the outcome because the usual
care group received usual care from nurses
whereas the intervention group received
usual care plus the services of a pharmacist
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition in both the intervention and con-
trol groups was comparable
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This is of less concern in our case as all of
our outcomes are objective (according to
the EPOC risk of bias criteria)
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Selective reporting (reporting bias) Low risk No evidence of a problem
Protection against contamination bias Low risk There is no evidence of contamination be-
tween the intervention and the control
groups
Other bias High risk Small sample may have produced low
power to detect an effect. Poor pharma-
cist-prescriber communication may have
reduced efficacy of intervention
Zermansky 2001
Methods RT of clinical medication review by a pharmacist against normal general practice review
Length of study: 12 months (study conducted: June 1999-June 2000)
Participants Participants from general practices
1188 participants aged ≥ 65 or over who were receiving at least 1 repeat prescription
and living in the community
Age: mean (SD) intervention, 74 (6.6) control, 73 (6.4)
Sex female n (%): intervention 339 (56%), control 325 (56%)
Country: UK
Comorbidity: not reported
Sociodemographics: not reported
Ethnicity: not reported
Interventions 1 intervention and 1 control; 601 participants in the intervention and 580 participants
in the control group
Intervention group: participants were invited to a consultation at which the pharmacist
reviewed theirmedical conditions and current treatment according to a specific algorithm
which includes history taking and data gathering, evaluation and implementation stages
Control group: participants in the control group continued to receive normal care from
their GP and primary healthcare staff. Participants were recalled for review of treatment
by the GP according to normal custom in the practice
Outcomes Hospital admission and mortality
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done by a computer.
Allocation concealment (selection bias) Low risk Practice based allocation.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk This would be impossible.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Some participants did not complete the
study and were reported in the study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No explanation given.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Protection against contamination bias Unclear risk It is unclear if there was a contamination
between the intervention and the control
group
Other bias Unclear risk It is unclear to determine if there are other
biases.
Zermansky 2006
Methods An open randomised controlled trial of clinical medication review by a pharmacist of
elderly care home residents against usual care
Study duration: 6 months
Participants 661 participants (331 intervention group but only 315 received Intervention) and 330
participants in the control group
Setting: aged care facilities in Leeds, UK (nursing, residential and mixed care homes for
older people in Leeds, UK)
Diagnostic criteria: residents aged≥ 65, seeking to recruit all residents taking≥ 1 repeat
medicines
Age (years) (mean ± SD): age mean (interquartile range), Intervention 85.3 (81 to 90)
and control 84.9 (80 to 90)
Sex male n (%): intervention 75 (22.7), control 79 (23.9)
Country: UK
Comorbidity: not stated
Sociodemographics: not stated
Ethnicity: not stated
Date of study: not reported, but paper first published 12/8/2006
Interventions 1 intervention
A clinical medication review was conducted by the study pharmacist within 28 days
of randomisation. It comprised a review of the general practice clinical record and a
consultation with the participant and carer
The pharmacist formulated recommendations with the participant and carer and passed
them on a written proforma to the GP for acceptance and implementation. GP accep-
tance was signified by ticking a box on the proforma
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Control participants received usual GP care
Outcomes The primary outcomemeasure was the number of changes in medication per participant.
Secondary outcome measures were the following:
• medication outcomes: number of repeat medicines per participant, cost of 28
days of repeat medicines per participant at end date, recorded medication reviews in
the study period
• clinical outcomes in 6 months: falls, number of GP consultations, Barthel Index,
Standardised Mini-Mental State Examination, mortality, hospital admissions
• hospitalisation in 6 months per participant and number of deaths
Notes Randomisation was curtailed on 30 June 2003 when it became clear that the intended
sample size was not achievable within the available timescale. Data were analysed on an
intention-to-treat basis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly sized blocks.
Allocation concealment (selection bias) Unclear risk This is not mentioned in the study.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is not clear if the participants were
blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Some participants did not complete the
study and were reported in the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A nurse blind to the study assessed partici-
pants.
Selective reporting (reporting bias) Low risk All outcomes were reported.
Protection against contamination bias Unclear risk It is difficult to determine if the interven-
tion group was contaminated by the con-
trol group
Other bias Unclear risk It is difficult to determine if there are other
biases.
ADL: activities of daily living; BPMDL: best possible medication discharge list; CI: confidence interval; CHAP: Cardiovascular
Health Awareness Program; CHD: coronary heart disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary
disease; ED: emergency department; EuroQoL-5D: EuroQol Group Association (“The EuroQol Group”) comprises a network of
international, multilingual, multidisciplinary researchers;EQ-5D: a standardised instrument for use as a measure of health outcome;
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GP: general practitioner; ICU: intensive care unit; QoL: quality of life; RT: randomised trial; SD: standard deviation; SF-12: Short
Form-12; SF-36: Short Form-36; STOPP: Screening Tool of Older Persons Prescriptions; START: Screening Tool to Alert Doctors
to Right Treatment
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Arifi 2014 Irrelevant intervention
Alassaad 2014 Not primary care
Alicic 2016 Protocol of a study
Barker 2012 This study does not appear to be a primary care intervention
Barker 2016 Outcomes not relevant
Barnes 2014 Outcomes not relevant
Basheti 2016 Outcomes not relevant
Bell 2016 Not primary care
Benard-Laribiere 2015 Irrelevant intervention
Bhatt 2014 Study protocol
Billington 2015 Outcomes not relevant
Bonnet-Zamponi 2013 This was not a primary care intervention; it was done by geriatricians
Briggs 2015 Not primary care
Carrington 2013 Irrelevant intervention
Clyne 2013 Outcomes not relevant
Clyne 2015 Outcomes not relevant
Clyne 2016 Outcomes not relevant
Cowper 1998 Cost-effectiveness study that had data in a form not enabling data extraction
Desveaux 2016 Study protocol
Dhalla 2014 Outcomes not relevant
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(Continued)
Elliott 2014 Study protocol
Forster 2015 Study protocol
Fredericks 2013 Irrelevant intervention
Furniss 2000 Study was for a pre-post design not included in the protocol
Geurts 2016 Outcomes not relevant
Gorgas 2012 This study did not occur in primary care.
Graffen 2004 Study was for a pre-post design not included in the protocol
Guthrie 2016 Outcomes not relevant
Hallsworth 2016 Outcomes not relevant
Hanlon 1996 This study did not occur in primary care.
Hugtenburg 2009 This is not a randomised trial (it is described as a controlled intervention study and there is no evidence of
randomisation)
Huiskes 2014 Outcomes not relevant
Keane 2014 Not primary care
Knowlton 1994 Not possible to extract appropriate data
Lee 1996 This study was not a randomised trial.
Leendertse 2011 This study was not a randomised trial.
Leendertse 2013 This study was not a randomised trial.
Liu 2010 This study was a conference abstract only and did not address adverse drug reactions
Malin 2016 Outcomes not relevant
Mills 2001 This study is reported elsewhere (see Furniss 2000, also excluded)
Montero-Balosa 2016 Not a randomised trial
Moreno 2016 Not a randomised trial
Naunton 2003 This is a hospital intervention and not done in primary care. It appears that the study pharmacist is recruited
from the hospital. As it says, the pharmacist complied with the Society of Hospital Pharmacist clinical
pharmacy services. It is also published in a hospital journal
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(Continued)
Neven 2016 Not primary care
Ni 2016 Not a randomised trial
Perula 2014 Outcomes not relevant
Phung 2013 Study protocol
Pinnock 2013 Irrelevant intervention
Przytula 2015 Study protocol
Safran 1993 This study was not a randomised trial
Saltzberg 2011 This study was not a randomised trial
Setter 2009 The outcomes reported are not appropriate for this study
Sinnott 2015 Outcomes not relevant
Stingl 2016 Study protocol
Sturgess 2003 Reported elsewhere (see Bernsten 2001)
Wolf 2015 Outcomes not relevant
Wooster 2016 Study protocol
Xin 2014 Not primary care
Yuan 2003 Complex study, which made data extraction not possible.
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D A T A A N D A N A L Y S E S
Comparison 1. Professional interventions versus standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of hospital admissions 2 3889 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.79, 1.96]
2 Number of people admitted to
hospital
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Number of emergency
department visits
2 1067 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.50, 1.02]
4 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Organisational interventions versus standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of hospital admissions 11 6203 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.71, 1.03]
2 Number of people admitted to
hospital
13 152237 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.86, 0.99]
3 Number of emergency
department visits
5 1819 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.49, 1.15]
4 Mortality 12 154962 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.85, 1.03]
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Analysis 1.1. Comparison 1 Professional interventions versus standard care, Outcome 1 Number of hospital
admissions.
Review: Professional, structural and organisational interventions in primary care for reducing medication errors
Comparison: 1 Professional interventions versus standard care
Outcome: 1 Number of hospital admissions
Study or subgroup
Professional
intervention Standard/usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lapane 2011 39/1769 30/1769 93.4 % 1.30 [ 0.81, 2.08 ]
Murray 2004 2/180 3/171 6.6 % 0.63 [ 0.11, 3.74 ]
Total (95% CI) 1949 1940 100.0 % 1.24 [ 0.79, 1.96 ]
Total events: 41 (Professional intervention), 33 (Standard/usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Professional intervention Favours standard care
Analysis 1.2. Comparison 1 Professional interventions versus standard care, Outcome 2 Number of people
admitted to hospital.
Review: Professional, structural and organisational interventions in primary care for reducing medication errors
Comparison: 1 Professional interventions versus standard care
Outcome: 2 Number of people admitted to hospital
Study or subgroup
Professional
intervention Standard Care Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gurwitz 2014 827/1870 802/1791 0.99 [ 0.92, 1.06 ]
0.01 0.1 1 10 100
Favours professional care Favours standard care
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Analysis 1.3. Comparison 1 Professional interventions versus standard care, Outcome 3 Number of
emergency department visits.
Review: Professional, structural and organisational interventions in primary care for reducing medication errors
Comparison: 1 Professional interventions versus standard care
Outcome: 3 Number of emergency department visits
Study or subgroup
Professional
intervention Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Garcia-Gollarte 2014 43/372 54/344 88.7 % 0.74 [ 0.51, 1.07 ]
Murray 2004 4/180 7/171 11.3 % 0.54 [ 0.16, 1.82 ]
Total (95% CI) 552 515 100.0 % 0.71 [ 0.50, 1.02 ]
Total events: 47 (Professional intervention), 61 (Standard care)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours professional care Favours standard care
Analysis 1.4. Comparison 1 Professional interventions versus standard care, Outcome 4 Mortality.
Review: Professional, structural and organisational interventions in primary care for reducing medication errors
Comparison: 1 Professional interventions versus standard care
Outcome: 4 Mortality
Study or subgroup
Professional
intervention Standard care Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lapane 2011 211/1769 215/1769 0.98 [ 0.82, 1.17 ]
0.01 0.1 1 10 100
Favours professional care Favours standard care
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Analysis 2.1. Comparison 2 Organisational interventions versus standard care, Outcome 1 Number of
hospital admissions.
Review: Professional, structural and organisational interventions in primary care for reducing medication errors
Comparison: 2 Organisational interventions versus standard care
Outcome: 1 Number of hospital admissions
Study or subgroup Organisational care Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Coleman 1999 45/78 29/49 11.6 % 0.97 [ 0.72, 1.32 ]
Holland 2005 234/429 178/426 15.2 % 1.31 [ 1.13, 1.50 ]
Ibrahim 2013 12/120 30/120 5.8 % 0.40 [ 0.22, 0.74 ]
Krska 2001 6/168 8/164 2.7 % 0.73 [ 0.26, 2.06 ]
Lenaghan 2007 20/68 21/66 7.3 % 0.92 [ 0.55, 1.54 ]
Lowrie 2012 107/1090 114/1074 12.8 % 0.92 [ 0.72, 1.19 ]
Malone 2000 276/447 300/484 15.9 % 1.00 [ 0.90, 1.10 ]
Moertl 2009 8/48 21/48 4.8 % 0.38 [ 0.19, 0.77 ]
Nabagiez 2013 42/340 59/361 10.1 % 0.76 [ 0.52, 1.09 ]
Okamoto 2001 0/164 4/166 0.4 % 0.11 [ 0.01, 2.07 ]
Rytter 2010 67/148 86/145 13.4 % 0.76 [ 0.61, 0.95 ]
Total (95% CI) 3100 3103 100.0 % 0.85 [ 0.71, 1.03 ]
Total events: 817 (Organisational care), 850 (Standard care)
Heterogeneity: Tau2 = 0.05; Chi2 = 40.70, df = 10 (P = 0.00001); I2 =75%
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours organisational Favours standard care
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Analysis 2.2. Comparison 2 Organisational interventions versus standard care, Outcome 2 Number of
people admitted to hospital.
Review: Professional, structural and organisational interventions in primary care for reducing medication errors
Comparison: 2 Organisational interventions versus standard care
Outcome: 2 Number of people admitted to hospital
Study or subgroup Organisational care Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alvarez 2001 61/330 82/405 5.0 % 0.91 [ 0.68, 1.23 ]
Bernsten 2001 259/304 248/254 24.1 % 0.87 [ 0.83, 0.92 ]
Campins 2016 144/252 158/251 13.4 % 0.91 [ 0.79, 1.05 ]
Frankenthal 2014 80/160 73/146 7.7 % 1.00 [ 0.80, 1.25 ]
Hawes 2014 0/24 15/37 0.1 % 0.05 [ 0.00, 0.78 ]
Kaczorowski 2011 1951/69942 2274/75499 23.1 % 0.93 [ 0.87, 0.98 ]
Korajkic 2011 5/33 11/35 0.6 % 0.48 [ 0.19, 1.24 ]
Malet-Larrea 2016 31/688 52/715 2.6 % 0.62 [ 0.40, 0.95 ]
Nabagiez 2013 42/340 59/361 3.5 % 0.76 [ 0.52, 1.09 ]
Olesen 2014 77/253 73/264 5.9 % 1.10 [ 0.84, 1.44 ]
Triller 2007 39/77 32/77 3.9 % 1.22 [ 0.86, 1.72 ]
Zermansky 2001 110/579 92/550 6.5 % 1.14 [ 0.88, 1.46 ]
Zermansky 2006 47/331 52/330 3.6 % 0.90 [ 0.63, 1.30 ]
Total (95% CI) 73313 78924 100.0 % 0.92 [ 0.86, 0.99 ]
Total events: 2846 (Organisational care), 3221 (Standard care)
Heterogeneity: Tau2 = 0.01; Chi2 = 22.45, df = 12 (P = 0.03); I2 =47%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours organisational Favours standard care
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Analysis 2.3. Comparison 2 Organisational interventions versus standard care, Outcome 3 Number of
emergency department visits.
Review: Professional, structural and organisational interventions in primary care for reducing medication errors
Comparison: 2 Organisational interventions versus standard care
Outcome: 3 Number of emergency department visits
Study or subgroup Organisational care Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alvarez 2001 70/330 80/405 29.1 % 1.07 [ 0.81, 1.43 ]
Coleman 1999 18/78 13/49 19.7 % 0.87 [ 0.47, 1.61 ]
Gernant 2016 72/297 90/359 29.6 % 0.97 [ 0.74, 1.27 ]
Hawes 2014 0/24 11/37 2.2 % 0.07 [ 0.00, 1.07 ]
Ibrahim 2013 11/120 33/120 19.3 % 0.33 [ 0.18, 0.63 ]
Total (95% CI) 849 970 100.0 % 0.75 [ 0.49, 1.15 ]
Total events: 171 (Organisational care), 227 (Standard care)
Heterogeneity: Tau2 = 0.14; Chi2 = 14.93, df = 4 (P = 0.005); I2 =73%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours organisational Favours standard care
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Analysis 2.4. Comparison 2 Organisational interventions versus standard care, Outcome 4 Mortality.
Review: Professional, structural and organisational interventions in primary care for reducing medication errors
Comparison: 2 Organisational interventions versus standard care
Outcome: 4 Mortality
Study or subgroup Organisational care Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Campins 2016 18/252 15/251 1.8 % 1.20 [ 0.62, 2.32 ]
Holland 2005 49/415 63/414 5.9 % 0.78 [ 0.55, 1.10 ]
Kaczorowski 2011 2377/69942 2608/75499 32.1 % 0.98 [ 0.93, 1.04 ]
Lenaghan 2007 7/68 6/66 0.8 % 1.13 [ 0.40, 3.19 ]
Lowrie 2012 283/1090 266/1074 19.2 % 1.05 [ 0.91, 1.21 ]
Moertl 2009 9/48 13/48 1.5 % 0.69 [ 0.33, 1.47 ]
Olesen 2014 19/253 14/264 1.8 % 1.42 [ 0.73, 2.76 ]
Pai 2009 15/57 12/47 1.9 % 1.03 [ 0.54, 1.98 ]
Roberts 2001 323/905 998/2325 25.5 % 0.83 [ 0.75, 0.92 ]
Triller 2007 14/77 17/77 2.0 % 0.82 [ 0.44, 1.55 ]
Zermansky 2001 15/579 25/550 2.0 % 0.57 [ 0.30, 1.07 ]
Zermansky 2006 51/331 48/330 5.5 % 1.06 [ 0.74, 1.52 ]
Total (95% CI) 74017 80945 100.0 % 0.94 [ 0.85, 1.03 ]
Total events: 3180 (Organisational care), 4085 (Standard care)
Heterogeneity: Tau2 = 0.01; Chi2 = 17.44, df = 11 (P = 0.10); I2 =37%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours organisational Favours standard care
A D D I T I O N A L T A B L E S
Table 1. Tentative description of interventions (part 1)
Study Name Theory Materials Procedures Who provided
intervention
Modes of deliv-
ery
Alvarez 2001 Pharmaceutical
care
Phar-
maceutical care
is the provision
of drug therapy
Pharmacies in
the intervention
group provided
pharmaceutical
An Initial inter-
view and assess-
ment of the ther-
Pharmacists pro-
vided the inter-
vention.
Individual and
face-to-face
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Table 1. Tentative description of interventions (part 1) (Continued)
for the purpose
of achieving out-
comes that im-
prove a person’s
quality of life
care, which con-
sisted of offering
the pharmaceu-
tical care service
to participants
and to their cor-
responding GPs
apeutic plan was
undertaken, reg-
istration of data
during the sub-
sequent visits to
allow the identi-
fication of medi-
cation-re-
lated problems,
and an interven-
tion to solve the
problem.
The intervention
involved propos-
ing changes
in the medica-
tion participants
received, which
had to be com-
municated to the
patient’s GP
Bernsten 2001 Pharmaceutical
care
Pharmaceutical
care is the provi-
sion of drug ther-
apy for the pur-
pose of achieving
outcomes that
improve a per-
son’s quality of
life, although lit-
tle research has
been conducted
in commu-
nity-based phar-
maceutical care
with elderly peo-
ple
Training of phar-
macists was done
with
a study manual.
The man-
ual contained an
overview of the
concept of phar-
maceutical care
and its provision
to elderly people.
No reference was
provided for the
study manual
The intervention
group of phar-
macists iden-
tified actual and
potential drug-
related problems
using a struc-
tured approach.
These pharma-
cists utilised a
number of data
sources in this as-
sessment includ-
ing the partici-
pant, the partic-
ipant’s GP, and
pharmacy
records. Follow-
ing this assess-
ment, pharma-
cists
were instructed
to formulate an
intervention and
monitoring plan
Com-
munity pharma-
cists were trained
to provide the
structured phar-
maceutical care
intervention. A
study man-
ual helped facili-
tate this process.
It contained an
overview of the
concept of phar-
maceu-
tical care, its pro-
vision to elderly
people, informa-
tion on the ther-
apeutic manage-
ment of a num-
ber
of disease states
common in the
elderly, together
with other issues
Individual face-
to-face
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Table 1. Tentative description of interventions (part 1) (Continued)
pertinent to drug
therapy in the el-
derly
Campins 2016 Drug evaluation
and recommen-
dation
Several
instruments, cri-
teria, and algo-
rithms have been
developed to en-
able more ra-
tional and ap-
propriate use of
medication, but
limited evidence
exists with regard
to the outcomes
that were investi-
gated
TheGoodPallia-
tive-Geri-
atric Practice al-
gorithm
Garfinkel 2007)
and the STOPP/
START
criteriawere used
(O’Mahony
2015). Both of
these tools assess
the appropriate
use of medica-
tion in older peo-
ple
The intervention
was composed of
3 phases. In the
first phase, an ex-
perienced phar-
macist evaluated
all prescriptions
using theGP-GP
algorithm and
based their de-
cision about ap-
propriateness on
the STOPP/
START criteria.
In the second
phase, the phar-
macist discussed
recommen-
dations for each
drug
with the partic-
ipant’s physician
in order to come
up with a fi-
nal list of recom-
mendations. Fi-
nally, the recom-
mendations were
discussed
with the partic-
ipant and a fi-
nal decision was
agreed by physi-
cians and partic-
ipants
The intervention
was delivered by
a trained and ex-
perienced phar-
macist. No de-
tails are provided
concerning what
is a “trained and
experienced”
pharmacist
Individual and
face-to-face
Coleman 1999 Chronic care
clinics
Chronic
care clinics re-
design the struc-
ture and content
of primary care
services through
the delivery of
scheduled visits
de-
The chronic care
clinics included
an extended visit
with the physi-
cian
and nurse ded-
icated to plan-
ning chronic dis-
ease manage-
Frail older peo-
ple were invited
to participate in
visits
with the primary
care team. Dur-
ing these visits,
a shared treat-
ment plan was
The team that
provided the in-
tervention con-
sisted of the par-
tici-
pant’s physician,
a team nurse,
and a pharma-
cist. Physicians
The intervention
was delivered in-
dividually and in
groups in a face-
to-face format
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Table 1. Tentative description of interventions (part 1) (Continued)
voted to chronic
disease manage-
ment. Thismode
of service deliv-
ery has the po-
tential to im-
prove outcomes
for elderly peo-
ple
ment, a pharma-
cist visit that em-
phasised reduc-
tion of polyphar-
macy and high-
risk medications,
and a
patient self-man-
agement group
developed, a ses-
sion was con-
ducted with the
pharmacist that
addressed
polypharmacy
and medications
associated
with functional
decline, patient
self-manage-
ment group ses-
sions were con-
ducted, and the
pro-
vision of health
status assessment
information was
provided to the
practice team
and team nurses
received training
in population-
based medicine
and
management
strategies of geri-
atric syndromes.
Team nurses re-
ceived on-
the-job coaching
from study staff
Frankenthal
2014
Medica-
tion review and
drug recommen-
dations
Potentially inap-
propri-
ate prescriptions
are prevalent in
older people and
are associ-
ated with adverse
drug events. The
STOPP/START
cri-
teria are designed
to detect poten-
tially inappropri-
ate prescriptions
in elderly people.
However, little is
known about the
effects of an in-
tervention
involving the ap-
plication of the
STOPP/START
criteria on clini-
cal outcomes
The STOPP/
START criteria
were used to de-
liver the inter-
vention (
Gallagher 2008)
. The STOPP
criteria focus on
avoiding the use
of drugs that are
potentially inap-
propriate for
older people and
the START cri-
teria identify un-
dertreat-
ment or prescrib-
ing omissions in
older people
Medica-
tion reviews were
conducted by the
study pharmacist
for all residents.
Recommen-
dations made by
the phar-
macist were dis-
cussed with
the chief physi-
cian. The physi-
cian then de-
cided whether to
accept these rec-
ommenda-
tions and imple-
ment prescribing
changes
The
intervention was
conducted by the
study pharmacist
who applied the
STOPP/
START criteria
during the medi-
cation re-
view. The phar-
macist also dis-
cussed the rec-
ommendations
from the inter-
vention with the
chief physician,
who de-
cided whether to
accept these rec-
ommenda-
tions and imple-
ment prescribing
changes
Intervention was
deliv-
ered individually
and face-to-face.
Garcia-Gollarte
2014
Structured edu-
cational
intervention
In-
appropriate drug
prescription is a
Educational ma-
terial and refer-
ences were given
The educational
inter-
vention included
A nursing home
physician deliv-
ered the struc-
Face-
to-face interven-
tion delivered in
92Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Tentative description of interventions (part 1) (Continued)
common prob-
lem in people liv-
ing in nursing
homes and is
linked to adverse
health outcomes.
This study as-
sessed the effect
of an educational
intervention di-
rected to nursing
home physicians
in reducing in-
appropriate pre-
scription and im-
proving health
outcomes and re-
source utilisation
tophysicians and
two 1-h work-
shops were used
to review cases
and promote
practice changes.
The STOPP/
START crite-
ria were reviewed
with a random
sample of 10 res-
idents cared for
by each physi-
cian (Gallagher
2008). The con-
tent of the ed-
ucational inter-
vention is pro-
vided in an ap-
pendix (Garcia-
Gollarte 2014).
general aspects of
prescription and
drug use in geri-
atric pa-
tients, how to re-
duce the number
of drugs, to per-
form a regular re-
view of medica-
tions, to avoid
in-
appropriate drug
use, to discon-
tinue drugs that
donot showben-
e-
fits, and to avoid
under treatment
with drugs that
have shown ben-
efits. It also dis-
cussed some
drugs frequently
related to adverse
drug reactions in
older people
tured educa-
tional interven-
tion
a group and indi-
vidual format
Gernant 2016 Medicine recon-
ciliation and ac-
tion plan
Emergency de-
partment over-
crowding has
been linked to
increased mor-
tality, costs, and
length of stay.
This study eval-
uated the effec-
tiveness of a tele-
phone-based,
medicines-
management
service on reduc-
ing emergency
department util-
isation
Medication ther-
apymanagement
was
provided to par-
ticipants (APA
2008). A phar-
macy technician
completed tele-
phonic medica-
tion reconcilia-
tion, after which
a trained phar-
macist consulted
with the partici-
pant or caregiver
via telephone to
complete a
scheduled, com-
prehensive med-
ication therapy
review to iden-
The interven-
tion commenced
with a pharmacy
technician com-
pleting med-
ication reconcil-
iation with the
participant over
the tele-
phone. Then, a
pharmacist con-
sulted with the
participant
by telephone for
an average of 30
min to complete
a comprehensive
medication re-
view to identify
and resolve med-
ication-related
A phar-
macy technician
delivered the ini-
tialmedicine rec-
onciliation
with the partic-
ipant. A trained
pharmacist con-
ducted the
medication ther-
apy review, con-
structed a
personal medica-
tion record, and
a medication-re-
lated actionplan.
The pharmacist
also followed up
with the partic-
ipant’s prescriber
for resolution of
The inter-
vention was con-
ducted individu-
ally on the tele-
phone
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Table 1. Tentative description of interventions (part 1) (Continued)
tify and resolve
any medication-
related prob-
lems. The phar-
ma-
cist constructed a
personal medica-
tion record and
a medication-re-
lated action plan
for the partici-
pant. The action
planwas a partic-
ipant-centred
document that
assisted partici-
pants, caregivers,
and the pharma-
cist in the reso-
lution of identi-
fied medication-
related problems
problems. The
pharmacist con-
structed a person
medication-re-
lated action plan
and followed-up
with the partici-
pant’s prescriber
problems
that could not be
resolved with the
participant
Gurwitz 2014 Automated sys-
tem to facilitate
flow of informa-
tion and provide
warnings, alerts,
and recommen-
dations
Transitions
between the im-
patient and out-
patient setting is
a period of high
risk for older
adults. Most ap-
proaches to im-
proving tran-
sitions require a
substantial com-
mitment of re-
sources but au-
tomat-
ing these pro-
cesses may im-
prove the quality
and safety of care
An automated
system was used
to facilitate the
flow of informa-
tion to the med-
ical group’s pri-
mary care
providers
about individu-
als who were dis-
charged to home
from the hospital
(Field 2012).
An automated
system was de-
veloped to facil-
itate the flow of
information
to the medical
group’s primary
care providers. A
computer inter-
face linked
the primary care
provider’s
electronic health
records to the
hospital records,
which provided
informa-
tion about ad-
missions and dis-
charges. The sys-
tem
also provided in-
formation about
new drugs at dis-
charge, warnings
The automated
system delivered
the intervention.
The intervention
was delivered
electronically.
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about drug-drug
interactions, rec-
ommenda-
tions about dose
changes and lab-
oratory monitor-
ing of high-risk
medications, and
alerts
to the provider’s
support staff to
schedule a post-
hospitalisation
office visit within
1 week of dis-
charge if not al-
ready scheduled
Hawes 2014 Care transitions
clinic visit
Med-
ication errors re-
lated to hospital
discharge result
in rehospitalisa-
tions and emer-
gency
department vis-
its, whichmay be
reduced by phar-
macist
involvement
during postdis-
charge tran-
sitions of care.
This study eval-
uated the impact
of a transitional
care clinic visit
conducted by a
pharmacist
The Best Possi-
ble Medi-
cation Discharge
List was used to
identify medica-
tion discrep-
ancies (Wong
2008). It served
as the gold stan-
dard for the list
of medications
that the partici-
pant should take
after discharge
Participants
in the interven-
tion group were
scheduled for a
care transitions
clinic visit ap-
proximately 72 h
after hospital dis-
charge. The visit
involved per-
forming a com-
plete medication
history, identify-
ing and resolving
medication dis-
crepancies, cre-
ating a current
medication list,
and counselling
on appropriate
medication use
Clinical phar-
macists provided
the intervention.
They collab-
orated with the
inpatient medi-
cal team to create
the Best Possible
Medication Dis-
charge List
The intervention
was delivered in-
dividually and
face-to-face
Holland 2005 Pharmacist
home visits
Older people of-
ten have trouble
adhering to their
medica-
tions. This study
evaluated the ef-
fectiveness
of a home-based
medi-
A standardised
visit form was
used to record
the home visit
but no reference
was provided
Pharmacists ar-
ranged home vis-
its with the par-
ticipant during
which they as-
sessed the par-
ticipant’s ability
to self-medicate
and drug adher-
Pharmacists con-
ducted the home
visits. Pharma-
cists held a post-
graduate qualifi-
cation in phar-
macy practice or
had recent con-
tin-
The intervention
was delivered in-
dividually and
face-to-face
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cation review on
hospital admis-
sions among el-
derly people
ence. They edu-
cated the partici-
pant,
removed out-of-
date drugs, re-
ported drug reac-
tions or interac-
tions
to the physician,
and reported the
need for a com-
pliance aid
uing professional
development in
therapeu-
tics. The phar-
macists partici-
pated in a 2-day
training course,
which included
lectures on ad-
verse drug reac-
tions,
prescribing in el-
derly people, im-
proving concor-
dance, and com-
munication skills
Ibrahim 2013 Tele-
phone consulta-
tion with home
visits
Adherence
to warfarin treat-
ment and moni-
toring guidelines
may be subopti-
mal among pa-
tients and staff.
This study as-
sessed the im-
provement in ad-
herence
to warfarin ther-
apy with tele-
phone and home
visits
A
predesigned set
of questions was
used in the tele-
phone consulta-
tion,
but no reference
or any additional
details were pro-
vided
The intervention
group was coun-
selled with once-
a-week tele-
phone consulta-
tions and2home
visits per month
by either a nurse
or a pharmacist
that dealt with
warfarin use
A pharmacist or
a nurse provided
the home visits.
The telephone
consultation was
conducted by a
pharmacist
The intervention
was delivered in-
dividually us-
ing a face-to-face
format and tele-
phone calls
Kaczorowski
2011
Cardiovas-
cular risk assess-
ment and educa-
tion sessions
Strategies for
managing blood
pressure are es-
sential as high
blood pressure is
the leading risk
factor for death.
The study au-
thors evaluated
the effectiveness
of a community-
based cardiovas-
cular health pro-
motion and dis-
ease preven-
tion programme
The Cardio-
vascular Health
Awareness Pro-
gram was a stan-
dardised
intervention that
consisted of 10
weeks of cardio-
vascular risk as-
sessment, blood
pressure
measure-
ments, and edu-
cation sessions (
CHAP 2017).
The intervention
consisted of 10
weeks of cardio-
vascular risk fac-
tor
assessment and
educational ses-
sions. Volunteers
were recruited to
help participants
measure
their blood pres-
sure and sup-
ported self-man-
agement by pro-
viding
Volunteers were
recruited
and trained to
carry out the in-
tervention. The
volunteers were
trained accord-
ing to a standard-
ised curriculum
devel-
oped by a pub-
lic health nurse
and delivered by
nurses working
in the interven-
tion community
The inter-
vention was con-
ducted individu-
ally in a face-to-
face manner
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in reducing mor-
bidity
participants with
their risk profile,
risk-specific edu-
cational materi-
als and informa-
tion about ac-
cess to local ser-
vices. At the end
of the 10-week
programme and
6 months after
the programme
ended, the re-
sults were for-
warded to family
physicians who
rank-or-
dered their par-
ticipants by their
most recent sys-
tolic blood pres-
sure reading
Korajkic 2011 Educational in-
tervention with
pharmacist
Few studies have
examined a phar-
macist’s contri-
bution to im-
proving diuretic
compliance and
reducing rehos-
pitalisation and
health care use.
This study aimed
to determine the
impact of a phar-
macist-led inter-
vention on pa-
tient-guided di-
uretic dose ad-
justment
The in-
tervention group
adjusted their di-
uretic dose using
a flexible
frusemide dose-
adjust-
ment guide that
was provided in
the paper
The intervention
consisted of a 30-
min educational
session and
focused on im-
proving partici-
pant
self-care, recog-
nising symptoms
of fluid reten-
tion, measuring
weight daily, self-
adjusting the di-
uretic dose and
improv-
ing knowledge of
heart failure
and heart failure
medications
A pharmacist
provided the in-
tervention. The
frusemide dose-
adjustment
guide was devel-
oped in collabo-
ration with car-
diologists
Conducted indi-
vidually in a face-
to-face fashion.
Krska 2001 Pharmaceutical
care plan
Regular medica-
tion reviews can
reduce the risk of
medication-re-
lated problems.
This study aimed
Clinically-
trained pharma-
cists completed
a detailed profile
for each partici-
pant using medi-
A pharmaceuti-
cal care plan was
drawn up listing
all pharmaceuti-
cal care issues to-
gether
The pharmacist
performed the
medication re-
view. The partic-
ipants’ GP indi-
cated their level
The mode of de-
livery was indi-
vidual and face-
to-face.
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to evaluate the
effect of a phar-
macist-led medi-
cation review on
pharma-
ceutical care is-
sues and hospi-
talisations
cal
notes and com-
puter records. All
participants
were interviewed
in their home
about their use of
and responses to
medication
and their use of
health and social
services. No ref-
erences provided
with all the ac-
tions planned to
achieve the out-
comes
of any pharma-
ceutical care is-
sue. Copies of
the plan were
given to the GP
who was asked
to agree, after
which the phar-
macist imple-
mented the plan
of
agreement with
each pharmaceu-
tical care issue
and with the ac-
tions taken
Lapane 2011 Use of health in-
formation tech-
nology to iden-
tify people at risk
for delirium and
falls, implement
monitoring
plans, and pro-
vide reports to
pharmacists
Falls and delir-
ium
pose the great-
est threats to res-
ident
safety in nursing
homes and con-
tributes to fur-
ther functional
decline. Medica-
tion use is associ-
ated with greater
risk of delirium
and falls. There-
fore, this study
used health in-
formation tech-
nology to
identify residents
at risk for delir-
ium and falls due
to adverse drug
events
A Geriatric Risk
Assess-
ment MedGuide
was a database
designed to iden-
tify
medications that
potentially con-
tributed to delir-
ium and fall risk
(Tobias 1999). It
also facili-
tated early recog-
nition of signs
and symptoms
indicative of po-
tential medica-
tion-related
problems. Train-
ing was provided
to nursing staff
and pharmacists
in how to use the
reports gener-
ated by the Geri-
atric Risk Assess-
ment MedGuide
Health informa-
tion technology
was used to iden-
tify residents at
risk for delirium
and falls, imple-
ment moni-
toring plans, and
provide
reports to phar-
macists in con-
ducting medica-
tion reviews. The
consultant phar-
macist shared the
reports with the
nurse contact at
the facility and
used the reports
in their monthly
drug review
The intervention
was an au-
tomated system
that provided re-
ports to pharma-
cists and nurses,
whowere trained
to use these re-
ports. The train-
ing for nurses
provided infor-
mation regard-
ing medications
that cause, ag-
gravate, or con-
tribute to the risk
of falls and delir-
ium. The course
also reviewed
symptoms
and signs of ad-
verse medication
effects and rein-
forced the im-
portance of the
early observation
of symptoms
and signs of ad-
verse medication
effects. Pharma-
cists were trained
to provide a tar-
The intervention
was delivered in-
dividually and
face-to-face
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geted drug re-
view for all par-
ticipants who ex-
perienced delir-
ium and falls
Lenaghan 2007 Home-based
medication
review
Home-based
medication
reviews are con-
venient for the
patient and pro-
vide an oppor-
tunity to under-
stand their med-
ication-taking in
their home envi-
ronment. There-
fore, this
study looked at
whether home-
based medica-
tion reviews with
elderly
people could re-
duce hospital ad-
missions
The intervention
com-
prised 2 home
visits by a com-
munity pharma-
cist who edu-
cated the partici-
pant/carer about
their medicines,
noted any phar-
maceutical care
issues and as-
sessed the need
for an adherence
aid
At the home
visit, the phar-
macist educated
the participant,
removed out-of-
date drugs, and
assessed the need
for an adherence
aid. The phar-
macist held regu-
larmeetings with
the GP where
changes to the
par-
ticipant’s medi-
cations were dis-
cussed and
amendments
were
implemented by
the GP
A
pharmacist with
a post-graduate
qualification in
pharmacy prac-
tice conducted
the home-based
medication
review. They had
regular meetings
with the lead GP.
Possible changes
to
the participant’s
medication were
discussed and
agreed amend-
ments were
implemented by
the GP
The intervention
was delivered in-
dividually and
face-to-face
Lowrie 2012 Pharmacist med-
ication review
Although
angiotensin-
converting en-
zyme inhibitors
and beta-block-
ers reduce mor-
bidity and mor-
tality in people
with heart fail-
ure, these treat-
ments are under-
used. Phar-
macists may im-
prove treatment
through medica-
tion review. This
study inves-
tigatedwhether a
phar-
macist interven-
tion would re-
Pharmacists
received train-
ing covering
the aetiology,
symptoms, and
evidence-based
management
of heart fail-
ure. They also
participated
in monthly
discussions of
specific cases.
The pharmacist
used guidelines
to optimise
treatment for
participants with
left ventricular
systolic dys-
function. All of
Participants were
offered a 30-min
ap-
pointment with
the pharmacist If
there was agree-
ment between
the pharmacist
and the partici-
pant, and subse-
quently with the
doctor, medica-
tions were initi-
ated, discontin-
ued, or modified
by the pharma-
cist during 3-4
weekly or fort-
nightly consulta-
tions
The pharma-
cists, who deliv-
ered the medica-
tion review, had
between 3 and
16 years of post-
qualification ex-
perience, had ex-
perience deliver-
ing primary care-
based medica-
tion review clin-
ics for people re-
ceiving multiple-
drug treatment
and attended an
in-house train-
ing day cover-
ing the aetiology,
symptoms, and
The intervention
was delivered in-
dividually and
face-to-face
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duce hospital ad-
mission and
death for people
with heart prob-
lems
these materials
are available at
onlinelibrary.wiley.com/
journal
evidence-based
management of
heart failure. An
additional ses-
sion covered the
methods of the
trial
Malet-Larrea
2016
Pharmacist med-
ication review
Aging and the
use of polyphar-
macy are risk fac-
tors for drug-
related problems
and medication-
re-
lated hospital ad-
missions. There-
fore, this study
assessed the im-
pact of a com-
munity pharma-
cist-led medica-
tion review on
hospital admis-
sions in older
people
Pharmacists
in the interven-
tion group re-
ceived a training
course that cov-
ered the clinical
management of
older people and
the medication
review method.
No reference was
provided
The medication
review consisted
of the pharma-
cist collecting in-
formation about
the participant’s
health problems,
medica-
tion use, lifestyle
habits, and con-
cerns about dis-
eases and medi-
cations. The
pharmacist then
identified nega-
tive clinical out-
comes related to
medicines
and drug-related
problems. Subse-
quently, an ac-
tion
plan was agreed
upon which fo-
cused on partic-
ipant outcomes
and the medica-
tion use process
Pharmacists pro-
vided the medi-
cation review.
They received a
3-day train-
ing course cover-
ing clinical man-
agement of el-
derly people, the
medication
review with fol-
low-up method,
communica-
tion with partic-
ipants and doc-
tors, study pro-
tocol and docu-
mentation forms
The intervention
was delivered in-
dividually and
face-to-face
Malone 2000 Pharmacist visits Pharmacists have
adopted phar-
maceutical care,
which is the pro-
vision of drug
therapy to im-
prove a person’s
quality of life, to
reduce morbid-
ity and mortal-
ity. Unlike previ-
ous studies that
Con-
tacts between the
pharmacist and
participant were
recorded on a
data
collection form,
which contained
the method of
contact,
time spent, med-
ical problems ad-
The intervention
participants re-
ceived consulta-
tion and follow-
up care from a
clinical pharma-
cist
Pharmacists con-
ducted the in-
tervention. Most
had a Doctor of
Pharmacy degree
and over 70%
were either re-
ceiv-
ing or had com-
pleted postgrad-
uate training
The intervention
was delivered in-
dividually and
face-to-face
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did not focus
on people who
were most likely
to benefit, this
study examined
veterans who
were at high risk
for amedication-
related problem
dressed, drug-re-
lated prob-
lems addressed,
and drug-
related problems
resolved. This
form was not ref-
erenced
Moertl 2009 Home-based
nurse care
Home-
based nurse care
can reduce ad-
verse events
in people with
chronic heart
failure. High lev-
els of natriuretic
peptides in peo-
ple with heart
failure are pre-
dictors of death
and hospitalisa-
tions. The study
authors looked at
whether high
lev-
els of these pep-
tides can predict
whether people
with heart failure
bene-
fit from a home-
based nurse in-
tervention
The nurse
checked for and,
in co-ordination
with the treating
physician,
implemented
guide-
line-based medi-
cation (Remme
1997; Remme
2001).
At home
visits, the nurse
checked and
recorded weight,
recorded symp-
toms and signs
of heart failure
as well as heart
rate and blood
pressure, and or-
ganised and re-
viewed blood
analyses on de-
mand. The nurse
also gave the pa-
tient education
and self-manage-
ment skills
Nurses who spe-
cialised in caring
for people with
heart failure pro-
vided the inter-
vention
The intervention
was delivered in-
dividually and
face-to-face
Murray 2004 Computerised
care suggestions
Hyper-
tension is asso-
ciated with car-
diovascular mor-
bidity and mor-
tality, but is dif-
ficult to control.
Guidelines on
hypertension are
complicated and
can become out-
dated quickly, so
this study inves-
This study used
the pharma-
cist intervention
recording sys-
tem, which was
used to docu-
ment all pharma-
ceuti-
cal care interven-
tions (Overhage
1999). This sys-
tem
gave the pharma-
The pharma-
cist intervention
recording system
was used by in-
tervention phar-
macists to re-
ceive care sugges-
tions. The phar-
macist could fill
the prescription
as written, dis-
cuss the sugges-
tions with the
Pharmacists and
physicians pro-
vided the inter-
vention.
The intervention
was delivered in-
dividually and
face-to-face
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tigated the ben-
efits of evidence-
based treatment
for hypertension
using a comput-
erised system
cist care sugges-
tions, which they
could pass on to
the physician
The physician
used an order
writing worksta-
tion to write or-
ders for drugs,
tests, nursing ac-
tivities, and con-
sultations
(McDonald
1999).
The workstation
gave the physi-
cian care sug-
gestions for the
treatment of hy-
pertension
participant and
encourage dis-
cussions between
the participant
and physician, or
contact the or-
dering physician
The
physician inter-
vention used an
order-
writing worksta-
tion to write or-
ders for drugs,
tests, nursing ac-
tivities and con-
sulta-
tions and display
care suggestions.
All hypertension
care suggestions
were displayed as
suggested orders
along with pos-
sible actions and
a brief explana-
tion of the ratio-
nale for the sug-
gestion
Nabagiez 2013 Home visits by
physician assis-
tants
Stud-
ies suggest that
people who have
undergone coro-
nary artery by-
pass graft surgery
benefit from a
home interven-
tion, but there
are few studies
of home visits
by physicians or
physician assis-
tants. Therefore,
this study exam-
ined the hospi-
tal readmissions
of people who re-
ceived home vis-
A physician assis-
tant home
care form/check-
list was used to
record
all findings from
the home visit. A
copy of this form
was provided in
the paper
Cardiothoracic
physician assis-
tants conducted
home visits dur-
ing which they
performed
a physical exam-
ination and re-
viewed the par-
ticipant’s medi-
cations. Adjust-
ments
were made to
the participant’s
medications and
new medications
were prescribed
as needed. The
Physician as-
sistants provided
the intervention.
The intervention
was delivered in-
dividually and
face-to-face
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its by physician
assistants
surgical wounds
were exam-
ined and partici-
pant concerns
were addressed.
Prescriptions
were written for
antibiotics,
blood work, or
imaging studies
Okamoto 2001 Pharmacist-
managed hyper-
tension clinic
Hyperten-
sion can be con-
trolled, but this
study investi-
gated whether it
can be managed
at a reasonable
cost with mini-
mal adverse ef-
fects by pharma-
cists
Sitting blood
pressure was
measured with a
Datascope Accu-
torr auto-
mated sphygmo-
manometer
(Datascope Cor-
poration Mont-
vale, NJ, USA).
2 readings were
taken for each
participant and
the average of
the 2 readings
was recorded (
Datascope
Patient
Monitoring
1996).
Participants were
counselled by a
pharmacist who
told them that
efforts would be
made to decrease
the number
of antihyperten-
sive drugs or alter
their therapy by
giving more ap-
propriate or less
expensive drugs
to achieve simi-
lar or improved
blood
pressure control.
The pharmacist
deter-
mined the most
appropriate anti-
hypertensive reg-
imen for each
participant, or-
dered laboratory
tests as needed,
and provided ed-
ucation on non-
pharmacolog-
ical ways to con-
trol blood pres-
sure
Clinical phar-
macists provided
the intervention.
The intervention
was delivered in-
dividually and
face-to-face
Olesen 2014 Pharmacist med-
ication review
Pharma-
cists work with
partic-
ipants in design-
ing, implement-
Pharmacists ad-
hered to a man-
ual to deliver the
intervention
(Medication Re-
Participants were
visited at home
by a pharmacist
who examined
the medicines
Pharmacists who
had some practi-
cal experience or
courses in medi-
cation review
The intervention
was delivered in-
dividually. It was
conducted
by telephone and
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ing and moni-
toring therapeu-
tic plans, but el-
derly people may
have problems
with adhering to
their medica-
tion. This study
looked at treat-
ment adherence,
as well as hos-
pitalisations and
mortality, in el-
derly people who
received a home
visit
by a pharmacist
along with tele-
phone follow-up
view-Managing
Medicine Man-
ual, Danmarks
Apotekerforen-
ing, Pharmakon.
Medicingen-
nemgang
2004). This
man-
ual helps phar-
macists identify
and resolve drug-
related problems
(Danmarks
2004).
list with regard
to side-effects,
interactions and
administra-
tion. The phar-
macist tried to
make the regime
less complex, in-
formed partici-
pants, and moti-
vated adherence
provided the in-
tervention
face-to-face
Pai 2009 Pharmacist med-
ication review
People with end-
stage renal dis-
ease take mul-
tiple drugs and
experience mul-
tiple co morbidi-
ties, which places
them at greater
risk of drug-re-
lated prob-
lems. This paper
looked at the ef-
fects of a phar-
macist-led inter-
vention on drug-
related problems
and hospitalisa-
tions in ambula-
tory patients un-
dergoing
haemodialysis
Drug-
related problems
were recorded,
evaluated and as-
signed to 10 pos-
sible categories (
Hepler 1990).
The drug-related
problems were
also categorised
into therapeutic
drug classes and
the outcome re-
lated to the drug-
related problem
intervention was
captured
Participants as-
signed to phar-
ma-
ceutical care had
drug therapy re-
views conducted
by a nephrology-
trained
pharmacist. The
pharmacist con-
ducted a partic-
ipant interview,
generated a drug
therapy profile,
identified and
addressed drug-
related prob-
lems, and pro-
videdhealthcare-
provider
and participant
education. The
pharmacist also
provided consul-
tative services
that focused on
optimising drug
therapy
The
clinical pharma-
cists who con-
ducted the inter-
vention were ei-
ther nephrology-
trained or com-
pleting postdoc-
toral training in
nephrology
pharmacother-
apy
The intervention
was delivered in-
dividually and
face-to-face
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Roberts 2001 Medication
review, nurse ed-
ucation, and de-
velopment of
professional rela-
tionships
Pharmacist-
conductedmedi-
cation reviews
and nurse educa-
tion about med-
ication use may
have an impact
on drug use in
nursing homes.
This study
looked at the ef-
fect of medica-
tion review
and nurse educa-
tion on mortal-
ity and hospital-
isations in nurs-
ing homes
Prob-
lem-based edu-
cational sessions
were provided to
nurses and ad-
dressed ba-
sic geriatric phar-
macology
and some com-
monproblems in
long-term
care. No refer-
enced documen-
ta-
tion is provided
for these sessions
The interven-
tion introduced
a new profes-
sional role to
stakeholders
with relationship
building, nurse
education, and
a medication
review by phar-
macists. Profes-
sional contact
between nursing
home staff and
pharmacists
on issues such
as drug policy
and resident
problems was
conducted along
with problem-
based educa-
tional sessions
for nurses. These
sessions ad-
dressed geriatric
pharmacology
and problems
in long-term
care. The med-
ication reviews
highlighted
adverse drug
effects, ceasing
or adding drugs,
better use of
specific drug
therapy, non-
drug interven-
tions, and ad-
verse effect and
drug response
monitoring
Clinical phar-
macists delivered
the intervention.
The intervention
was delivered in-
dividually and in
groups over the
phone and face-
to-face
Rytter 2010 Structured home
visits by GP and
nurse
Many hos-
pital admissions
are due to inap-
propri-
atemedical treat-
The
joint home visits
were guided by
an agenda. Dur-
ing the struc-
There was a joint
home visit by
the GP and dis-
trict nurse ap-
proximately one
GPs and district
nurses provided
the intervention.
The intervention
was delivered in-
dividually and
face-to-face
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Table 1. Tentative description of interventions (part 1) (Continued)
ment, and the
discharge of frag-
ile elderly pa-
tients is associ-
ated with a high
risk of readmis-
sion. This study
ex-
amined whether
home visits by
GPs and district
nurses reduced
the risk of read-
mission of dis-
charged elderly
patients
tured home visit
the agenda in-
cluded checking
the discharge let-
ter for recom-
mended follow-
up, checking the
need for adjust-
ment of medica-
tion, checking if
social and
personal support
was arranged,
and checking the
family’s
medicine cabi-
net. This agenda
was provided in
the article
week after dis-
charge from the
hospital. 2 more
contacts
were conducted
by the GP in
the GP’s clinic or
as a home visit.
These visits in-
cluded checking
the discharge let-
ter, checking the
need for adjust-
ment of medica-
tion, checking if
social and
personal support
was arranged,
and checking the
family’s
medicine cabinet
Triller 2007 Pharmacist med-
ication reviews
Adverse drug
events are fre-
quently caused
by cardiovascular
drugs. Pharma-
cists can identify
and resolve drug-
related problems
for peo-
ple at home and
reduce re-hos-
pitalisation rates.
This study inves-
tigatedwhether a
phar-
macist-led inter-
vention could re-
duce re-hospital-
isations and
death in people
with heart failure
Using a prede-
fined check-
list, the pharma-
cist tried to re-
duce the use of
in-
appropriate me-
diations, encour-
age smoking ces-
sation, suggest
improvements in
the participant’s
diet, and pro-
motemedication
adherence, self-
monitoring, and
vaccination. The
checklist is not
provided in the
paper
The pharmacist
in the interven-
tion group con-
ducted an in-
home medica-
tion assessment
and 2 follow-
up visits. This
involved assess-
ing and review-
ing physician
notes and labo-
ratory test val-
ues and inter-
acting with pre-
scribers on be-
half of the partic-
ipants. The
pharmacist cata-
logued all medi-
ca-
tions and inter-
viewed the par-
ticipant regard-
ing medication
use
A clinical phar-
macist, who had
over 20 years of
combined expe-
rience as a hos-
pital and com-
munity pharma-
cist and had re-
ceived a doctor
of pharmacy de-
gree and com-
pleted a 1-year
clinical residency
in home care,
provided the in-
tervention
The intervention
was delivered in-
dividually and
face-to-face
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Table 1. Tentative description of interventions (part 1) (Continued)
Zermansky 2001 Pharmacist med-
ication review
Repeat prescrib-
ing
is poorly man-
aged in the UK,
which puts peo-
ple at risk. Phar-
macists could re-
view these pre-
scriptions and re-
duce the
pressure on GPs.
This study tested
whether phar-
macists can re-
view repeat pre-
scriptions to re-
duce hospital ad-
missions and
deaths
The process for
reviewing repeat
prescriptions in-
volved
discussing each
condition
with the partici-
pant and asking
about symptoms
(Lowe 2000). If
clinical or patho-
logical monitor-
ing was due, the
pharmacist di-
rected the partic-
ipant to the prac-
tice nurse
or doctor. Partic-
ipants with new
clinical problems
were referred to
the doctor
The
pharmacists con-
ducted a medica-
tion review dur-
ing which they
evaluated the
therapeutic effi-
cacy of each drug
and the progress
of the
conditions being
treated. Compli-
ance, actual and
potential adverse
effects, interac-
tions, and the
participant’s un-
derstanding
of the condition
and its treatment
were considered.
The outcome of
the review was
a decision about
the continuation
of the treatment
A
pharmacist pro-
vided the medi-
cation review.
The intervention
was delivered in-
dividually and
face-to-face
Zermansky 2006 Pharmacist med-
ication review
Elderly
people take mul-
tiple medicines,
which
increases the risk
of adverse drug
events. Pharma-
cists can improve
medicine man-
agement for el-
derly people in
the community.
In this study, the
authors looked at
whether
a pharmacist-led
review would re-
duce hospitalisa-
tions and deaths
among
elderly people in
The clin-
ical medication
review (Lowe
2000), which
was conducted
by the pharma-
cist, comprised a
review of the GP
clinical record,
and a consul-
tation with the
participant and
carer. The phar-
macist made rec-
ommenda-
tions and passed
them on a writ-
ten proforma to
theGP for accep-
tance and recom-
mendation
The
pharmacist con-
ducted a medi-
cation review in
which the phar-
macist identified
the drugs that
were taken, iden-
tified the original
indication
for each drug, as-
sessed adherence
to
medication, and
identified unad-
dressed medical
problems. They
also considered
the
continuing need
for each drug,
The study phar-
macist provided
the intervention.
The intervention
was delivered in-
dividually and
face-to-face
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Table 1. Tentative description of interventions (part 1) (Continued)
nursing homes identified side ef-
fects, identified
drug interactions
or contraindica-
tions, and con-
sidered costs. Fi-
nally, the phar-
macist
implemented
and documented
any changes
GP: general practitioner
Table 2. Tentative description of interventions (part 2)
Study Location of in-
tervention
When and how
much of the in-
tervention was
delivered
Tailoring Modifications Adherence
planning
Adherence
assessment
Alvarez 2001 83 commu-
nity pharmacies
in the provinces
of Asturias,
Barcelona,
Madrid and Bis-
cay
The
intervention was
delivered once.
There was no tai-
loring made to
the intervention.
Two
additional semi-
nars were given
to the interven-
tion group on
real cases in or-
der to approve
the intervention
Not undertaken Not undertaken
Bernsten 2001 Community
pharmacies in 7
European coun-
tries; Denmark,
Germany, The
Netherlands,
Northern Ire-
land (co-ordinat-
ing centre), Por-
tugal,
Republic of Ire-
land and Swe-
den.
A minimum of
12 sites
per country were
chosen
according to spe-
The intervention
was delivered at
least once ac-
cording to the
study manual.
However, Each
site was free to
provide as much
informa-
tion as possible
to the interven-
tion group as per
the studymanual
A study manual
describing the
intervention was
developed for all
the participating
countries. Each
country trans-
lated the manual
into their own
language
Each coun-
try adapted the
manual, translat-
ing and modify-
ing sections
where appropri-
ate, according to
differing na-
tional practices
Not undertaken Not undertaken
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Table 2. Tentative description of interventions (part 2) (Continued)
cific criteria
set
within each par-
ticipating coun-
try relating to the
population of el-
derly people who
visited the phar-
macy, staffing
levels within
the phar-
macy and work-
ing relationships
with local GPs.
Campins 2016 7 Pri-
maryHealth care
clinics in Mataró
and Argentona
The inter-
vention included
3 phases and the
participants were
followed up for
12 months. It is
not clear if the
intervention was
repeated more
than once
There was no tai-
loring made to
the intervention.
There
were no modifi-
cations made to
the intervention
during the study
Not undertaken Not undertaken
Coleman 1999 9 primary care
physician prac-
tices inWashing-
ton State. Clin-
ics were allowed
to select their tar-
get condition of
focus: frail older
adults or
people with dia-
betes. The physi-
cians were board
certified in Fam-
ily Practice and
did not have for-
mal training or
certification in
geriatric
medicine.
The intervention
was undertaken
once. However
there was vari-
ability in the fre-
quency of one of
its components
There was no tai-
loring made to
the intervention.
There
were no modifi-
cations made to
the intervention
during the study
A priori process
of care measures
for
each of the geri-
atric syndromes
were developed
with decision
rules for accept-
able documenta-
tion by the study
reviewers for the
interventions
The chart ab-
straction of as-
sessing the doc-
umentation for
the interventions
was performed
by one member
of the study team
alongwith an ad-
ditional reviewer
blinded to
knowledge of the
study group and
study hypothe-
sis. The overall
level of agree-
ment
between the 2 re-
viewers was ac-
cept-
able based on
published ranges
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Table 2. Tentative description of interventions (part 2) (Continued)
(kappas for geri-
atric syndrome
process measures
0.75 to 0.85)
Frankenthal
2014
Chronic care
geriatric facilities
in Central Israel
The intervention
was done once at
6 months and 12
months later
There was no tai-
loring made to
the intervention.
There
were no modifi-
cations made to
the intervention
during the study
Not undertaken Not undertaken
Garcia-Gollarte
2014
A private organi-
sation
of 37 nursing
homes in Spain
It is unclear how
many times the
intervention was
given as the edu-
cator offered
fur-
ther on-demand
advice on pre-
scription for the
next 6 months
There was no tai-
loring made to
the intervention.
There
was no modifi-
cations made to
the intervention
during the study
Not undertaken Not undertaken
Gernant 2016 Home health pa-
tients within a
medicare insured
home health
population in
Canada
The intervention
was undertaken
at
least once how-
ever, some par-
ticipants re-
ceivedmore than
one phone call as
additional tele-
phone follow-up
was provided as
needed per the
pharmacists’ dis-
cretion during
the first 30
days of the 60-
day
home healthcare
episode.
Some
participants re-
ceived additional
follow-
up depending on
their conditions
There
were no modifi-
cations made to
the intervention
during the study
Not undertaken Not undertaken
Gurwitz 2014 Large multispe-
cialty
group
practice employ-
ing 265 physi-
cians, including
66 primary care
Daily records
generated by the
computer system
were examined
There was no tai-
loring made to
the intervention.
There
were no modifi-
cations made to
the intervention
during the study
Not undertaken Not undertaken
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Table 2. Tentative description of interventions (part 2) (Continued)
providers caring
for adults in the
outpatient
setting
Hawes 2014 804-bed aca-
demic medical
centre in North
Carolina, USA
The intervention
took place once.
There was no tai-
loring made to
the intervention.
Only hospitali-
sations
and ED visits at
the study institu-
tion were
in-
cluded for those
participants who
were not able to
be contacted af-
ter 3 phone call
attempts
Not undertaken Not undertaken
Holland 2005 Home-based
medica-
tion review after
discharge from
acute or commu-
nity hospitals in
Norfolk and Suf-
folk, UK
The
intervention was
performed once.
It is possible that
a small number
of participants in
both groups may
have
had their med-
ication reviewed
during the fol-
low-up period by
their GP or com-
munity pharma-
cist
There
were no modifi-
cations made to
the intervention
during the study
Not undertaken.
No data on ad-
herence were col-
lected.
Not undertaken
Ibrahim 2013 Tele-
phone consulta-
tion with home
visits
The
intervention was
performed once.
Any
additional con-
tact as requested
by the partici-
pant in the in-
tervention group
was undertaken
There
were no modifi-
cations made to
the intervention
during the study
Not undertaken Not undertaken
Kaczorowski
2011
Community-
based pharma-
cies in Canada
The intervention
was performed
once as planned.
The local lead or-
ganisations used
several strategies
to recruit volun-
teer peer health
educators. These
strate-
gies included us-
ing the local lead
organisation’s ex-
When required,
Cardio-
vascular Health
Awareness
Program support
staff produced
and mailed invi-
tation letters on
behalf of par-
ticipating physi-
Feedback of re-
sults was given to
primary health-
care providers
Evaluation data
collected for the
purpose of on-
going evaluation
and quality im-
provement:
1.
Success of differ-
ent advertising/
invitation strate-
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Table 2. Tentative description of interventions (part 2) (Continued)
isting volunteer
base, advertising
in the local
media, and giv-
ing presentations
at local seniors’
clubs.
cians (CHAP
2017).
gies
2. Attendance,
con-
sent, completed
assessments
3. Nurse assess-
ments,
pharmacist con-
sults, fax/call to
family physician
the same day
Feedback to fam-
ily physicians,
pharmacists, and
participants
Korajkic 2011 Out-
patients clinic in
Melbourne, Aus-
tralia
The intervention
was performed
once as planned.
There was no tai-
loring made to
the intervention.
There
were no modifi-
cations made to
the intervention
during the study
There were writ-
ten instruc-
tions on how to
adjust the dose
of frusemide per
weight increase
Data on dosage
adjustment of
frusemide were
col-
lected and com-
pared against the
initial criteria
Krska 2001 General medical
practices in
theGrampian re-
gion of Scotland
The intervention
was performed
once as planned.
In the con-
trol group, when
pharmacists con-
sidered a review
to be serious and
beneficial to the
participants, an
indepen-
dent medical as-
sessor decided on
the need to with-
draw the partici-
pants on clinical
grounds
There
were no modifi-
cations made to
the intervention
during the study
Any outstanding
care issues
in both groups
were communi-
cated to the par-
ticipant’s GP
Not undertaken
Lapane 2011 25 nurs-
ing homes ser-
viced by 2 long-
term care phar-
macies in North-
ern Ireland
It is unclear the
number of times
the reports were
generated and
used by the phar-
macists for every
resident
The Geri-
atric Risk Assess-
ment MedGuide
database
software for falls
and deliriumwas
integrated into
the phar-
macies’ commer-
cial pharmacy
It is unclear if
there were any
modifications to
the interventions
The com-
puter system did
not capture if the
recommenda-
tions done by the
pharmacist were
accepted
Not undertaken
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Table 2. Tentative description of interventions (part 2) (Continued)
software system
(Rescot LTCP
System) for the
inter-
vention homes (
Tobias 1999).
Lenaghan 2007 A GP setting in
Norfolk, UK
It is unclear how
many times the
pharmacist
and the GP met
to discuss partic-
ipant’s care plan
A follow-up visit
with the partici-
pant occurred 6-
8 weeks later to
reinforce
the original ad-
vice, and assess
whether there
were any further
pharmaceuti-
cal care issues to
address with the
GP.
It is unclear if
there were any
modifications to
the interventions
Not undertaken Not undertaken
Lowrie 2012 The study was
conducted
within the NHS
which provides
free health care
to the popula-
tion of the UK.
27 primary care-
based
pharmacists em-
ployed by the
NHS to work
with family doc-
tors
It is unclear how
many times the
pharma-
cist met the par-
ticipant and the
GP
If there was
agreement be-
tween the phar-
macist and the
participant dur-
ing the consulta-
tion and subse-
quently with the
fam-
ily doctor, medi-
cations were ini-
tiated, discontin-
ued, or modified
by the pharma-
cist during 3-4
subse-
quent weekly or
fortnightly con-
sultations
It is unclear if
there were any
modifications to
the interventions
Not undertaken Not undertaken
Malet-Larrea
2016
The study was
conducted
in 178 commu-
nity pharmacies
in Spain
It is unclear how
many times the
intervention was
undertaken
A specifically
trained pharma-
cist called a prac-
tice change facil-
ita-
tor helped phar-
macists of the in-
tervention group
It is unclear if
there were any
modifications to
the interventions
The prac-
tice change facil-
itator ensured fi-
delity to the in-
tervention
and
supported phar-
macists of both
The experts were
requested to an-
swer individually
for each case and
the degree
of agreement be-
tween them was
later established.
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in the provision
of the medica-
tion review with
follow-up ser-
vice, identifying
barriers specific
to each phar-
macy and pro-
viding solutions
study groups on
queries
about documen-
tation forms
Inter-rater relia-
bility
wasmeasuredus-
ing Fleiss’s kappa
Malone 2000 9 Veter-
ans Affairs medi-
cal centres in the
USA
It is unclear how
many times par-
tic-
ipants were seen
by the pharma-
cist in the inter-
vention group as
the protocol in-
dicated
that each partici-
pant should have
at least 3 visits
with the clinical
pharmacist dur-
ing the study,
but participants
could be seen as
frequently
as deemed neces-
sary to ensure ap-
propriate care
To prevent con-
tamination,
some sites
marked medical
records of inter-
vention and con-
trol participants
to alert clin-
ical pharmacists
that participants
were in the study.
Other sites noted
this distinc-
tion in electronic
medical records
One site dis-
tributed a list of
participants en-
rolled in
the study to all
pharmacists pro-
viding primary
care.
Clinical pharma-
cist intervention,
how-
ever, occurred in
one control par-
ticipant; this par-
ticipant was
withdrawn from
the study and his
data were not in-
cluded in the re-
sults
Each
contact with the
participant was
recorded on a
stan-
dard data collec-
tion form that
contained infor-
mation about the
method of con-
tact, estimated
time spent with
the participant,
medi-
cal problems ad-
dressed, drug-re-
lated prob-
lems addressed,
and drug-
related problems
resolved
Each
month after en-
rolment the co-
ordinating cen-
tre received elec-
tronic data
on each partic-
ipant’s prescrip-
tion
drugs dispensed
in the preceding
month. When
participants
either completed
the study or died,
data on resource
use from enrol-
ment to termi-
nation were re-
trieved
Moertl 2009 Ambulatory pa-
tients participat-
ing in the Euro-
Heart Fail-
ure Survey pro-
gramme in Vi-
enna
It is unclear how
many times the
nurse visited the
intervention par-
ticipants as more
visits were made
optional for par-
ticipants
More frequent
contacts such as
visits or
tele-
phone calls be-
tween the nurse
and the partici-
pants
were optional in
case the partici-
pant or the nurse
considered them
necessary
The nurse was in
charge
of individualised
participant and
caregiver educa-
tion and
enhancement of
self-man-
agement. If the
nurse noted any
de-
terioration in the
participant’s sta-
tus, she reported
to the treating
Not undertaken Not undertaken
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physician or ad-
vised the partici-
pant to
visit the treating
physician
Murray 2004 Academic
primary care in-
ternal medicine
practice in the
USA
It is unclear how
many times the
intervention was
undertaken
There was no tai-
loring made to
the intervention.
There were
no modifications
made to the in-
terventions.
Data necessary
to generate care
suggestions were
derived from the
computer pro-
gramme. Treat-
ment sugges-
tions fell into 5
major categories
Not undertaken
Nabagiez 2013 Ambulatory pa-
tients discharged
from a large 702-
bed hospi-
tal in StatenUni-
versity Hospital,
USA
It is unclear how
many times the
physician visited
each participant
in the home after
their discharge
There was no tai-
loring made to
the intervention.
There were some
modifications
done to the in-
terventiondue to
the participants
not being avail-
able at the week-
end. Participants
were not seen di-
rectly after dis-
charge as per the
study protocol
All findings were
documented on
the intervention
visit form.
It is unclear if
this was under-
taken.
Okamoto 2001 Man-
aged care organi-
sation in Califor-
nia, USA
It is unclear how
many times
participants were
seen by the phar-
macist in the in-
tervention group
as additional fol-
low-up was or-
gan-
ised by the phar-
macists for some
participants
Addi-
tional follow-up
was organised by
the pharmacists
for some partici-
pants
The intervention
was not modi-
fied.
Not undertaken Not undertaken
Olesen 2014 Patients living at
home in the mu-
nici-
pality of Aarhus,
Denmark
The intervention
was performed at
the intended fol-
low-up.
Pharmacists
could consult the
project
physician if they
considered a par-
ticipant’s medi-
cation
The intervention
was not modi-
fied.
Adherence to the
medications
were assessed by
a pill-count in all
participants dur-
ing 1 year
Pill count was
undertaken
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problems to be
life-threatening.
Pai 2009 The study took
place in a non-
profit university-
affiliated dialysis
clinic in Albany,
USA
It is unclear if all
participants re-
ceived the same
number of fol-
low-up visits by
the pharma-
cist or the physi-
cian in the inter-
vention group
It is unclear if
there was any tai-
loring made to
the intervention
The intervention
was not modi-
fied.
Not undertaken Not undertaken
Roberts 2001 52 nurs-
ing homes lo-
cated in south-
east Queensland
and north-
east New South
Wales, Australia
There was
variability in the
number of edu-
cational sessions
provided to staff
in each nursing
home as well as
the number of
visits by the in-
tervention phar-
macists
It is unclear if
there was any tai-
loring made to
the intervention
It is unclear if the
intervention was
modified.
Valida-
tion of prescrip-
tion claim data
with par-
ticipants’ medi-
cations profiles
To validate pre-
scription claims
data, a sample
of 1328 cross-
sectional medi-
cation
profiles were col-
lected for 8 nurs-
ing home clus-
ters for control
and intervention
homes at post-
intervention
An audit, com-
paring
original post-in-
tervention medi-
cation data with
the same
data recollected
up to 6 weeks
later for a 6%,
random sample,
showed an over-
all reproducibil-
ity of 97%(range
92% to 100%)
Rytter 2010 Patients
discharged from
Glostrup Hospi-
tal, Denmark.
The intervention
was performed as
prescribed.
There was no tai-
loring made to
the intervention.
There
was no modifica-
tion made to the
intervention.
Not undertaken Not undertaken
Triller 2007 Heart failure pa-
tients discharged
from hospital in
The intervention
was performed as
prescribed.
The
clinical pharma-
cist accessed and
There
was no modifica-
tion made to the
Not undertaken Not undertaken
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Albany, Scotland reviewed all per-
tinent physician
notes and labo-
ratory test values
via
the National En-
dowment for the
Humanities data
system and inter-
acted with pre-
scribers on be-
half of the partic-
ipants, as neces-
sary
intervention.
Zermansky 2001 4 GPs in Leeds,
UK
It is unclear how
many times the
pharmacist vis-
ited the partici-
pant
Immobile partic-
ipants were vis-
ited at
home. Non-at-
tenders were in-
vited once more
by telephone
The study au-
thors agreedwith
each practice the
level of interven-
tion
that the pharma-
cist could make
without seeking
prior approval
It is unclear if
this was under-
taken.
It is unclear if
this was under-
taken.
Zermansky 2006 65 care homes
for the elderly in
Leeds, UK
It is unclear how
many times the
pharmacist re-
viewed each par-
ticipant
There was no tai-
loring made to
the intervention.
There
was no modifica-
tion made to the
intervention.
Pharmacists
filled in a pro-
forma sheet in-
cluding their rec-
ommendations
GP acceptance
of the recom-
mendations was
signified by tick-
ing a box on the
proforma
ED: emergency department; GP: general practitioner; NHS: National Health Service
117Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. EPOC Taxonomy
Professional interventions
• Distribution of educational materials (distribution of published or printed recommendations for clinical care, including clinical
practice guidelines, audiovisual materials and electronic publications; the materials may have been delivered personally or through
mass mailings).
• Educational meetings (healthcare providers who have participated in conferences, lectures, workshops or traineeships)
• Local consensus processes (inclusion of participating providers in discussion to ensure that they agreed that the chosen clinical
problem was important and the approach to managing the problem was appropriate).
• Educational outreach visits (use of a trained person who met with providers in their practice settings to give information with the
intent of changing the provider’s practice. The information given may have included feedback on the performance of the providers).
• Local opinion leaders (use of providers nominated by their colleagues as ’educationally influential’. The investigators must have
explicitly stated that their colleagues identified the opinion leaders).
• Patient-mediated interventions (new clinical information (not previously available) collected directly from patients and given to
the provider e.g. depression scores from an instrument).
• Audit and feedback (any summary of clinical performance of health care over a specified period of time. The summary may also
have included recommendations for clinical action. The information may have been obtained from medical records, computerised
databases, or observations from patients).
The following interventions are excluded
• Provision of new clinical information not directly reflecting provider performance which was collected from patients, e.g. scores
on a depression instrument, abnormal test results. These interventions should be described as patient-mediated.
• Feedback of individual patients’ health record information in an alternate format (e.g. computerised). These interventions
should be described as organisational.
• Reminders (patient- or encounter-specific information, provided verbally, on paper or on a computer screen, which is designed
or intended to prompt a health professional to recall information. This would usually be encountered through their general
education; in the medical records or through interactions with peers, and so remind them to perform or avoid some action to aid
individual patient care. Computer-aided decision support and drugs dosage are included).
• Marketing (use of personal interviewing, group discussion (’focus groups’), or a survey of targeted providers to identify barriers
to change and subsequent design of an intervention that addresses identified barriers)
• Mass media (i. varied use of communication that reached great numbers of people including television, radio, newspapers,
posters, leaflets, and booklets, alone or in conjunction with other interventions; ii. targeted at the population level)
• Other (other categories to be agreed in consultation with the EPOC editorial team)
Financial interventions
Provider
• Fee-for-service (provider has been paid for number and type of service delivered)
• Prepaid (no other description)
• Capitation (provider was paid a set amount per patient for providing specific care)
• Provider salaried service (provider received basic salary for providing specific care)
• Prospective payment (provider was paid a fixed amount for health care in advance)
• Provider incentives (provider received direct or indirect financial reward or benefit for doing specific action)
• Institution incentives (institution or group of providers received direct or indirect financial rewards or benefits for doing specific
action)
• Provider grant/allowance (provider received direct or indirect financial reward or benefit not tied to specific action)
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• Institution grant/allowance (institution or group of providers received direct or indirect financial reward or benefit not tied to
specific action)
• Provider penalty (provider received direct or indirect financial penalty for inappropriate behaviour)
• Institution penalty (institution or group of providers received direct or indirect financial penalty for inappropriate behaviour)
• Formulary (added or removed from reimbursable available products)
• Other (other categories to be agreed in consultation with the EPOC editorial team)
Patient
• Premium (patient payment for health insurance. It is important to determine if the patient paid the entire premium, or if the
patient’s employer paid some of it. This includes different types of insurance plans).
• Co-payment (patient payment at the time of healthcare delivery in addition to health insurance, e.g. in many insurance plans
that cover prescription medications, the patient may pay AUD 5 per prescription, with the rest covered by insurance).
• User fee (patient payment at the time of healthcare delivery)
• Patient incentives (patient received direct or indirect financial reward or benefit for doing or encouraging them to do specific
action)
• Patient grant/allowance (patient received direct or indirect financial reward or benefit not tied to specific action)
• Patient penalty (patient received direct or indirect financial penalty for specified behaviour, e.g. reimbursement limits on
prescriptions)
• Other (other categories to be agreed in consultation with the EPOC editorial team)
Organisational interventions
Provider-orientated
• Revision of professional roles (also known as ’professional substitution’, ’boundary encroachment’ and includes the shifting of
roles among health professionals. For example, nurse midwives providing obstetrical care; pharmacists providing drug counselling that
was formerly provided by nurses and physicians; nutritionists providing nursing care; physical therapists providing nursing care. Also
includes expansion of role to include new tasks).
• Clinical multidisciplinary teams (creation of a new team of health professionals of different disciplines or additions of new
members to the team who work together to care for patients)
• Formal integration of services (bringing together of services across sectors or teams or the organisation of services to bring all
services together at one time also sometimes called ’seamless care’)
• Skill mix changes (changes in numbers, types or qualifications of staff )
• Continuity of care (including one or many episodes of care for inpatients or outpatients)
• Arrangements for follow-up
• Case management (including co-ordination of assessment, treatment and arrangement for referrals)
• Satisfaction of providers with the conditions of work and the material and psychic rewards (e.g. interventions to ’boost morale’)
• Communication and case discussion between distant health professionals (e.g. telephone links; telemedicine; there is a
television/video link between specialist and remote nurse practitioners)
• Other (other categories to be agreed in consultation with the EPOC editorial team)
Patient-orientated
• Mail order pharmacies (e.g. compared to traditional pharmacies)
• Presence and functioning of adequate mechanisms for dealing with patients’ suggestions and complaints
• Consumer participation in governance of healthcare organisation
• Other (other categories to be agreed in consultation with the EPOC editorial team)
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Structural
• Changes to the setting/site of service delivery (e.g. moving a family planning service from a hospital to a school)
• Changes in physical structure, facilities and equipment (e.g. change of location of nursing stations, inclusion of equipment
where technology in question is used in a wide range of problems and is not disease specific, for example an MRI scanner)
• Changes in medical records systems (e.g. changing from paper to computerised records, patient-tracking systems)
• Changes in scope and nature of benefits and services
• Presence and organisation of quality monitoring mechanisms
• Ownership, accreditation, and affiliation status of hospitals and other facilities
• Staff organisation
• Other (other categories to be agreed in consultation with the EPOC editorial team)
Regulatory interventions
Any intervention that aims to change health service delivery or costs by regulation or law. (These interventions may overlap with
organisational and financial interventions).
• Changes in medical liability
• Management of patient complaints
• Peer review
• Licensure
• Other (other categories to be agreed in consultation with the EPOC editorial team)
Appendix 2. Search Strategies
MEDLINE
Epub Ahead of Print, In-Process &OtherNon-Indexed Citations, OvidMEDLINE(R) Daily andOvidMEDLINE(R) 1946 to Present
Searched 4 October 2016
No. Search terms Results
1 *community pharmacy services/ 2635
2 (prevent* adj2 medication error?).ti,ab. 436
3 (((medication or drug) adj2 event) and ((primary adj2 care)
or ((family or general) adj (practice or practitioner?)))).ti,ab
46
4 (“safety of medications” or prescribing safety or safe prescrib-
ing or (safely adj prescribing)).ti,ab
325
5 ((structured adj2 (assessment? or care)) and drug?).ti,ab. 175
6 (changes adj4 prescription?).ti,ab. 568
7 (medication adherence/ or patient compliance/) and pharma-
cists/
634
8 (pharmacist? adj2 (driven or directed or managed)).ti. 243
9 or/1-8 4923
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(Continued)
10 ((adverse drug or adverse medication?) adj2 (admission? or
readmission? or event or reduce? or prevent*)).ti,ab
1126
11 ((medication related or drug related) adj2 (event? or adverse
or admission? or readmission? or readmitted or admitted or
problem?)).ti,ab
4316
12 ((prevent* or reduce? or reducing or reduction or improve or
lower or fewer) adj3 adverse drug).ti,ab
890
13 dt.fs. and ((readmission? or readmit*) adj4 (avoid* or fewer
or improv* or less or lower or preventable or rate or rates or
reduce? or reduction? or related or unnecessary or avoidable)
).ti,ab
504
14 patient readmission/ and ((drug or prescription? or medica-
tion?) adj2 (error? or inappropriat* or problem? or related)).
ti,ab
85
15 inappropriate prescribing/ 1557
16 medication reconciliation/ 580
17 community pharmacy services/ 3350
18 (community pharmacy or community pharmacist?).ti. 1577
19 (exp drug therapy/ or (pharmaceutical? or prescrib* or pre-
scription? or medication?).ti,ab,hw.) and (near miss or near
misses or never event?).ti,ab
274
20 (changes adj3 (medication? or prescription? or prescribing)).
ti,ab
2865
21 patient readmission/ and (preventing or preventable or pre-
vent? or unnecessary or avoidable or reduce? or reducing or
reduction? or fewer).ti
740
22 (self administration/ or medication adherence/) and medica-
tion errors/
239
23 medication errors/ and (prevent*.ti. or (preventable or avoid-
able).ab.)
931
24 (medication adherence and self care).ti,ab. 199
25 medication adherence.ti,ab. and (self care.ti,ab. or patient ed-
ucation.ti,ab,hw.)
848
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(Continued)
26 (medication review and (community or home)).ti. or (medi-
cation review adj2 (community or home)).ab
48
27 (pharmacist? adj2 (driven or directed or managed)).ab. 390
28 decision support systems, clinical/ and ((drug? ormedication?)
adj3 (management or prevent* or adverse or event? or related)
).ti,ab
284
29 or/10-28 17871
30 medication errors/ 11484
31 (medication review or medication reconciliation).ti,ab. or
clinical audit/
2574
32 exp *drug therapy/ and ((adverse and event?).ti. or (adverse
drug event? or adverse medication*).ab.)
1070
33 ((problem? or hospitali?ation? or mortality or morbidity or
illness*) adj2 (drug related or drug induced)).ti,ab
1571
34 ((error? or mistake? or wrong or adverse event? or near miss or
nearmisses or never event? or incorrect* or inappropriat*) adj3
(drug? or dose or doses or dosage or dosing or pharmaceutical
or medication? or prescription? or prescribing)).ti,ab
17195
35 (dispensing adj2 (error? or mistake? or wrong)).ti,ab. 262
36 (drug therapy/ or prescription drugs/ or drug prescriptions/
or pharmaceutical preparations/ or drug dosage calculations/
or drug repositioning/ or drug substitution/ or “off-label use”/
or “drug therapy, combination”/ or “drug therapy, computer-
assisted”/ or polypharmacy/) and (mortality/ or (((preventable
or avoidable or prescrib* or medication) adj2 (error? or event?
)) or mistake? or wrong or incorrect* or inappropriat*).ti,ab.)
4290
37 or/30-36 29692
38 primary health care/ or general practice/ or family practice/ or
general practice, dental/ or primary care nursing/
130955
39 ((primary adj4 (care or healthcare)) or ((general or family) adj2
practice)).ti,ab
148502
40 (primary care or family medic* or general practice or family
practi*).jn
8882
122Professional, structural and organisational interventions in primary care for reducing medication errors (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
41 community medicine/ or community health nursing/ or com-
munity health services/ or community health centers/ or home
care services/
79553
42 (community care or community healthcare).ti,ab. 4095
43 ambulatory care facilities/ or ambulatory care/ 54315
44 ((ambulatory or walk-in or neighbo?rhood or community)
adj2 (clinic? or care centre or care centres or care center? or
health* centre or health* centres or health* center?)).ti,ab
10784
45 maternal-child health centers/ or outpatient clinics, hospital/
or pain clinics/ or community mental health centers/
21343
46 nursing homes/ or intermediate care facilities/ or skilled nurs-
ing facilities/
34654
47 (nursing home? or care facility).ti,ab. 30670
48 or/38-47 398235
49 general practitioners/ or physicians, family/ or physicians, pri-
mary care/
22546
50 ((general or family) adj2 (practitioner? or physician? or doctor?
)).ti,ab
65949
51 nurse practitioners/ or physician assistants/ 19913
52 (physician? assistant? or doctor? assistant? or physician? ex-
tender? or feldsher?).ti,ab. and (ambulatory or community or
outpatient? or out-patient?).ti,ab,hw
672
53 (structured assessment? or structured care or case manage-
ment).ti,ab
10118
54 nurses.ti. or (nurse? adj2 prescrib*).ti,ab. 57795
55 *pharmacists/ 8741
56 pharmacist?.ti. 10013
57 or/49-56 174871
58 pharmacists/ or pharmacists’ aides/ or pharmaceutical services/
or drug information services/ or clinical pharmacy informa-
tion systems/
23085
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(Continued)
59 medication review.ti,ab. 667
60 (pharmaceutical care or pharmacy or pharmacies or pharma-
cist? or prescriber? or prescribing or prescription? or drug ther-
apy).ti
61398
61 ((pharmacist? or prescription? or prescribing or medication?)
adj3 (consult* or review* or service or services)).ab
6688
62 ((medication? or prescrib* or pharmac*) adj2 (manage? or
management or service? or system?)).ti,ab
18502
63 (drug? assess* or drug? audit? or drug? reconcil*).ti,ab. 387
64 ((“drug therapy” or dosage? or dose? or medication? or pre-
scription? or prescrib* or pharmacist? or pharmaceutical care)
adj2 (managing or management or monitor*)).ti,ab
9624
65 ((improv* or optimi?ing or optimi?e? or optimal*) and (dos-
ing or dosage)).ti. or ((improv* or optimi?ing or optimi?e? or
optimal*) adj2 (pharmaceutical care or pharmacy or prescrib*
or prescript*)).ab
3363
66 ((drug therapy or drug regime? or medication? or medicines
or pharmacy or pharmacist? or pharmaceutical or prescrib* or
prescription?) adj2 (audit* or monitor* or reconcil* or review?
)).ti,ab
7239
67 drug utilization review/ 3363
68 medication adherence/ or self administration/ 21980
69 or/58-68 118774
70 ((unexpected or return) adj2 (emergency adj2 (department?
or room? or visit?))).ti,ab
62
71 (emergency adj3 (visit? or room? or clinic? or admission?) adj3
(reduc* or fewer or lower)).ti,ab
922
72 reduc* hospital admissions.ti,ab. 362
73 (readmission? adj3 (reduc* or fewer or lower)).ti,ab. 2124
74 ((hospital admission? or (readmit* or readmission?)) adj3 (re-
duc* or fewer or lower)).ti,ab. or patient readmission/
13305
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(Continued)
75 ((preventable or avoidable) adj3 (admission? or readmission?
or readmit*)).ti,ab
573
76 patient compliance.ti,ab. 7649
77 (adverse drug or adverse event?).ti,ab. 122534
78 (improve or improvement or improv* patient? or patient out-
comes).ti,ab
1028191
79 (ambulatory or outpatient? or out-patient?).ti,ab,hw. 267824
80 or/70-79 1376183
81 (randomized controlled trial or controlled clinical trial).pt. or
randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti
1071692
82 exp animals/ not humans.sh. 4323394
83 81 not 82 988060
84 37 and (or/48,57) 4572
85 69 and (or/48,57) and 80 7995
86 or/9,29 19108
87 84 or 85 or 86 27506
88 (clinical decision and drug?).ti. 83
89 (collaborative and (drug? or medication?) and management).
ti
45
90 ((safe or safety) and ((medication? or drug?) adj management)
).ti
26
91 ((reduce or reducing or reduced or reduction) and ((medica-
tion? or prescrib*) adj2 (error? or mistake or adverse or event?
))).ti
269
92 or/88-91 422
93 87 and 83 4692
94 92 or 93 5101
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(Continued)
95 ((prevent* or reduce or reducing) adj2 (medication error? or
adverse drug or adverse medication)).ti,ab
1483
96 medication errors/ and (avoid* or intervention or prevent* or
reducing or rate or improv* or quality).ti,ab,hw
5124
97 ((medication? or drug or prescription?) adj (error? or mistake?)
adj5 (avoid* or intervention? or prevent* or reducing or quality
improv*)).ti,ab
1052
98 inappropriate prescribing/ and (avoid* or intervention or pre-
vent* or reducing or rate or improv* or quality).ti,ab,hw
759
99 decision support systems, clinical/ and ((drug? or medication?
) adj2 (management or adverse or event? or related)).ti,ab
241
100 ((structured adj2 (assessment? or care)) and (drug? or medica-
tion?)).ti,ab
277
101 (structured assessment? or structured care or case manage-
ment).ti,ab. and (drug therapy or medication? or pharmaco*
therapy or prescription? or prescribing).ti,ab,hw
780
102 (“safety of medications” or prescribing safety or safe prescrib-
ing or (safely adj prescribing)).ti,ab
325
103 ((safe or safety or quality improv*) and ((medication? or drug?
) adj management)).ti
31
104 (quality improv* adj10 ((medication? or drug?) adj manage-
ment)).ab
8
105 (clinical decision and drug?).ti. 83
106 ((clinical decision making or decision support) adj4 (prescrib-
ing or drug therap* or drug management or medication man-
agement or (managing adj2 (drug? or drug therapy or medi-
cation?)))).ti,ab
170
107 (collaborative and (drug? or medication?) and management).
ti
45
108 medication reconciliation/ 580
109 (drug? assess* or drug? audit? or drug? reconcil* or ((medica-
tion or drug or prescribing or prescription?) adj2 (reconcilia-
tion or review* or audit))).ti,ab
5413
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(Continued)
110 ((medication? or prescrib* or pharmac*) adj2 (manage? or
management or service? or system?)).ti,ab
18502
111 ((“drug therapy” or dosage? or dose? or medication? or pre-
scription? or prescrib* or pharmacist? or pharmaceutical care)
adj2 (managing or management or monitor*)).ti,ab
9624
112 drug utilization review/ 3363
113 community pharmacy.ti. or (community adj (pharmacy or
pharmacist? or pharmacies)).ab
4021
114 pharmacist?.ti. or (pharmacist? adj2 (collaborat* or driven or
directed or led or managed or team*)).ab
10533
115 ((pharmacist? or prescription? or prescribing or medication?)
adj3 (consult* or review* or service or services)).ab
6688
116 patient readmission/ and (prescription? or drug therapy).ti,hw 179
117 patient readmission/ and (((adverse drug or adverse medica-
tion?) adj2 (event or related)) or ((medication related or drug
related) adj2 (event? or problem?))).ti,ab
22
118 ((drug related or medication related or adverse drug or ad-
verse medication) adj5 (emergency department? or emergency
unit? or emergency centre? or emergency center? or emergency
room? or afterhours or after hours or (emergency adj2 (admis-
sion? or admitting)))).ti,ab
163
119 ((drug related or medication related or adverse drug or adverse
medication) adj5 (readmission? or readmitted or emergency
visit or unexpected visit?)).ti,ab
51
120 (((hospital admission? or (readmit* or readmission?)) adj3 (re-
duc* or fewer or lower)) or ((avoidable or preventable or re-
duced or reducing) adj5 (admission? or readmission?))).ti,ab.
and (drug or medication? or prescription?).ti,ab,hw
922
121 or/95-120 52001
122 community pharmacy services/ 3350
123 primary health care/ or general practice/ or family practice/ or
general practice, dental/ or primary care nursing/
130955
124 ((primary adj2 care) or ((general or family) adj2 practice)).ti,
ab
141092
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(Continued)
125 (primary care or family medic* or general practice or family
practi*).jn
8882
126 community medicine/ or community health nursing/ or com-
munity health services/ or community health centers/ or home
care services/
79553
127 (community or ambulatory).ti,ab,hw. 556987
128 ambulatory care facilities/ or ambulatory care/ 54315
129 ((walk-in or neighbo?rhood) adj2 (clinic? or care centre or care
centres or care center? or health* centre or health* centres or
health* center?)).ti,ab
848
130 maternal-child health centers/ or outpatient clinics, hospital/
or pain clinics/ or community mental health centers/
21343
131 nursing homes/ or intermediate care facilities/ or skilled nurs-
ing facilities/
34654
132 ((patient? adj2 (home or homes)) or home visit?).ti,ab. 14823
133 or/123-132 798316
134 general practitioners/ or physicians, family/ or physicians, pri-
mary care/
22546
135 ((general or family) adj2 (practitioner? or physician? or doctor?
)).ti,ab
65949
136 ((primary care or family or general practice or community or
home care) adj2 (nurse or nurses)).ti,ab
6697
137 or/134-136 82852
138 121 and (or/133,137) 13867
139 138 or 122 14799
140 (randomized controlled trial or controlled clinical trial).pt. or
randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti
1071692
141 exp animals/ not humans.sh. 4323394
142 140 not 141 988060
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(Continued)
143 139 and 142 1916
144 94 or 143 5768
145 (pharmacist? and (adverse drug event? or adverse medication
event?)).ti
23
146 (pharmacist? and adverse drug reaction?).ti. 58
147 (admission? and (adverse drug event? or adverse medication
event? or adverse drug reaction?)).ti
101
148 (prevent$ and medication error?).ti. 224
149 (prevent$ and (adverse drug event? or adverse medication
event? or adverse drug reaction?)).ti
214
150 or/145-149 597
151 83 and 150 32
152 144 or 151 5774
Embase
Embase 1974 to 2016 October 03
Searched 4 October 2016
No. Search terms Results
1 (((primary adj2 care) or general practi*) and (adverse drug?
or adverse medication? or medication related or drug related
or preventable drug? or preventable medication? or (avoidable
and (drug? or medication? or pharmacother*)))).ti
101
2 ((ambulatory or outpatient?) and (adverse drug? or adverse
medication? or medication related or drug related or pre-
ventable drug? or preventable medication? or (avoidable and
(drug? or medication? or pharmacother*)))).ti
158
3 or/1-2 257
4 ((prevent* or reduce or reducing) adj2 (drug related or medi-
cation related or medication error? or adverse drug or adverse
medication)).ti,ab
2780
5 *“drug use”/ and (adverse or readmission? or readmit* or emer-
gency or problem or safety or safely or harm*).ti,ab
4163
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(Continued)
6 ((drug? or medication?) adj4 (emergency or readmission* or
readmit* or (urgent adj2 (care or visit?)))).ti,ab
3206
7 *medication error/ and (avoid* or intervention or prevent* or
reducing or rate or improv* or quality).ti,ab
3616
8 ((medication? or drug or prescription?) adj (error? or mistake?)
adj5 (avoid* or intervention? or prevent* or reducing or quality
improv*)).ti,ab
1733
9 *inappropriate prescribing/ and (avoid* or intervention or pre-
vent* or reducing or rate or quality improv*).ti,ab,hw
404
10 (*clinical decision making/ or *medical decision making/) and
(drug? therapy or medication? management or prescribing or
pharmaceutical care or adverse drug or adverse medication or
medication related).ti,ab
286
11 ((clinical decision making or decision support) adj4 (prescrib-
ing or drug therap* or drug management or medication man-
agement or (managing adj2 (drug? or drug therapy or medi-
cation?)))).ti,ab
198
12 ((structured adj2 (assessment? or care)) and (drug? or medica-
tion?)).ti,ab
423
13 (case management and (drug therapy or medication? or phar-
maco* therapy or prescription? or prescribing)).ti,ab
883
14 (“safety of medications” or prescribing safety or safe prescrib-
ing or (safely adj prescribing)).ti,ab
554
15 ((safe or safety or quality improv*) and ((medication? or drug?
) adj2 management)).ti
87
16 (quality improv* adj10 ((medication? or drug?) adj manage-
ment)).ab
15
17 (collaborative and (drug? or medication?) and management).
ti
73
18 (computer assisted drug therapy/ or *drug therapy/ or *drug
choice/ or *drug dose regimen/ or *pharmaceutical care/) and
(((readmission? or readmit*) adj3 (patient? or rate or rates or
reduce? or avoid* or prevent*)) ormedication related or (emer-
gency adj3 (vist? or admission? or admitt* or readmission? or
readmit*)) or medication related or ((adverse or avoid* or drug
or medication or prevent*) adj2 event?)).ti,ab
4260
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(Continued)
19 *medication therapy management/ 2813
20 (drug? assess* or drug? audit? or drug? reconcil* or ((medica-
tion or drug or prescribing or prescription?) adj2 (reconcilia-
tion or review* or audit))).ti,ab
9698
21 ((medication? or prescrib* or pharmac*) adj2 (manage? or
management or service? or system?)).ti,ab
30705
22 ((“drug therapy” or dosage? or dose? or medication? or pre-
scription? or prescrib* or pharmacist? or pharmaceutical care)
adj2 (managing or management or monitor*)).ti,ab
14843
23 *“drug use”/ and (adverse or avoidable or emergency or pre-
ventable or readmission? or mortality).ti,ab
2412
24 (community adj (pharmacy or pharmacist? or pharmacies)
adj5 (quality improv* or readmission? or readmitt* or mortal-
itly or (adverse adj2 (reduc* or prevent* or avoid*)))).ab
20
25 pharmacist?.ti. or (pharmacist? adj2 (collaborat* or driven or
directed or led or managed or team*)).ab
21725
26 ((pharmacist? or prescription? or prescribing or medication?)
adj3 (consult* or review* or service or services)).ab
12144
27 *hospital readmission/ and (adverse drug or adverse medica-
tion or medication related or adverse event? or ((avoidable or
preventable) adj2 (adverse or event?))).ti,ab
240
28 ((drug related or medication related or adverse drug or ad-
verse medication) adj5 (emergency department? or emergency
unit? or emergency centre? or emergency center? or emergency
room? or afterhours or after hours or (emergency adj2 (admis-
sion? or admitting)))).ti,ab
247
29 ((drug related or medication related or adverse drug or adverse
medication) adj5 (readmission? or readmitted or emergency
visit or unexpected visit?)).ti,ab
87
30 ((((hospital admission? or (readmit* or readmission?)) adj3
(reduc* or fewer or lower)) or ((avoidable or preventable or
reduced or reducing) adj5 (admission? or readmission?))) and
(drug? or medication? or prescription?)).ti,ab
1724
31 ((problem? or hospitali?ation? or mortality or morbidity or
illness*) adj2 (drug related or drug induced)).ti,ab
2687
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(Continued)
32 *medication error/ and (reduc*.ti. or ((prevent* or avoid* or
rate or rates or reduc* or fewer) adj3 (admission? or readmis-
sion? or emergency or prevent* or quality improv*)).ti,ab.)
2027
33 medication therapy management/ and (adverse or avoidable
or emergency or preventable or readmission? or mortality).ti,
ab
1596
34 *drug therapy/ and adverse event?.ti,ab. 2290
35 ((*hospital readmission/ anddt.fs.) or (dt.fs. and (readmission?
or readmit*)).ti,ab.) and (preventable or avoidable or adverse)
.ti,ab
392
36 (drug therapy/ or (pharmaceutical? or prescrib* or prescrip-
tion? or medication?).ti,ab.) and (near miss or near misses or
never event?).ti,ab
399
37 ((appropriat* or inappropriate or unsafe) adj3 (medicine? or
prescrib* or drug therap* or pharmacotherap*)).ti,ab
5847
38 or/4-37 94819
39 *primary health care/ or *primary medical care/ or *general
practice/
97127
40 ((primary adj2 care) or ((general or family) adj2 practice)).ti,
ab
171036
41 (primary care or family medic* or general practice or family
practi*).jn
10436
42 *community medicine/ or *community health nursing/ or
*community care/ or *home care/
67132
43 (community or ambulatory).ti,ab. 514922
44 *outpatient/ or *outpatient care/ or *outpatient department/
or *community mental health center/
40935
45 ((walk-in or neighbo?rhood) adj2 (clinic? or care centre or care
centres or care center? or health* centre or health* centres or
health* center?)).ti,ab
997
46 *nursing home/ or *residential home/ 28324
47 ((patient? adj2 (home or homes)) or home visit?).ti,ab. 20542
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(Continued)
48 *general practitioner/ 21735
49 ((general or family) adj2 (practitioner? or physician? or doctor?
)).ti,ab
82552
50 or/39-49 857629
51 (ecstasy or marijuana or methamphet* or illegal* or street
drug? or cocaine? or cannabis or inject* drug or drug user?).
ti,ab,hw
136236
52 ((drug? or alcohol?) adj2 (abus* or addict* or dependence)).
ti,ab,hw
165048
53 (placebo or “head to head”).ti,ab. 251431
54 or/51-53 504531
55 multicenter study/ 152623
56 controlled clinical trial/ or controlled study/ or randomized
controlled trial/
5318787
57 randomi?ed.ti. or ((random* or control) adj3 (group? or co-
hort? or patient? or hospital* or department?)).ab. or (con-
trolled adj2 (study or trial)).ti
894626
58 (random sampl* or random digit* or random effect* or ran-
dom survey or random regression).ti,ab. not randomized con-
trolled trial/
74604
59 (exp animals/ or exp invertebrate/ or animal experiment/ or
animal model/ or animal tissue/ or animal cell/ or nonhuman/
) and (human/ or normal human/ or human cell/)
18016161
60 (exp animals/ or exp invertebrate/ or animal experiment/ or
animal model/ or animal tissue/ or animal cell/ or nonhuman/
) not 59
5847628
61 (or/55-57) not (or/58,60) 3860921
62 medication safety.ti,ab. 1951
63 ((optim* or evidence based or rational*) adj2 prescrib*).ti,ab 1711
64 hospitali?ation?.ti,ab. 181464
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65 (emergency or urgent care or visit? or adverse or medication
related or drug related or safely or safety or fewer or drug
therapy or pharmacotherap* or improve? patient? outcome or
readmission? or ((lower* or reduc*) adj2 admission?)).ti,ab,hw
2550209
66 *drug interaction/ and (prevent* or avoid* or reduc*).ti. 1132
67 (drug drug interaction? adj4 (reduc* or avoid* or prevent*)).
ti,ab
382
68 or/62-67 2664679
69 ((38 and 50 and 61 and 68) not 54) or 3 2877
70 (2013* or 2014* or 2015* or 2016*).dp,dd,yr,em. 29074507
71 69 and 70 2695
The Cochrane Library
Searched 4 October 2016
No. Search terms Results
#1 ((prevent* or reduce or reducing) near/2 (medication error? or
adverse drug or adverse medication)):ti,ab
61
#2 [mh “medication errors”] and (avoid* or intervention or pre-
vent* or reducing or rate or improv* or quality):ti,ab,kw
250
#3 ((medication? or drug or prescription?) near/1 (error? or mis-
take?) near/5 (avoid* or intervention? or prevent* or reducing
or quality improv*)):ti,ab
2
#4 [mh “inappropriate prescribing”] and (avoid* or intervention
or prevent* or reducing or rate or improv* or quality):ti,ab,kw
64
#5 [mh “decision support systems, clinical”] and ((drug? or med-
ication?) near/2 (management or adverse or event? or related)
):ti,ab
0
#6 ((structured near/2 (assessment? or care)) and (drug? or med-
ication?)):ti,ab
18
#7 (structured assessment? or structured care or case manage-
ment):ti,ab and (drug therapy or medication? or pharmaco*
therapy or prescription? or prescribing):ti,ab,kw
1074
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#8 (“safety of medications” or prescribing safety or safe prescrib-
ing or (safely next prescribing)):ti,ab
259
#9 ((safe or safety or quality improv*) and ((medication? or drug?
) near/1 management)):ti
0
#10 (quality improv* near/10 ((medication? or drug?) near/1man-
agement)):ab
1
#11 (clinical decision and drug?):ti 0
#12 ((clinical decision making or decision support) near/4 (pre-
scribing or drug therap* or drug management or medication
management or (managing near/2 (drug? or drug therapy or
medication?)))):ti,ab
19
#13 (collaborative and (drug? or medication?) and management):
ti
0
#14 [mh “medication reconciliation”] 40
#15 (drug? assess* or drug? audit? or drug? reconcil* or ((medica-
tion or drug or prescribing or prescription?) near/2 (reconcil-
iation or review* or audit))):ti,ab
14511
#16 ((medication? or prescrib* or pharmac*) near/2 (manage? or
management or service? or system?)):ti,ab
626
#17 ((“drug therapy” or dosage? or dose? or medication? or pre-
scription? or prescrib* or pharmacist? or pharmaceutical care)
near/2 (managing or management or monitor*)):ti,ab
222
#18 [mh “drug utilization review”] 134
#19 community pharmacy:ti or (community next pharmac*):ab 491
#20 pharmacist?:ti or (pharmacist? near/2 (collaborat* or driven or
directed or led or managed or team*)):ab
268
#21 ((pharmacist? or prescription? or prescribing or medication?)
near/3 (consult* or review* or service or services)):ab
200
#22 [mh “patient readmission”] and (prescription? or drug ther-
apy):ti,kw
59
#23 [mh “patient readmission”] and (((adverse drug or adverse
medication?) near/2 (event or related)) or ((medication related
or drug related) near/2 (event? or problem?))):ti,ab
4
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#24 ((drug related or medication related or adverse drug or ad-
verse medication) near/5 (emergency department? or emer-
gency unit? or emergency centre? or emergency center? or
emergency room? or afterhours or after hours or (emergency
near/2 (admission? or admitting)))):ti,ab
3
#25 ((drug related or medication related or adverse drug or adverse
medication) near/5 (readmission? or readmitted or emergency
visit or unexpected visit?)):ti,ab
8
#26 (((hospital admission? or (readmit* or readmission?)) near/3
(reduc* or fewer or lower)) or ((avoidable or preventable or
reduced or reducing) near/5 (admission? or readmission?))):
ti,ab and (drug or medication? or prescription?):ti,ab,kw
124
#27 {or #1-#26} 17390
#28 [mh “community pharmacy services”] 250
#29 [mh “primary health care”] or [mh “general practice”] or [mh
“family practice”] or [mh “general practice, dental”] or [mh
“primary care nursing”]
8243
#30 ((primary near/2 care) or ((general or family) near/2 practice)
):ti,ab
14278
#31 [mh “communitymedicine”] or [mh “community health nurs-
ing”] or [mh “community health services”] or [mh “commu-
nity health centers”] or [mh “home care services”]
12860
#32 (community or ambulatory):ti,ab,kw 36494
#33 [mh “ambulatory care facilities”] or [mh “ambulatory care”] 5379
#34 ((walk-in or neighbo?rhood) near/2 (clinic? or care centre or
care centres or care center? or health* centre or health* centres
or health* center?)):ti,ab
4
#35 [mh “maternal-child health centers”] or [mh “outpatient clin-
ics, hospital”] or [mh “pain clinics”] or [mh “community men-
tal health centers”]
842
#36 [mh “nursing homes”] or [mh “intermediate care facilities”]
or [mh “skilled nursing facilities”]
1204
#37 ((patient? near/2 (home or homes)) or home visit?):ti,ab 3045
#38 {or #29-#37} 61131
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#39 [mh “general practitioners”] or [mh “physicians, family”] or
[mh “physicians, primary care”]
747
#40 ((general or family) near/2 (practitioner? or physician? or doc-
tor?)):ti,ab
3101
#41 ((primary care or family or general practice or community or
home care) near/2 (nurse or nurses)):ti,ab
457
#42 {or #39-#41} 3950
#43 #27 and (#38 or #42) 2668
#44 #28 or #43 2719
CINAHL (EBSCO)
Searched 4 October 2016
No. Search terms Results
S1 MHMedication errors 8,902
S2 TI ((medication review or medication reconciliation)) ORAB
((medication review or medication reconciliation))
1,484
S3 MH “Drug Therapy+” AND (TI adverse event# OR AB ad-
verse event#)
2,408
S4 TI (((problem# or hospitali#ation# or mortality or morbidity
or illness*) N2 (drug related or drug induced))) OR AB ((
(problem# or hospitali#ation# or mortality or morbidity or
illness*) N2 (drug related or drug induced)))
512
S5 TI (((error# or mistake# or wrong or adverse event# or near
miss or near misses or never event# or incorrect* or inappro-
priat*)N3 (drug# or dose or doses or dosage or dosing or phar-
maceutical or medication# or prescription# or prescribing)))
OR AB (((error# or mistake# or wrong or adverse event# or
near miss or near misses or never event# or incorrect* or inap-
propriat*) N3 (drug# or dose or doses or dosage or dosing or
pharmaceutical or medication# or prescription# or prescrib-
ing)))
6,946
S6 TI ((dispensing N2 (error# or mistake# or wrong))) OR AB (
(dispensing N2 (error# or mistake# or wrong)))
62
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S7 ((MHMortality) AND (MHDrug therapyORMHPrescrip-
tions, Drug OR MH Drugs, Prescription OR MH Dosage
Calculation ORMHDrugs, Off-Label ORMH “Drug Ther-
apy, Combination” OR MH “Drug Therapy, Computer-As-
sisted” OR MH Polypharmacy)) OR (TI ((((preventable or
avoidable or prescrib* or medication) N2 error#) or mistake#
or wrong or incorrect* or inappropriat*)) OR AB ((((pre-
ventable or avoidable or prescrib* or medication) N2 error#)
or mistake# or wrong or incorrect* or inappropriat*)))
20,695
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 31,409
S9 MH Primary Health Care OR MH Family practice 43,304
S10 TI (((primary N4 (care or healthcare)) or ((General or family)
N2 practice))) OR AB (((primary N4 (care or healthcare)) or
((General or family) N2 practice)))
47,581
S11 MHCommunity medicine ORMH community health nurs-
ing ORMH community health services ORMH community
health centers OR MH home health care
49,837
S12 TI ((community care or community healthcare)) OR AB (
(community care or community healthcare))
14,011
S13 MH Ambulatory Care Facilities OR MH Ambulatory Care 9,934
S14 TI (((ambulatory or walk-in or neighbo#rhood or commu-
nity) N2 (clinic# or care centre or care centres or care center#
or health* centre or health* centres or health* center#))) OR
AB (((ambulatory or walk-in or neighbo#rhood or commu-
nity) N2 (clinic# or care centre or care centres or care center#
or health* centre or health* centres or health* center#)))
4,226
S15 MH Pain Clinics OR MH Nursing Homes OR MH Skilled
Nursing Facilities
18,610
S16 TI ((nursing home# or care facility)) OR AB ((nursing home#
or care facility))
22,849
S17 S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR
S16
162,691
S18 MH Physicians, Family 9,090
S19 TI (((general or family) N2 (practitioner# or physician# or
doctor#))) OR AB (((general or family) N2 (practitioner# or
physician# or doctor#)))
12,972
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S20 (MH nurse practitioners ORMH physician Assistants) AND
(TI community OR AB community OR MW community)
834
S21 (TI ((physician# assistant# or doctor# assistant# or physi-
cian# extender# or feldsher#)) OR AB ((physician# assistant#
or doctor# assistant# or physician# extender# or feldsher#))
) AND ((TI community OR AB community OR MW com-
munity))
170
S22 S18 OR S19 OR S20 OR S21 20,115
S23 MH Pharmacists OR MH Pharmacy Technicians OR MH
Drug Information Services ORMHClinical Pharmacy Infor-
mation Systems
6,238
S24 TI medication review OR AB medication review 1,119
S25 TI (pharmaceutical care or pharmacy or pharmacies or phar-
macist# or prescriber# or prescribing or prescription# or drug
therapy)
19,149
S26 AB ((pharmacist# or prescription# or prescribing or medica-
tion#) N3 (consult* or review* or service or services))
2,074
S27 TI (((medication# or prescrib* or pharmac*) N2 (manage# or
management or service# or system#))) ORAB (((medication#
or prescrib* or pharmac*) N2 (manage# or management or
service# or system#)))
6,368
S28 TI ((drug# assess* or drug# audit# or drug# reconcil*)) OR
AB ((drug# assess* or drug# audit# or drug# reconcil*))
2,283
S29 TI (((“drug therapy” or dosage# or dose# or medication# or
prescription# or prescrib* or pharmacist# or pharmaceutical
care) N2 (managing or management or monitor*))) OR AB (
((“drug therapy” or dosage# or dose# or medication# or pre-
scription# or prescrib* or pharmacist# or pharmaceutical care)
N2 (managing or management or monitor*)))
3,702
S30 TI (((improv* or optimi#ing or optimi#e# or optimal*) and
(dosing or dosage))) OR AB (((improv* or optimi#ing or op-
timi#e# or optimal*) N2 (pharmaceutical care or pharmacy
or prescrib* or prescript*)))
846
S31 TI (((drug therapy or drug regime# or medication# or
medicineS or pharmacy or pharmacist# or pharmaceutical or
PRESCRIB* or prescription#) N2 (audit* or monitor* or rec-
oncil* or review#))) OR AB (((drug therapy or drug regime#
3,183
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or medication# or medicineS or pharmacy or pharmacist# or
pharmaceutical or PRESCRIB* or prescription#) N2 (audit*
or monitor* or reconcil* or review#)))
S32 MH Drug Utilization 4,070
S33 S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR
S30 OR S31 OR S32
35,911
S34 TI ((emergency N3 (visit# or room# or clinic# or admission#
) N3 (reduc* or fewer or lower))) OR AB ((emergency N3
(visit# or room# or clinic# or admission#) N3 (reduc* or fewer
or lower)))
412
S35 TI reduc* hospital admissions OR AB reduc* hospital admis-
sions
552
S36 TI ((readmission# N3 (reduc* or fewer or lower))) OR AB (
(readmission# N3 (reduc* or fewer or lower)))
989
S37 MH Readmission AND (TI (((hospital admission# or (read-
mit* or readmission#)) N3 (reduc* or fewer or lower))) OR
AB (((hospital admission# or (readmit* or readmission#)) N3
(reduc* or fewer or lower))))
725
S38 S34 OR S35 OR S36 OR S37 1,902
S39 S8 and S17 2,345
S40 S8 and S22 464
S41 S33 and S17 4,462
S42 S33 and S22 945
S43 S33 and S38 102
S44 S39 OR S40 OR S41 OR S42 OR S43 6,625
S45 (MM “Clinical Trials+”) OR (MH “Multicenter Studies”) 23,509
S46 TI (“clinical study” or “clinical studies”) or AB (“clinical study”
or “clinical studies”)
8,089
S47 TI random* or AB random* 130,238
S48 TI (control group or control groups OR control* experiment*
or control* design or controlled study) OR AB (control group
OR control groups or control* cohort* or controlled experi-
ment* controlled design or controlled study)
58,722
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S49 TI (cluster N2 trial* or cluster N2 study or cluster N2 group
or cluster N2 groups or cluster N2 cohort or cluster N2 design
or cluster N2 experiment*) ORAB (cluster N2 trial* or cluster
N2 study or cluster N2 group or cluster N2 groups or cluster
N2 cohort or cluster N2 design or cluster N2 experiment*)
2,286
S50 TI multicentre or multicenter or multi-centre or multi-center 25,954
S51 AB ((multicent* n2 design*) or (multicent* n2 study) or (mul-
ticent* n2 studies) or (multicent* n2 trial*)) or AB ((multi-
cent* n2 design*) or (multi-cent* n2 study) or (multi-cent*
n2 studies) or (multi-cent* n2 trial*))
8,384
S52 TI controlled AND TI (trial or trials or study or experiment*
or intervention)
23,532
S53 S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR
S52
192,373
S54 S44 and S53 835
S55 TI ((((medication or drug) N2 event) and ((primary N2 care)
or ((family or general) N2 (practice or practitioner#))))) OR
AB ((((medication or drug) N2 event) and ((primary N2 care)
or ((family or general) N2 (practice or practitioner#)))))
58
S56 S54 OR S55 871
S57 S56 Limiters - Exclude MEDLINE records 116
Appendix 3. GRADE evidence profile: professional interventions compared to standard care for
preventation of medication errors
Grade evidence profile: professional interventions compared to standard/usual care for prevention of medication errors
Patient or population: adults receiving medication in primary care
Setting: primary and community care
Intervention: professional interventions (using health information technology to identify patients at risk or help to generate a care
plan for patients)
Comparison: standard/usual care
Quality assessment Effect Quality Impor-
tance
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of par-
ticipants/
studies
Study de-
sign
Risk of
bias
Inconsis-
tency
Indirect-
ness
Impreci-
sion
Other
considera-
tions
Relative/
absolute
(95% CI)
Number of hospital admissions
PI: 41/
1949 (2.
1%)
SC: 33/
1940 (1.
7%)
(2 studies)
Ran-
domised
trials
Not
serious
Not
serious
Not
serious
Seriousa None Relative:
RR 1.24
(0.79 to 1.
96)
Absolute:
4more per
1000
(from 4
fewer to 16
more)
⊕⊕⊕©
Moderate
Not
Important
Number of people admitted to hospital
PI: 827/
1870 (44.
2%)
SC: 802/
1791 (44.
8%)
(1 study)
Ran-
domised
trials
Not
serious
Not
serious
Not
serious
Not
serious
None Relative:
RR 0.99
(0.92 to 1.
06)
Absolute:
5 fewer
per 1000
(from 27
more to 36
fewer)
⊕⊕⊕⊕
High
Not
Important
Number of emergency department visits
PI: 47/552
(8.5%)
SC: 61/
515 (11.
8%)
(2 studies)
Ran-
domised
trials
Seriousb Not
serious
Not
serious
Seriousa None Relative:
RR 0.71
(0.50 to 1.
02)
Absolute:
33 fewer
per 1000
(from 2
more to 59
fewer)
⊕⊕©©
Low
Important
Mortality
PI: 211/
1769 (11.
9%)
SC:215/
Ran-
domised
trials
Seriousb Not
serious
Not
serious
Not
serious
None Relative:
RR 0.98
(0.82 to 1.
⊕⊕⊕©
Moderate
Not
Important
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1769 (12.
2%)
(1 study)
17)
Absolute:
3 fewer
per 1000
(from 21
more to 22
fewer)
CI: confidence interval; PI: professional intervention; RR: risk ratio; SC: standard care
aWe downgraded one level due to imprecision.
bWe downgraded one level due to risk of bias (selection bias).
Appendix 4. GRADE evidence profile: organisational Interventions compared to standard care for
prevention of medication errors
Organisational interventions compared to standard/usual care for prevention of medication errors
Patient or population: adults receiving medication in primary care
Setting: primary care
Intervention: organisational interventions (provision of pharmaceutical care, medication reviews, follow-up visits by a healthcare
professional (e.g. pharmacist, nurse or physician)
Comparison: standard/usual care
Quality assessment
of participants/ studies
Number of hospital admissions
OI: 817/3100 (26.4%)
SC: 850/3103 (27.4%)
(11 studies)
Number of people admitted to hospital
OI: 2846/73,313 (3.9%)
SC: 3221/78,924 (4.1%)
(13 studies)
Number of emergency departments visits
OI: 171/849 (20.1%)
SC: 227/970 (23.4%)
(5 studies)
Mortality
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OI: 3180/74,017 (4.3%)
SC: 4085/80,945 (5.0%)
(12 studies)
CI: confidence interval; OI: organisational intervention; RR: risk ratio; SC: standard care
aWe downgraded one level for unclear risk of bias (selection and attrition bias).
bWe downgraded one level for inconsistency (high heterogeneity across studies).
cWe downgraded one level for imprecision.
dWe downgraded one level for high risk of bias (selection, performance and attrition bias).
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